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Clinically significant antibiotic resistance has evolved against virtually every antibiotic 
currently deployed, therefore it is critical for human health to discover new antibacterial agents 
with novel modes of action. Thiopeptides are a family of ribosomally synthesized and post-
translationally modified peptides (RiPPs) that have outstanding biological profile, including high 
potency against a variety of antibiotic resistant pathogenic strains. Their new modes of action have 
attracted many efforts to develop chemical syntheses, and to study their biological function and 
biosynthetic origin. However, the complex architecture and poor physicochemical properties have 
plagued this otherwise-promising class of antibiotics. To address these challenges, this dissertation 
used the thiopeptide thiomuracin as a model to establish the reconstitution of the biosynthesis of 
thiopeptide in vitro, and to characterize the activity of the highly unusual modification enzymes 
involved in thiopeptide biosynthetic pathway. This work will guide future efforts to improve the 
properties of thiopeptide natural products. 
The biosynthesis of the thiopeptide thiomuracin is a well-orchestrated process involving a 
multitude of post-translational modifications. Chapter 2 presents the first in vitro biosynthesis of 
the core scaffold of thiopeptide thiomuracin, while Chapter 3 will provide insights into the 
substrate specificities, directionality, and timing of catalysis by six proteins involved in the 
formation of this core scaffold of thiopeptides. Characterization and mechanistic investigation of 
TbtI, a radical S-adenosyl-L-methionine thiazole C-methyltransferase involved in the tailoring 
modification of thiomuracin, are presented in Chapter 4. Lastly, Chapter 5 discusses the 
characterization of an ATP and tRNA dependent peptidyl transferase involved in a pathway where 
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a ribosomally synthesized small peptide serves as a catalytic scaffold on which a small-molecule 
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CHAPTER 1: INTRODUCTION 
 
1.1 Ribosomally synthesized and post-translationally modified peptide (RiPP) natural 
products 
Natural products have played key roles in human history in advancing our knowledge of 
chemistry, biology and in the development of medicine (1-3). In the 20th century, four groups of 
natural products, terpenoids, alkaloids, polyketides, and non-ribosomal peptides, were identified 
as the most prevalent classes. Then, at the turn of the 21st century, genome sequencing programs 
revealed the ribosomally synthesized and post-translationally modified peptides (RiPPs) as an 
additional large class of natural products that are produced in all three domains of life (4). Despite 
starting from a ribosomal origin, RiPPs are able to reach a similar level of chemical diversity and 
structural complexity as other groups of natural products through extensive post-translational/co-
translational modifications (Figure 1.1B). These modifications are chemically diverse and 
typically restrict conformational flexibility to improve metabolic and chemical stability, and allow 
better target recognition. Thus, RiPPs may be endowed with a wide variety of highly potent 
biological activities such as anticancer, antibacterial, antifungal, and antiviral activity (5-9).  
Indeed, by virtue of their diverse pharmacological properties, this underexplored source of natural 





Figure 1.1 (A) Schematic RiPP biosynthetic pathway. Representative RiPP biosynthetic gene cluster wherein each 
gene encodes a biosynthetic enzyme color-coded by the modification it catalyzes. Dashed circles represent amino 
acids of the leader peptide, which is removed in the late stage of maturation. Full circles represent amino acids within 
the core peptide. (B) Chemical structures of select members of some RiPP subfamilies. Structural features defining a 
particular RiPP subfamily are shown in blue. Additional post-translational modifications are shown in red. a 
 
Unlike non-ribosomal peptide biosynthesis, in which the peptide backbone is constructed 
by incorporating non-proteinogenic amino acid scaffolds using large multi-modular enzyme 
complexes, the production of RiPPs starts from a ribosomally synthesized linear precursor peptide 
                                                 
a. The figure was reprinted from: Ortega, M. A., & van der Donk, W. A. (2016). New Insights into the Biosynthetic Logic of Ribosomally 
Synthesized and Post-translationally Modified Peptide Natural Products. Cell Chem. Biol., 23, 31-44. Copyright (2016), with permission from 
Elsevier. 
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encoded by a structural gene (10, 11). This precursor peptide usually contains an N-terminal leader 
peptide (LP), which is removed in the late stages of maturation, and a C-terminal core peptide that 
is converted into the mature product. The leader peptide carries important recognition elements for 
key biosynthetic enzymes, which in turn allows these enzymes a high degree of tolerance with 
respect to sequence variation in the core peptide (12). A ribosomally synthesized precursor peptide 
undergoes modification by a set of enzymes usually encoded in the local genomic region (Figure 
1.1A), and these modifications include, but are not limited to, dehydrations, cyclizations, 
methylations, oxidations, and rearrangements. All of these modifications are responsible for 
endowing the peptide with a rigidified structure and biological activity. The enzymes encoded in 
a biosynthetic gene cluster govern the posttranslational modifications that a precursor peptide 
receives, and in some cases, the structure of the final product can be accurately predicted (13, 14). 
Modification of the core is typically followed by the proteolytic cleavage of the N-terminal leader 
peptide, and the mature compound is exported. Using this simple strategy, a plethora of chemically 
diverse natural products can be constructed from a minimal amount of genetic space. In fact, the 
investigation of RiPPs has overturned the longstanding paradigm that large genomes are required 
for an organism to produce architecturally complex natural products (15, 16).  
The gene-encoded nature of the precursor peptide coupled with the highly promiscuous 
biosynthetic enzymes of this class of natural products allows for the facile generation of unnatural 
compound derivatives. Recent studies on many unrelated RiPP families have also revealed a 
structurally similar precursor peptide binding domain homologous to PqqD  the RiPP precursor 
peptide recognition element (RRE) (17-21). These findings suggest several future applications, 
including the engineering of new precursor peptide specificities via RRE swapping, which has 
garnered a great deal of excitement due to the potential to develop therapeutically relevant 
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derivatives of this underutilized class of natural products (22-25), and offers the tantalizing 
opportunity to engineer hybrid RiPPs, not only within RiPP classes (26-28), but also between 
different RiPP classes (29).  
 
1.2 Thiopeptides and their potential as clinical therapeutics 
Thiopeptides, or thiazolyl peptides, are highly modified sulfur-rich peptides belonging to 
the RiPP family. This class is defined by a series of common chemical moieties that differentiate 
them from other peptide-derived and/or azole-containing natural products. Their most 
characteristic feature is a central tri- or tetra-substituted nitrogen-containing six-membered ring, 
which serves as scaffold to at least one macrocycle and a tail, which both can be decorated with 
various dehydroamino acids and azoles/azolines (30, 31). All these moieties are formed through 
dehydration/cyclodehydration of Ser, Thr, and Cys residues present in the core region of the 
precursor peptide (32-35). Other compound-specific tailoring side-chain modifications, such as 
oxidations, cyclizations, methylations, and even the presence of another macrocyclic motif are also 
present in this class of natural product. 
Thiopeptides have been classified into different series based on the different oxidation state 
of the central ring (Figure 1.2) (30). Thus, the a series possesses a totally reduced central 
piperidine, whereas the b series is oxidized to contain a 1, 2-dehydropiperidine ring. Only one 
thiopeptide of the c series has been isolated to date (36), and its central moiety is somewhat 
unexpected, as it displays a piperidine ring fused with an imidazoline. All members of the a, b, 
and c series have a second quinaldic acid containing macrocycle. The d series is oxidized further 
and presents a tri-substituted pyridine ring, the major feature of this subgroup, which is the most 
prevalent among thiopeptides. The e series is oxidized even more and is easily differentiated by 
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the presence of a hydroxyl group in the central pyridine ring. The e series also possesses a very 
characteristic second macrocycle appending from the main one that is formed by a modified 3,4-
dimethylindolic acid moiety. 
 
 
Figure 1.2 Representatives of the five series of thiopeptide classes. Their characteristic central six-member ring is 
highlighted in red. 
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The individual chemical identity of structurally distinct compounds isolated from natural 
sources and classified as thiopeptide antibiotics is relatively diverse. It is an intriguing fact that, 
despite many similarities in biosynthetic origin, these secondary metabolites have been isolated 
from a number of different strains of actinomycetes, predominantly soil bacteria but also from 
marine sources, and elicit a wide range of different biological responses. In 1948, the first known 
member of the family, micrococcin (37), was isolated from a sample of Oxford’s sewage waters. 
Accounting for the highly diverse origin of thiopeptides, micrococcin P1 was more recently 
isolated from a completely different source, a French cheese (38). However, more conventional 
samples, such as from soil, are the main source of most thiopeptides. In fact, thiostrepton, the most 
famous member of the family, has been isolated from different soil samples (39), including one 
from Hawaii in 1955 (40), shortly after it was first discovered in 1954 (41). Although a few more 
thiopeptides were isolated during the following years, it was after the 1980s, especially during the 
1990s, that most of the known members were discovered. Many novel entities have also been 
described during the last decade. Remarkably, the first thiopeptide antibiotics isolated from a 
marine source were YM-266183 and YM-266184, discovered in 2003 in Japan (42). During the 
last few years some more thiopeptides have been isolated and characterized (43-47). 
Thiopeptides, with their impressive in vitro profile against Gram-positive bacteria, and 
their diverse mechanisms of action, have gathered the attention of many groups, both in academia 
and industry. What makes thiopeptides attractive is that they pose an alternative to other antibiotics 
presently facing resistance by old pathogens. Although thiopeptides are best regarded as 
antibacterial agents, their therapeutic potential is surprisingly broad as they have been found to 
possess anticancer (48-52), anti-malarial (53-56), antifungal (57), RNA polymerase inhibition 
(58), renin inhibitory (59), and even immuno-suppressive activities (60). This wide variety of 
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biological functions has resulted in a very prolific literature, and suggests that the macrocyclic 
scaffold of thiopeptides is a privileged structure.  
Thiopeptides exert their antibacterial function via the inhibition of ribosomal protein 
synthesis. However, this antimicrobial activity is the result of different mechanisms of action that 
depend on macrocycle size. Thiopeptides exhibit macrocycles of three different sizes, 26-, 29-, 
and 35-membered rings, depending on the number of amino acid residues present. On the one 
hand, thiopeptides of 26-membered macrocycles, such as micrococcin P1 and the siomycins, are 
known to bind the GTPase-associated region of the ribosome/L11 protein complex. By doing so, 
the thiopeptide blocks the binding region of elongation factor G (EF-G) and does not allow 
translocation of the growing-peptide/tRNA complex in the ribosome to occur (61-63). On the other 
hand, thiopeptides with a 29-membered ring, such as GE2270A or thiomuracin, bind to elongation 
factor thermo unstable (EF-Tu), blocking its amino acyl tRNA complex binding site (64-66). As a 
consequence, the complex would not be able to be delivered into the ribosome and further peptide 
elongation cannot take place. Thiopeptides with larger macrocycles, the 35-membered rings 
thioxamycin for example, still possess potent antibacterial activity, but their mode of action has 
still remained enigmatic. 
Somewhat related to antibacterial activity is the tipA promoter, which controls transcription 
of two thiostrepton-induced proteins (Tip), TipAL and TipAS (67). The latter protein, TipAS, 
serves as a mechanism of defense for bacteria, as it sequesters and covalently binds a thiopeptide 
molecule, which can no longer inhibit ribosomal protein synthesis. tipA promoters have been used 
to identify thiopeptides in a high-throughput screening program, which detected transcription of 
the promoter of tipA and led to the discovery of several thiopeptides, such as geninthiocin (68), 
thiotipin (69) and promothiocins (70). Interestingly, the 35-membered thiopeptide radamycin is 
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completely devoid of antibacterial activity, but is a very strong inducer of tipA gene expression. It 
seems that the induction of the tipA promoter is dependent on the presence of a dehydroalanine-
containing tail close to the six-membered central scaffold (71, 72). 
Thiopeptides known or presumed to bind to EF-Tu, those with 29-membered macrocycles, 
also possess a very conserved residue in their macrocycle, pointing to a key interaction required 
to exert their biological activity (73). The GE2270s, GE37468 A, thiomuracin, amythiamicins, as 
well as baringolin, all belong to the d series, and contain an Asn residue in the same position that 
is either methylated or not. Codon randomization experiments by the Walsh laboratory produced 
various GE37468 A analogs that substituted Asn with Ala, Cys, His, and Ser; however, none of 
these analogs retained antibacterial activity, supporting the key role of this residue (74). Except 
for providing a key contact with EF-Tu, the Asn residue provides a transannular hydrogen bond, 
thus participating in the stabilization of the bioactive conformation of the macrocycle (75). 
One of the biological properties of thiopeptides of major interest is their anticancer activity. 
In this regard, thiostrepton was found to selectively kill cancer cells without showing any 
cytotoxicity against healthy tissues. Such a promising effect has been demonstrated to arise from 
selective inhibition of transcription factor fork-head box M1 (FOXM1) (51, 52). FOXM1 
overexpression is associated with the development and progression of cancer and its selective 
targeting is a very important achievement, as transcription factors have been considered 
undruggable for a long time (76, 77). 
Many thiopeptides have been found to possess anti-malarial activity (53-56). Although the 
Plasmodium falciparum parasite is a eukaryote, thiopeptides target apicoplast protein synthesis 
(78), which resembles that of prokaryotic organisms. Although it has been demonstrated that 
thiostrepton binds to the apicoplast 23S rRNA, thiopeptides of the d series, such as micrococcin 
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P1 and amythiamicin A, are much more potent inhibitors of P. falciparum growth (79). Recently, 
the use of thiostrepton semi-synthetic analogs has demonstrated that it targets both the apicoplast 
ribosomes and the proteasome of P. falciparum (56). This dual mode of action could make 
thiostrepton and similar thiopeptides less likely to develop resistance than drugs with single targets. 
A screening program in search of immune-suppressants identified siomycin as inhibitor of 
antibody production by murine B-cells (60). Comparison with thiostrepton showed the superior 
behavior of the structurally similar siomycin. Both thiopeptides are thought to possess a different 
mechanism of action than that of FK506, a common immunosuppressant drug, and to  act directly 
on B-cells. 
To date, more than one hundred members of the thiopeptide family have been identified; 
however, their large molecular size and poor physical-chemical properties have been a major 
hurdle for introducing them into the clinic. This drawback has become their major limitation and 
has restricted their use to topical treatments, and thus far, only two agents are in commercial use 
with both restricted to animal usage (thiostrepton for skin infections; nosiheptide for growth 
promotion) (31). Impressive efforts in the semi-synthetic derivatization of GE2270A led to 
LFF571 (80), which recently completed a phase II trial for moderate Clostridium difficile 
infections (81, 82). This trial underscores the opportunities for improving the pharmacological 
properties of thiopeptides.  
 
1.3 Biosynthesis of thiopeptides 
The biosynthetic pathway of thiopeptides has been elusive for a long time. However, recent 
discoveries have shed light on the biosynthesis of these highly modified natural products. Peptide-
based natural products can have two distinct origins depending on how their amino acids are 
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condensed to form the parent peptides. These can be either synthesized by the ribosome as product 
of mRNA translation or can be assembled by non-ribosomal peptide synthetases (NRPSs). 
Although most highly modified peptide-derived natural products are synthesized by NRPSs, there 
was no evidence of such origin for thiopeptides. In 2009, four different groups demonstrated that 
the pre-peptide of thiopeptide is ribosomally synthesized and, thus, is genetically encoded. 
Genome mining efforts have identified genes that encode the precursor peptide and the enzymatic 
machinery necessary for its subsequent post-translational modifications. The gene encoding the 
precursor peptide has been discovered for many thiopeptides and, in all cases, there is a perfect 
agreement of expected amino acid sequence with the final product (32-35, 45, 46, 83-85).  
The function of most enzymes found in thiopeptide gene clusters has been established 
through homology to known enzymes, gene deletion studies, or in vitro biochemical analysis (86-
92). Through these studies, it has been shown that the characteristic thiazoline/oxazoline rings are 
initially formed through the cyclodehydration of target Ser, Thr, and Cys residues by YcaO 
enzymes. Oxidation of these rings to the corresponding thiazole/oxazole structures can then be 
accomplished through the activity of flavin mononucleotide dependent dehydrogenases (Figure 
1.3A) (23). In addition, key dehydroalanine (Dha) and dehydrobutyrine (Dhb) moieties are 
produced in the core peptide by split class I lanthipeptide dehydratases.  These enzymes utilize 
tRNAGlu to first glutamylate target Ser and Thr residues prior to eliminating glutamate in order to 
form the dehydrated product. This mechanism was recently established through the study of the 
tRNA-dependent lanthipeptide dehydratase NisB involved in nisin biosynthesis (Figure 1.3B) 
(21). The last step in the biosynthesis of the thiopeptide core scaffold is the proposed 
intramolecular aza-Diels-Alder-like cycloaddition reaction between two Dha residues to form the 
central six-membered ring, followed by dehydration and subsequent elimination of the leader 
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peptide (Figure 1.3C) (93, 94). Further side-chain modifications, such as C-terminal amidation, 
oxidation, glycosylation, methylation, and incorporation of indolic or quinaldic acid moieties are 
thought to occur in later stages of the biosynthetic pathway. 
 
 
Figure 1.3 (A) A general scheme for thiazol(in)e/oxazol(in)e heterocycle biogenesis. Select Cys, Ser, and Thr residues 
are cyclized by the ATP-dependent cyclodehydratase. Azoline heterocycles can then be oxidized by a flavin-dependent 
dehydrogenase to afford the aromatic azole. (B) Proposed dehydration mechanism employed by Class I lanthipeptide 
dehydratases. Select Ser and Thr residues are first glutamylated by the N-terminal domain of LanB dehydratases using 
Glu-tRNAGlu. The elimination of the glutamate yields the dehydrated amino acids. (C) Proposed mechanism for the 
central nitrogen-containing six-membered ring formation. The [4+2] cyclase catalyzes the intramolecular aza-Diels-
Alder-like cycloaddition reaction between two distant Dha residues to generate the macrocyclic scaffold of 
thiopeptides with the elimination of a water molecule and the leader peptide.  
 12 
1.4 Summary and outlook 
Thiopeptides, with their unique structural features and diverse modes of action, have 
attracted much interest aimed at understanding their biosynthetic origin and pharmacological 
potential. Their biosynthesis and application have proven to be a challenging pursuit, however, 
given their complex architecture and poor physicochemical properties. Although prior studies had 
been successful in providing the general framework, a detailed biochemical and mechanistic 
understanding of the biosynthetic processes had remained elusive. To address these challenges, in 
collaboration with the Mitchell laboratory we have reconstituted the biosynthesis of the model 
thiopeptide, thiomuracin, in vitro and characterized the activity of many of the enzymes encoded 
in its biosynthetic gene cluster.  In Chapter 2, I present our findings regarding the reconstitution 
the activities of six proteins that together biosynthesize the core structure of thiomuracin via 22 
chemical transformations;  I further discuss in Chapter 3 the substrate specificities, directionality, 
and timing of catalysis by the six proteins involved in this well-orchestrated set of enzymatic 
reactions, as well as the mechanistic and crystallographic characterization of the enzyme 
catalyzing the [4+2] aza-cyclization reaction; in Chapter 4, the biochemical and mechanistic 
investigation of a radial S-adenosyl-L-methionine C-methyltransferase will be presented. 
Together, this work lays the foundation for development of a large library of non-natural 
thiopeptide analogues for pharmacological study. Finally, Chapter 5 discusses a protein related to 
the thiopeptide glutamylation enzymes but carries out very different chemistry. 
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CHAPTER 2: RECONSTITUTION OF THE BIOSYNTHESIS OF THE CORE 
SCAFFOLD OF THE THIOPEPTIDE THIOMURACINb 
 
2.1 Introduction 
Thiopeptides are potent antibiotics that inhibit protein synthesis. They are made by a 
remarkable post-translational modification process that transforms a linear peptide into a 
polycyclic structure. The biosynthesis of thiopeptides utilizes Ser/Thr dehydratases that produce 
dehydro-amino acids alongside cyclodehydratases that convert Ser, Thr and Cys residues to the 
corresponding azolines (1-4). The presence of both types of post-translational modifications 
facilitated the evolution of new chemistry, including a formal [4+2] cycloaddition enzyme that 
converts two dehydroalanine (Dha) moieties to the class-defining central pyridine [or 
(dehydro)piperidine] (5-7). Recent advances in our mechanistic understanding of RiPP 
cyclodehydratases (8-11) and lanthipeptide dehydratases (12, 13) prompted us to attempt the in 
vitro biosynthetic reconstitution of this class of natural products. In collaboration with Prof. 
Douglas Mitchell’s lab, we developed the first in vitro biosynthesis system to reconstitute the 
activities of six proteins that together biosynthesize the core structure of thiomuracin via 22 
chemical transformations (Figure 2.1A). This chapter describes the insights into the order of 
events and requirements for catalysis.  
 
                                                 
b Parts of the chapter are reprinted with permission from: Hudson, G. A., Zhang, Z., Tietz, J. I., Mitchell, D. A., & van der Donk, W. A. (2015). In 
Vitro Biosynthesis of the Core Scaffold of the Thiopeptide Thiomuracin. J. Am. Chem. Soc., 137, 16012-16015. Copyright © 2015 American 
Chemical Society. https://pubs.acs.org/doi/abs/10.1021/jacs.5b10194.  
The in vitro studies of cyclodehydratase and dehydrogenase TbtF, TbtG and TbtE were performed by Graham A. Hudson.  
The in vitro study of the [4+2] cycloaddition enzyme TbtD was a collaboration with Graham Hudson. 
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Figure 2.1 (A) Biosynthetic route to the thiomuracin core scaffold 4. (B) Gene clusters for the biosynthesis of 
thiomuracin, GE2270A, and thiocillin. Sequence of the His6-tagged leader peptide (LP): 
PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA 
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The gene-encoded nature of the precursor peptide coupled with the promiscuous 
biosynthetic enzymes of thiopeptides (5) allows for the facile generation of unnatural compound 
derivatives, and facilitates the potential production of libraries of unnatural analogues for 
pharmacological property improvement. Heterologous expression is an appealing option for 
library construction as it will circumvent the labor invested in enzyme purification for in vitro 
studies, as well as the time and effort required for organic synthesis, thus making the generation 
of derivatives faster and more convenient. At the onset of our studies, all heterologous expression 
of thiopeptides was performed in actinobacteria, such as GE2270 in Nonomuraea ATCC39727 
(14), berninamycin in Streptomyces venezuelae (15), lactazole in Streptomyces lividans (16) and 
thiostrepton in Streptomyces actuosus (17). However, the intractability to genetic editing, as well 
as the instability of the intermediates inside the organism during long growths are disadvantages 
of these heterologous expression hosts. Escherichia coli, with its attractive features such as fast 
growth rate, ease of manipulation and the ability to introduce nonproteinogenic amino acids (18, 
19), could provide an attractive alternative. Although no E. coli expression of thiopeptides has 
been reported, several lanthipeptides, another class of RiPPs family, have been produced in E. coli 
by co-expressing precursor peptides together with their corresponding biosynthetic machinery to 
afford the fully modified lantibiotics (20-23). Thus in this chapter, in addition to the in vitro 
studies, I will also discuss the construction of an E. coli heterologous producing system to lay the 
basis for the production of thiopeptide analogues. 
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2.2 Results and discussion 
2.2.1 In vitro biosynthesis of the thiopeptide thiomuracin core scaffold 
The thiopeptide family is comprised of >100 members, with many compounds adorned 
with a second macrocycle (e.g. thiostrepton) (5). To begin our effort, we restricted our thiopeptide 
in vitro reconstitution targets to mono-macrocyclic compounds whose gene clusters and 
bioactivities were firmly established. Our top candidates thus became GE2270A and thiomuracin 
(Figure 2.1) (3). Although mono-macrocyclic thiopeptides are more “minimalistic”, they harbor 
high chemical complexity and biological activity. Planobispora rosea ATCC53733 and 
Nonomuraea sp. Bp3714-39 are the canonical producers of GE2270A and thiomuracin, 
respectively (3). We did not have access to a thiomuracin-producing strain of Nonomuraea, but 
genome-mining efforts predicted that Thermobispora bispora DSM 43833 would produce an 
identical molecule owing to the presence of a nearly identical biosynthetic gene cluster (Figure 
2.1B). Derived from a thermophilic organism, the T. bispora proteins were envisioned to have the 
desired stability for efficient heterologous expression in E. coli. 
All genes encoding the biosynthetic proteins from T. bispora (tbt) were codon optimized 
for E. coli expression. Based on previous reports (11), genes for F-protein dependent 
cyclodehydratase (tbtF, tbtG), thiazoline dehydrogenase (tbtE), and the [4+2] cycloaddition 
enzyme (tbtD) were subcloned into a previously-described plasmid that fuses maltose-binding 
protein (MBP) to the N-terminus of the protein of interest. In contrast, genes encoding the 
precursor peptide (tbtA) and the split LanB-type dehydratase (13) (tbtB, tbtC) were expressed as 
N-terminally His6-tagged proteins. The purity of all proteins used in the study was assessed 
visually by Coomassie-stained SDS-PAGE analysis (Figure 2.2). The TbtE/F/G proteins were 
expressed and purified by Graham Hudson in the Mitchell laboratory. 
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Figure 2.2 SDS-PAGE analysis of proteins used in this study. The minor impurity found at ~45 kDa is the result of 
endogenous protease activity on the MBP fusion proteins. Cleavage occurs in the linker region between MBP and the 
protein of interest. Enrichment occurs due to the use of amylose resin for affinity purification. 
 
The precursor peptide TbtA was initially expressed and purified as an N-terminally His6-
tagged fusion protein (1) (Figure 2.3A). Reaction of TbtA with purified TbtB/C under conditions 
previously reported for the NisB dehydratase (12, 13) did not result in any chemical transformation 
(Figure 2.4). In contrast, Graham Hudson showed that reaction of 1 with the cyclodehydratase 
TbtG, the dehydrogenase TbtE and TbtF, an ortholog of HcaF that was recently shown to function 
as an auxiliary leader peptide binding protein (11), resulted in a mass shift of -120 Da (Figure 
2.3B). This observation is consistent with successful cyclodehydration and dehydrogenation of the 
six cysteines in the core peptide to the corresponding thiazoles. When TbtE was omitted, a mass 
consistent with six thiazoline modifications was observed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Further, when TbtF 
or ATP were omitted from the reaction, no product formation was detected. 
TbtB is an ortholog of the glutamylation domain of the NisB dehydratase that uses 
glutamyl-tRNA to glutamylate Ser residues (13). TbtC is a member of the SpaB_C family of 
proteins (PF14028) and has sequence homology to the second domain of NisB that eliminates the  
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Figure 2.3 MALDI-TOF-MS of (A) His6-TbtA (1); calc. m/z, 6173; (B) hexazole 2, calc. m/z, 6053; (C) glutamylated 
2; calc. m/z, 6182; (D) tetra-dehydrated hexazole 3, calc. m/z, 5981; and (E) thiomuracin GZ 4, calc. m/z, 1366. For 




Figure 2.4 TbtB/C do not process unmodified TbtA. The top MALDI-TOF mass spectrum shows unmodified TbtA 
precursor peptide (1). The middle spectrum spectrum shows 1 treated with TbtB/C in the presence of other necessary 
reaction components [E. coli GluRS and E. coli tRNAGlu]. The bottom spectrum is an equivalent reaction except with 
T. bispora GluRS and T. bispora tRNAGlu (CUC). These data suggest that the split LanB dehydratase (TbtB/C) requires 
a thiazol(in)e-containing substrate, implicating cyclodehydration (TbtF/G) and dehydrogenation (TbtE) as the initial 
two steps of thiopeptide biosynthesis. 
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glutamate from the glutamylated Ser to install Dha. Reaction of the purified hexazole-containing 
intermediate 2 with TbtB in the presence of Glu, ATP, E. coli tRNAGlu and E. coli glutamate tRNA 
transferase (GluRS) did not result in any change in mass (Figure 2.5). We reasoned that sequence 
differences between E. coli and T. bispora tRNAGlu might contribute to the lack of activity. Hence, 
the two tRNAGlu isoacceptors encoded in the T. bispora genome were prepared by in vitro 
transcription. Reaction of 2 with Glu, ATP, T. bispora tRNAGlu (CUC) and E. coli GluRS resulted 
in glutamylation of 2 (Figure 2.3C). When TbtC was added to an otherwise identical reaction, 




Figure 2.5 TbtB/C is selective for a particular tRNAGlu. (A) MALDI-TOF mass spectrum of 2 (starting material). (B) 
E. coli tRNAGlu (UUC) is not accepted by TbtB/C. (C) In contrast, four dehydrations are observed upon treating 2 
with TbtB/C and tRNAGlu (CUC) from T. bispora.  (D) An identical reaction with the alternative tRNAGlu (UUC) from 
T. bispora yielded a mixture of dehydrated species, primarily the didehydrated peptide. (E) A reaction that omitted 
TbtC (elimination domain), while employing the optimal tRNA and d5-Glu, yielded a mono-glutamylated species. (F) 
Sequence alignment of the three pertinent tRNAGlu. Top, T. bispora tRNAGlu (CUC); middle, T. bispora tRNAGlu 







*  *** ******** ** * ***** ******* *** *****   *   ***********  * ***    *** 
F 
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Use of T. bispora tRNAGlu (UUC) resulted only in partial dehydration (Figure 2.5); this result may 
either indicate that TbtB preferentially uses T. bispora tRNAGlu (CUC) or that E. coli GluRS is less 
efficient in charging T. bispora tRNAGlu (UUC). Using the same conditions with 1 did not result 
in an observable reaction (Figure 2.4), demonstrating for the first time that dehydration activity 
requires prior cyclodehydration. Further, all assay components were required for activity (Figure 
2.6). These experiments establish the first activity of a split LanB and extend the use of Glu-




Figure 2.6 MALDI-TOF-MS analysis of TbtB/C reaction requirements. Shown in the top spectrum is hexazole 2, 
which is the six-fold cyclodehydration and dehydrogenation product of TbtA. Reaction of 2 with the split LanB 
dehydratase (TbtB/C) in the presence of E. coli GluRS and T. bispora tRNAGlu (CUC) results in a four-fold dehydrated 
product (3). The formation of 3 was dependent on the presence of all reaction components, as individual omission of 
TbtB/C, E. coli GluRS, or T. bispora tRNAGlu (CUC) did not result in any change in mass. Residues modified to a 
thiazole are shown in blue, and residues that are transformed to dehydroalanine are colored green. All reactions also 






Figure 2.7 TbtD requires the leader peptide for activity. (A) HR-ESI-MS of the TbtA leader peptide generated by 
macrocyclization (theoretical [M+H]+, 4593.143 Da, 0.4 ppm). The sequence of the His6-TbtA-derived substrate 3 is 
given below the figure with modifications present color-coded (blue, thiazoles; green, dehydroalanines). The asterisk 
designates the end of the leader peptide. Shown italicized are additional N-terminal residues present on the substrate 
(His-tag and cloning remnants). (B) MALDI-TOF-MS of 3 after treatment with endoproteinase GluC. This treatment 
removes all but three residues (VGA, boldfaced and underlined) of the leader peptide. (C) Reaction of GluC-treated 
3 with TbtD. No reaction was observed. 
 
 
Figure 2.8 ESI-MS/MS of the His6-TbtA leader peptide (m/z 1149) generated by macrocyclization. 
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Treatment of the hexazole-containing, tetra-dehydrated His6-TbtA (3) with TbtD resulted 
in the consumption of 3 and appearance of two new masses consistent with the excised leader 
peptide and the desired macrocycle (Figure 2.3E & 2.7). The identity of the leader peptide was 
confirmed by high-resolution, tandem electrospray ionization MS (HR-ESI-MS/MS, Figure 2.8). 
The data indicated that the leader peptide terminates in a carboxamide rather than a carboxylic 
acid, providing the first evidence that the cycloaddition enzyme uses elimination chemistry, rather 
than hydrolysis, to release the leader peptide. The generation of the macrocyclic core scaffold of 
thiocillin by the TbtD-ortholog TclM using a semi-synthetic substrate was also reported shortly 
before our work appeared (24, 34). Interestingly, like TbtC, TbtD (and TclM) is a member of the 
SpaB_C protein family, suggesting that elimination reactions may be common in PF14028 (13). 
Removal of the N-terminal 31 (of 34) amino acids of the leader peptide from 2 by treatment with 
endo-proteinase GluC resulted in a peptide that was no longer a substrate for TbtD (Figure 2.7). 
In NisB, where the glutamylation enzyme is covalently linked to the SpaB_C elimination domain, 
leader peptide binding occurs in the glutamylation domain (13, 25). To probe whether TbtB, which 
contains this binding domain, would accelerate catalysis by TbtD, TbtB was added to the 
cycloaddition reaction. Analysis of macrocycle formation suggested that TbtB afforded no rate 
enhancement (Figure 2.9). The same was observed upon addition of TbtF, which also contains a 
leader peptide-binding domain (11). Thus it appears that TbtD independently engages the leader 
peptide by a different strategy that will be discussed in Chapter 4. 
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Figure 2.9 TbtD activity is not enhanced by known leader peptide-binding Tbt proteins. Addition of TbtB or TbtF did 
not increase the rate of macrocycle formation by TbtD as monitored by UV-Vis spectroscopy at 315 nm (owing to the 
generation of the tri-thiazole-substituted pyridine). Both TbtB and TbtF contain RiPP leader peptide Recognition 
Elements (RREs) while TbtD does not appear to, despite its activity being leader peptide-dependent (Figure 2.7).  
 
To obtain the quantities of 4 required for structure confirmation, the entire in vitro process 
was optimized and scaled up using MBP-TbtA as the starting material by Graham Hudson. The 
molecular formula of 4 was deduced by HR-ESI-MS, and its structure was confirmed by Dr. 
Jonathan Tietz using NMR spectroscopy. The overall chemical shift values were highly consistent 
with those of the closely-related thiomuracin series reported by Morris et al (3). Correlations 
obtained via 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC, and 1H-13C HMBC 
experiments (Figure 2.10) allowed assignment of all 1H and 13C resonances in the molecule, with 
the exception of the carboxylic acid proton, which was not observed.  
To assess the bioactivity of 4, Graham Hudson determined the minimal inhibitory 
concentration (MIC) towards a panel of Gram-positive, Gram-negative, and fungal species by 
microbroth dilution (Table 2.1). While 4 was inactive against the tested Gram-negative bacteria 
and fungi, growth inhibition was found for all Gram-positive bacteria in the panel. The most potent 
activity was toward vancomycin-resistant Enterococcus faecium U503 (VRE), followed by 
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methicillin-resistant Staphylococcus aureus USA300 (MRSA). Despite lacking other 
posttranslational modifications including C-methylation of thiazole, beta-hydroxylation of Phe, 
and oxidation/cyclization of Ile, the bioactivity of 4 is on par with fully modified thiomuracin A, 
which has MICs of 0.25 μg/mL and 0.5 μg/mL against VRE and MRSA, respectively (3, 26). We 
termed the structure of 4 thiomuracin GZ. 
 
 
Figure 2.10 NMR correlations used to assign the structure of 4. Data collected and figure made by Dr. Jonathan Tietz. 
 
Table 2.1 Bioactivity of thiomuracin GZ. a. MIC, minimum inhibitory concentration. Data collected and table made 
by Graham Hudson. 
Organism MICa (μg/mL) MICa (μM) 
Staphylococcus aureus USA300 0.25 0.18 
Enterococcus faecium U503 0.063 0.046 
Bacillus anthracis str. Sterne 2 1.5 
Escherichia coli MC4100 >64 >47 
Pseudomonas aeruginosa PA01 >64 >47 
Mycobacterium smegmatis B-14616 >64 >47 
Aspergillus niger >128 >94 
Saccharomyces cerevisiae >128 >94 





Figure 2.11 PbtD accepts 3 as a substrate. (A) The amino acid composition of His6-TbtA is shown. In peptide 3 the 
residues shown in blue are thiazoles and in green are dehydroalanines. In the top spectrum, 3 is not visible owing to 
the mass window shown. Reaction of 3 with PbtD (homolog of TbtD from the GE2270A biosynthetic gene cluster) 
shows the formation of m/z 1366 Da (compare to Figure 2.3E) and the corresponding sodium adduct. (B) The aligned 
amino acid sequences of the thiomuracin GZ and GE2270A precursor peptides, labeled TbtA and PbtA, respectively. 
(C) Structural comparison between thiomuracin GZ and GE2270A. While structurally related, there exist key 
differences in amino acid composition and post-translational modifications. 
 
GE2270A has a similar macrocyclic structure to thiomuracin (Figure 2.11), differing in 
three of the four amino acids that are present in the macrocycle (3). We therefore wondered 
whether the TbtD ortholog in the GE2270A biosynthetic gene cluster (PbtD) would also be able 
to catalyze the non-cognate [4+2] cycloaddition of 3. Reaction of PbtD with 3 indeed resulted in 
the clean formation of 4 with concomitant elimination of the leader peptide (Figure 2.11). This 
observation is promising with respect to thiopeptide engineering for structure-activity relationship 
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efforts, because it illustrates that the [4+2] enzyme is tolerant of substantial changes in the amino 
acid sequence of the macrocycle (Phe, Tyr, Ile in thiomuracin are Val, Gly, Phe in GE2270A, 
respectively). 
 
2.2.2 Heterologous expression of thiomuracin in E. coli 
After the successful in vitro reconstitution of the activities of six proteins that together 
biosynthesize the core structure of thiomuracin, I further went on to build an E. coli heterologous 
producing system using the knowledge obtained from the in vitro study to lay the basis for the 
potential production of a library of thiopeptide analogues (Figure 2.12). 
 
 


























A plasmid compatible with the T7 expression system in E. coli was designed using the 
pTrc99a vector backbone. Based on our observation that the cyclodehydration reactions precede 
the formation of Dha residues, I first cloned the genes encoding the TbtF, TbtG, and TbtE proteins 
essential for thiazole installation into the plasmid. Both TbtF and TbtG were cloned as N-terminal 
MBP fusion proteins, because this should help solve any expression and solubility issues of the 
modification enzymes while retaining their activity, as our work demonstrated that MBP-tagged 
TbtF, TbtG, and TbtE can be purified in high yield from E. coli without losing their in vitro 
catalytic ability. The precursor peptide gene tbtA was cloned with an N-terminal His6-tag. The 
expression of the three modification enzymes was under the control of an IPTG inducible Trc 
promoter, whose transcription intensity is five times weaker than that of the T7 promoter, while 
the precursor peptide gene was cloned under control of a T7 promoter. This design was based on 
the potent activity of the enzymes involved in thiazole formation, and suppressing the transcription 
of these modification enzymes while increasing the transcription efficiency of the precursor 
peptide would result in higher yield of the product. To test the formation of six thiazoles in TbtA, 
a heterologous expression experiment was performed with the newly constructed 
pTrc99a_TbtF,G,E_TbtA plasmid in E. coli. A product consistent with six thiazoles installed onto 
the TbtA precursor peptide was observed by MALDI-TOF MS analysis after immobilized metal 




Figure 2.13 MALDI-TOF-MS analysis of (A) purified His6-TbtA, (B) product from the expression of the plasmid 
pTrc99a_TbtF,G,E_TbtA, and (C) the purified co-expression product of both pTrc99a_TbtF,G,E_TbtA and 
pTrc33_TbtB,C_T.b-GluRS,tRNA in E. coli. 
 
To introduce the lanthipeptide dehydratases responsible for the formation of the four Dha 
into the system, another plasmid compatible with the T7 expression system in E. coli was designed 
using the pTrc33 vector backbone. Similar to the cyclodehydratase and dehydrogenase, the genes 
for the split lanthipeptide dehydratase TbtB and TbtC were also cloned under the control of a Trc 
promoter. Since the in vitro studies of TbtB have clearly shown that E. coli tRNAGlu is not 
accepted, the gene for the tRNAGlu (CUC) from the thiomuracin native producer T. bispora was 
introduced into the system to ensure enzymatic activity. Each gene encoding a tRNA copy was 
flanked with a T7 promoter at the 5’ end and an rrnC terminator sequence at the 3’end. To ensure 
that sufficient level of T. bispora glutamyl-tRNAGlu was available during the co-expression 
experiment, the gene for the T. bispora GluRS was also cloned into the plasmid (27). To test the 
dehydration efficiency of this system, a heterologous expression experiment was performed with 
both the pTrc99a_TbtF,G,E_TbtA and pTrc33_TbtB,C_T.b-GluRS,tRNA plasmids in E. coli. As 
shown by MALDI-TOF-MS analysis after IMAC, only a very small amount of the four-fold 
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dehydrated species could be detected, with the major product carrying two dehydrations and a 
glutathione (GSH) addition (Figure 2.13C). The major product was analyzed by HR-ESI-MS/MS, 
and the GSH was found attached to the dehydrated Ser14 residue (Figure 2.14). I reasoned that 
the GSH addition may hamper the downstream dehydration reaction, thus resulting in incomplete 
dehydration. However, attempts to use the E. coli SHuffle strain, which overexpresses a disulfide 




Figure 2.14 HR-ESI-MS/MS analysis of the GluC-digested GSH-added di-dehydrated TbtA hexazole. Tandem MS 
of the ion of m/z 1971 Da gives a fragmentation pattern consistent with GSH addition at the Ser14 position. 
 
In vitro assays with different concentrations of GSH indicated that, even with up to 50 mM 
of GSH in the reaction, no significant inhibition of the dehydration reaction was detected. The 
GSH was found to add to the dehydrated product only after all the dehydration steps had finished 
(Figure 2.15). These data suggest that the incomplete dehydration during E. coli heterologous 
expression may result from the poor activity of the dehydratases, which could result from a low 
effective concentration of T. bispora glutamyl-tRNAGlu in the E. coli cytoplasm. 
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Finally, we probed whether the E. coli heterologous expression was able to produce the 
thiomuracin macrocycle or not. The gene for the [4+2] aza-cycloaddition enzyme TbtD was cloned 
into a pET28b vector backbone that is compatible with the other two plasmids. After co-expressing 
all three plasmids in E. coli, the thiomuracin macrocycle was successfully produced, as shown by 
UPLC-HR-ESI-MS after purification of the peptide from the cell pellet (Figure 2.16). However, 
the yield was very low, possibly because the E. coli we used for thiomuracin production was not a 
resistant strain. We also detected a very small amount of thiomuracin from the growth media. 
Many problems still remain to be solved for the construction of an effective heterologous 
expression system, such as optimization of this system to overcome the GSH addition issue to push 
the dehydration reaction to completion.  
 
 
Figure 2.15 MALDI-TOF-MS analysis of TbtB/C dehydration reaction in the absence (A) and in the presence of 10 




Figure 2.16 HR-ESI-MS analysis of the product formed by co-expression of pTrc99a_TbtF,G,E_TbtA, 
pTrc33_TbtB,C_T.b-GluRS,tRNA and pET28b_TbtD in E. coli. 
 
Table 2.2 Plasmids constructed in this chapter. 
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2.3 Experimental methods 
General materials and methods  
Reagents used for molecular biology experiments were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Escherichia coli DH5α and BL21 (DE3) strains were used for plasmid maintenance and protein 
overexpression, respectively. Thermobispora bispora DSM 43833 was obtained from DSMZ 
(Braunschweig, Germany). Planobispora rosea ATCC53733 was obtained from the USDA 
Agricultural Research Service (ARS) Culture Collection. Plasmid inserts were sequenced at 
ACGT Inc. (Wheeling, IL). MALDI-TOF-MS analysis was performed using a Bruker 
UltrafleXtreme MALDI TOF-TOF mass spectrometer (Bruker Daltonics) in reflector positive 
mode at the University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. 
ESI-MS/MS analyses were performed using a SYNAPT ESI quadrupole TOF Mass Spectrometry 
System (Waters) equipped with an ACQUITY Ultra Performance Liquid Chromatography 
(UPLC) system (Waters). Kinetic assays were performed using a Varian Cary 4000 UV-Vis 
spectrophotometer. HiTrap columns for Ni-NTA affinity chromatography were purchased from 
GE Healthcare.  
 
Molecular biology techniques  
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). 
Primers for E. coli tRNAGlu were designed and the dsDNA template for in vitro transcription was 
prepared as previously described (28). Thermobispora bispora was identified as a potential 
producer of a thiomuracin-like thiopeptide using BLAST to identify homologs of genes from the 
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relevant biosynthetic gene cluster of thiomuracin producer Nonomurea sp. Bp3714-39 (3). Genes 
optimized for recombinant expression in Escherichia coli were synthesized by GenScript 
(Piscataway, NJ) in pUC57 (kanamycin, Kan) vectors with BamHI and XhoI sites flanking each 
gene at the 5′ and 3′ ends (Table 2.4), respectively. E. coli DH5α were transformed with pUC57-
Kan vectors containing each gene for replication and subsequent isolation using a QIAprep Spin 
Miniprep Kit (Qiagen). The isolated DNA was then treated with BamHI-HF and XhoI-HF (New 
England Biolabs). The digested genes were separated on a 1% (w/v) agarose gel, purified using a 
QIAQuick gel extraction kit (Qiagen), and ligated into an appropriately endonuclease-digested and 
gel-purified pET28a vectors using T4 DNA ligase (NEB). Ligation reactions were used to 
transform chemically competent DH5α cells, which were plated on Luria-Bertani (LB) agar plates 
containing 50 μg/mL kanamycin and grown at 37 °C. Colonies were picked at random and grown 
in LB broth for 16–20 h prior to plasmid isolation using a QIAprep Spin Miniprep Kit. For TbtA 
and TbtD, the vector encoded a tobacco etch virus (TEV) cleavable, N-terminal maltose binding 
protein (MBP) affinity tag, while TbtE, TbtF, and TbtG constructs did not encode a TEV 
proteolysis site. All recombinant constructs featuring an MBP-tag were sequenced using a custom 
MBP forward primer, whereas constructs encoding His6-tagged proteins were sequenced using the 
T7 forward primer. All constructs were reverse-sequenced using a T7 reverse primer as well as an 
internal primer if necessary (Table 2.3). 
The gene encoding PbtD (TbtD ortholog) from Planobispora rosea ATCC 23866 was 
amplified from genomic DNA using the primers listed in Table 2.3. The resulting DNA was 
purified using a QIAprep Spin Miniprep Kit. The purified DNA was then digested using BamHI-
HF and XhoI-HF before being ligated into an appropriately digested pET28b vector encoding an 
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N-terminal MBP tag featuring a TEV proteolysis site. The resulting construct was then used to 
transform E. coli, propagated, and sequenced as described above (notebook reference 6/5/2014).  
The tbtA gene was cloned into pRSFDuet-1 with an N-terminal His6-tag following standard 
cloning procedures. In addition, the GlySerSer residues preceding the His6 tag were mutated to a 
single Pro to suppress gluconoylation (29). The PCR product was purified by gel extraction on a 
1% (w/v) agarose gel using the QIAquick Gel Extraction Kit (Qiagen). The vector pRSFDuet-1 
was digested using BamHI-HF and HindIII-HF (NEB) restriction endonucleases and purified by 
gel extraction as described above. Insertion of the DNA fragment was achieved by Gibson one-
step isothermal DNA assembly as previously described (30). An aliquot (20 μL) of the Gibson 
assembly reaction was used to transform E. coli DH5 cells using the heat shock method. The 
cells were plated on LB plates supplemented with kanamycin (50 μg/mL) and single colonies were 
grown at 37 °C for 12–15 h. The plasmid His6-TbtA-pRSFDuet-1 was isolated using a QIA Spin 
Miniprep Kit. Insert integrity was verified by sequencing the plasmids with the appropriate primers 
(Table 2.3) (notebook reference 11/26/2014). 
The gene coding for the dehydratase TbtB was cloned into pET28a encoding an N-terminal 
His6-tag. The tbtB gene was amplified by PCR, and purified by gel extraction from a 1% (w/v) 
agarose gel using the QIAquick Gel Extraction Kit. The vector pET28a and the tbtB PCR fragment 
were digested using BamHI-HF and XhoI-HF (NEB) restriction endonucleases, and purified by 
gel extraction as described above. The DNA fragment was inserted by Gibson one-step isothermal 
DNA assembly, and an aliquot of 20 μL of the Gibson assembly reaction was used to transform E. 
coli DH5α cells using the heat shock method. The cells were plated on LB plates supplemented 
with kanamycin (50 µg/mL) and the plates were incubated at 37 °C for 12–15 h. Single colonies 
were picked and grown in LB supplemented with kanamycin (50 µg/mL) at 37 °C for 12–15 h and 
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the plasmid His6-TbtB-pET28a was isolated using a QIA prep Spin Miniprep Kit. Insert integrity 
was verified by sequencing the plasmids with the appropriate primers (Table 2.3). All the other 
genes and their corresponding His6-tagged proteins were cloned using the same procedures 
(notebook reference 11/26/2014).  
 
Expression, and purification of His6-TbtA 1 
E. coli BL21 (DE3) cells (50 μL) were electroporated with His6-TbtA-pRSFDuet-1 (50 ng), 
plated on LB agar plates supplemented with kanamycin (as above) and grown at 37 °C for 12–15 
h. A single colony was used to inoculate 60 mL of LB broth supplemented with kanamycin, grown 
for 12–15 h at 37 °C, and the culture was used to inoculate 6 L of LB media, supplemented with 
kanamycin, to an OD600 of 0.025. Cultures were grown at 37 °C to an OD600 of 1.0. Peptide 
expression was induced by the addition of IPTG to a final concentration of 1 mM and cultures 
were grown at 37 °C for 3 h. Peptide purification was performed following a previously described 
method (31) (notebook reference 12/2/2014). 
 
Expression, and purification of His6-TbtB  
E. coli BL21 (DE3) cells (50 μL) were electroporated with His6-TbtB-pET28a (50 ng), and 
cells were plated on LB agar plates supplemented with kanamycin and grown at 37 °C for 12–15 
h. A single colony was used to inoculate 20 mL of LB broth supplemented with kanamycin, grown 
for 12–15 h at 37 °C, and the culture was used to inoculate 2 L of TB media, supplemented with 
kanamycin, to an OD600 of 0.025. Cultures were grown at 37 °C to a final OD600 of 0.6–0.8. Protein 
overexpression was induced by the addition of IPTG to a final concentration of 0.2 mM, and 
cultures were grown at 18 °C for 18 h. Protein purification was performed following a similar 
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protocol as described before (12). All other His6-tagged proteins were purified using the same 
procedure (notebook reference 1/10/2015).  
 
In vitro transcription of T. bispora tRNAGlu (CUC)  
Primers for T. bispora tRNAGlu were designed according to a previously described method 
(28). The tRNAGlu dsDNA template was generated from two overlapping synthetic 
deoxyoligonucleotides (Table 2.3). To prepare the dsDNA template for in vitro transcription, 5′ 
overhangs were filled in using the following conditions: NEB Buffer 2 (1×), primers (4 μM each), 
dNTP (100 μM each), and DNA polymerase I large (Klenow) fragment (1 U μg–1 DNA) in a final 
volume of 50 μL. The reaction was incubated at 25 °C for 15 min, quenched with EDTA (10 mM) 
at 75 °C for 25 min, and dsDNA tRNAGlu template was precipitated with cold EtOH overnight. In 
vitro transcription was performed using a previously described method (32). The transcribed 
tRNAGlu was then purified by acidic phenol extraction using a previously described method (33) 
(notebook reference 2/15/2015). 
 
In vitro dehydration of 2 to produce 3 
The following reaction conditions were used for dehydration assays: HEPES pH 7.5 (100 
mM), MgCl2 (5 mM), KCl (150 mM), glutamate (10 mM), ATP (5 mM), TbtA hexazole (50 μM), 
T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), and thermostable 
inorganic pyrophosphatase (TIPP; 0.02 U μL–1) in a final volume of 25 μL. The reaction mixture 
was incubated at 30 °C for 3 h, centrifuged to remove insoluble material (14,000 × g, 5 min, 25 
°C), and desalted using C18 ZipTips (EMD Millipore). The sample was mixed in a 1:1 ratio with 
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2,5-dihydroxybenzoic acid matrix, spotted on a Bruker MALDI plate, and analyzed by MALDI-
TOF-MS (notebook reference 2/30/2015). 
 
Purification of 3 
The reaction mixtures to produce 3 were lyophilized, and the residue was extracted with a 
volume of 40% aq. MeCN equal to the volume used for the dehydration reaction. The insoluble 
material was removed by centrifugation at 10,000 × g for 10 min, and the supernatant was purified 
on a Shimadzu Prominence Preparative Liquid Chromatography system equipped with a 
Phenomenex Luna C18 column (250 × 10 mm, 10 μm particle size, 100 Å pore size). Acetonitrile 
and 10 mM aq. NH4HCO3 were used as the mobile phases, and a gradient of 2-80% aq. MeCN 
over 45 min at 1 mL/min was used for separation (notebook reference 3/18/2015).  
 
Purification of TbtA-hexazole-tetradehydrated core peptide 
HPLC-purified 3 was dissolved in 50 mM Tris-HCl (pH 7.5) to a final concentration of 
100 M. GluC endoproteinase (Worthington Biochemical Corporation) was added to a 
concentration of 0.02 mg/mL, and the reaction mixture was incubated at 37 °C for 1 h, followed 
by addition of MeCN to 50% (v/v) to precipitate proteins. The insoluble material was removed by 
centrifugation at 16,100 × g for 10 min, and the supernatant was purified on an Agilent 1260 
Infinity HPLC system with a Phenomenex Luna C18 column (250 × 4.6 mm, 10 μm particle size, 
100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were used as the mobile phases, and a 




In vitro production of 4  
Purified 2 was dissolved in DMSO to a concentration of 1 mM. The in vitro production of 
macrocycle was performed using: HEPES pH 7.5 (100 mM), MgCl2 (5 mM), KCl (150 mM), ATP 
(5 mM), 2 (100 μM), T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 
μM), MBP-TbtD (5 μM), and TIPP (0.02 U μL–1). The reaction mixture was allowed to proceed 
at 30 °C for 4 h (notebook reference 4/16/2015).  
 
UPLC-MS and MS/MS of ejected His6-TbtA leader  
HPLC-Purified ejected His6-TbtA leader after the macrocylization reaction was dissolved 
in water, and LC-MS/MS was performed using the same procedure as above. A gradient of 2–
100% aq. MeCN with 0.1% formic acid (v/v) over 20 min was used. A ramping of cone voltage 
of 16–19 kV during the scan was performed to generate peptide fragments for MS/MS analysis 
(notebook reference 4/22/2015).  
 
Kinetic assay to probe if TbtB/TbtF accelerate the macrocyclization reaction  
HPLC-purified 3 was dissolved to a concentration of 200 M in 50 mM Tris-HCl, 150 mM 
KCl, pH 7.5. Before starting the reaction, each enzyme and the substrate were incubated at 30 °C 
separately for 5 min. MBP-TbtF was pre-treated with thrombin in order to release the MBP tag. 
The reaction was performed with 150 μM of substrate 3, 5 μM of TbtD and either TbtB or 
thrombin-treated TbtF protein at 30 °C. Macrocycle formation was monitored by absorbance at 
315 nm. Time points were collected every 2 s and initial reaction rates were calculated (notebook 
reference 9/19/2015).  
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Construction of the thiomuracin E. coli heterologous expression system  
The genes coding for the MBP-tagged TbtF, MBP-tagged cyclodehydratase TbtG, 
dehydrogenase TbtE, dehydratases TbtB/C, T. bispora GluRS, T. bispora tRNAGlu, and [4+2] 
cyclase TbtD, were amplified by PCR using appropriate primers (Table 2.3), and purified by gel 
extraction from a 1% (w/v) agarose gel using the QIAquick Gel Extraction Kit. The vector pTrc99a 
was digested using NcoI-HF and SalI-HF (NEB) restriction endonucleases, while both the pTrc33 
and pET28b plasmids were linearized by digestion using BamHI-HF and HindIII-HF (NEB) 
restriction endonucleases. All three plasmids were purified by gel extraction as described above. 
The DNA fragment was inserted by Gibson one-step isothermal DNA assembly, and an aliquot of 
20 μL of the Gibson assembly reaction was used to transform E. coli DH5α cells using the heat 
shock method. The cells were plated on LB plates supplemented with ampicillin (100 μg/mL) for 
pTrc99a, chloramphenicol (25 μg/mL) for pTrc33 and kanamycin (50 μg/mL) for pET28b, and the 
plates were incubated at 37 °C for 12–15 h. Single colonies were picked and grown in LB 
supplemented with the corresponding antibiotics at 37 °C for 12–15 h and the plasmids were 
isolated using a QIA prep Spin Miniprep Kit. Insert integrity was verified by sequencing the 
plasmids with the appropriate primers (Table 2.3) (notebook reference 2/13/2015).  
 
Heterologous expression and purification of co-expression products 
E. coli BL21 (DE3) cells were co-transformed with the heterologous expression plasmids. 
Cells were grown for 16 h on LB agar plates containing corresponding antibiotics at 37 °C. Single 
colonies were used to inoculate LB and the cells were grown at 37 °C for 16 h. This culture was 
used for 1:100 inoculation into Terrific Broth (24 g/L yeast extract, 12 g/L tryptone, 0.4% glycerol 
(v/v), 17 mM KH2PO4, and 72 mM K2HPO4) and grown at 37 °C to an optical density at 600 nm 
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(OD600) of 0.6 before being placed on ice for 20 min. Production of the peptide of interest was then 
induced with the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The 
expression was allowed to proceed for 16-18 h at 18 °C. Cells were harvested by centrifugation at 
5,000 × g for 10 min. Cell pellets were resuspended in LanA start buffer (20 mM Na2HPO4, 150 
mM NaCl, 20% glycerol, pH 7.5). Cells were homogenized by sonication (50% amplitude, pulse 
on: 2.0 s, pulse off: 5.0 s, total pulse time: 5 min). Insoluble debris was removed by centrifugation 
at 13000 × g for 30 min and the supernatant was then applied to Ni resin pre-equilibrated with 
LanA start buffer. The column was washed with 20 column volumes (CV) of LanA washing buffer 
(20 mM Na2HPO4, 30 mM imidazole, 300 mM NaCl, pH 7.5). The peptides of interest were eluted 
with elute buffer (20 mM Na2HPO4, 500 mM imidazole, 100 mM NaCl, pH 7.5). Finally, the 
peptides in the elute buffer were desalted via C18 ZipTip (EMD Millipore) according to the 
manufacturer’s instructions, and was eluted using a saturated solution of sinapinic acid in 50% aq. 
MeCN. The final product was analyzed by MALDI-TOF MS (notebook reference 5/28/2015).  
 
Table 2.3 Oligonucleotide primers used in this study. All sequences are provided 5′ to 3′. F indicates a forward primer 
while R indicates the reverse. Lowercase m indicates 2′ O-methylation of the following residue; methylation 
suppresses random addition of bases at the end of the RNA by T7 RNA polymerase. 










tbtA Gibson F GCATCACCATCATCACCACAGCCAGATGGACCTGAATGATCTGCC 
tbtA Gibson R GACTTAAGCATTATGCGGCCGCATTAGGCGCTGCTGCAG 
tbtB Gibson F CTGGTGGACAGCAAATGGGTCGCGGAATGCGTCTGGTGGAAC 
tbtB Gibson R GTGGTGGTGCTCGAGTGCGGCCGCATTATTCACCCAGTTCAACCAG 
tbtC Gibson F CTGGTGGACAGCAAATGGGTCGCGGAATGACCCCGCACGAAG 
tbtC Gibson R GTGGTGGTGCTCGAGTGCGGCCGCATTAAACGGTCACTTCCGCTTC 




Table 2.3 (cont.) 
 
 
Primer Name Oligonucleotide Sequence 
E. coli gluRS 
Gibson R 
GTGGTGGTGCTCGAGTGCGGCCGCTTACTGCTGATTTTCGCG 
E. coli tRNA F AATTCCTGCAGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGACACC 













tbtG Internal GTGATACCCAAGGCGGTCT 
tbtF Internal TGCACATCACTTTATTCCGCA 







pbtD (BamHI) F AAGGATCCGTGACCTGGCGACGCTTTGAC 
pbtD (XhoI) R AACTCGAGTCACATGCCTCCTACGGCGATC 
MBP-TbtF F GAGCGGATAACAATTTCACACAGGAGACAGACCATGAAAATCGAAGAAGGTAAAC 








RBS TbtE F GTTTCCGTAATTAATAAGGAGATAATCCATGACCATTCCGCCGG 
RBS TbtE R CAGCCAAGCTTGCATGCCTGCAGGTCGACTTACGATTCTTCAACCGTG 
T7_TbtA_F GCTCCACGGTTGAAGAATCGTAAGGGATCTCGACGCTCTCC 





















Table 2.3 (cont.) 
 
 









Table 2.4 Sequence of tbt biosynthetic genes for optimal E. coli expression. All sequences are provided 5′ to 3′. 
Restriction sites for cloning are underlined (5′ BamHI, 3′ XhoI). These gene constructs were synthesized by GenScript 
(Piscataway, NJ, USA). 
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CHAPTER 3: CHARACTERIZATION OF ENZYMES INVOLVED IN THE 
BIOSYNTHESIS OF THE CORE SCAFFOLD OF THIOPEPTIDE THIOMURACINc 
 
3.1 Introduction 
As described in the previous chapter, thiopeptides are a structurally complex class of 
antibiotics that belong to the rapidly expanding group of ribosomally synthesized and post-
translationally modified peptides (RiPPs) (1). The in vitro reconstitution of the biosynthesis of 
thiomuracin GZ (4) (2), which only lacks the ancillary tailoring post-translational modifications 
found in naturally produced thiomuracins (3) has been discussed in Chapter 2. In summary, the 
inactive, linear precursor peptide TbtA (1) is converted into a nanomolar potency antibiotic by 
cyclodehydration by TbtF/G and dehydrogenation by TbtE of six Cys residues to the 
corresponding thiazoles (2). Subsequently, four alcohol groups are dehydrated in a process that 
involves glutamylation with Glu-tRNAGlu by TbtB, followed by Glu elimination by TbtC (3). 
Finally, two of the dehydrated residues react in a formal [4+2] cycloaddition catalyzed by TbtD, 
followed by elimination of water and the leader peptide (LP) to yield 4 (Figure 2.1A). After the 
successful reconstitution of the biosynthetic pathway of thiomuracin, we further characterized the 
molecular details underlying this well-orchestrated set of enzymatic reactions to provide insights 
into the substrate specificities, directionality, and timing of catalysis by the six proteins involved 
in thiomuracin formation.  
                                                 
c Parts of the chapter are reprinted with permission from: Zhang, Z., Hudson, G. A., Mahanta, N., Tietz, J. I., van der Donk, W. A., & Mitchell, D. 
A. (2016). Biosynthetic Timing and Substrate Specificity for the Thiopeptide Thiomuracin. J. Am. Chem. Soc., 138, 15511-15514. Copyright © 
2016 American Chemical Society. https://pubs.acs.org/doi/abs/10.1021/jacs.6b08987 
Parts of the chapter are reprinted with permission from: Cogan, D. P., Hudson, G. A., Zhang, Z., Pogorelov, T. V., van der Donk, W. A., Mitchell, 
D. A., & Nair, S. K. (2017). Structural insights into enzymatic [4+2] aza-cycloaddition in thiopeptide antibiotic biosynthesis. Proc. Natl. Acad. Sci. 
U. S. A., 114, 12928-12933. http://www.pnas.org/content/114/49/12928 
Crystallographic studies of TbtD and PbtD were performed by Dillon P. Cogan and Prof. Satish. K. Nair. 
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The thiopeptide gene clusters are endowed with a unique enzyme that illustrates nature’s 
amazing ability to perform complex chemical transformations: a long-hypothesized unusual [4+2] 
cyclase that catalyzes the formation of the central pyridine. Enzymatic [4+2] cycloadditions are 
relatively rare and therefore of great interest. While other enzymes have been identified as [4+2] 
cycloaddition catalysts, they frequently serve only to enhance a reaction that can occur 
spontaneously and/or favor product stereochemistry via conformational restriction of the reactant 
(4). In contrast, the reaction catalyzed by the thiopeptide pyridine synthase is not spontaneous and 
synthetically equivalent reactions require either prolonged incubation (~1 week) at high 
temperatures, or microwave irradiation for non-enzymatic catalysis (5). The thiopeptide-forming 
pyridine synthases are dedicated [4+2] cycloaddition catalysts whose function is to catalyze the 
cyclization of two Dha residues within the precursor peptide (6, 7). Notably, pyridine synthases 
catalyze the unique formation of an aza-cyclic product, in contrast to the carbocyclic and 
dihydropyran products formed in other biosynthetic pathways, such as those for spinosyn A (8, 9), 
pyrroindomycins (10), trans-decalin containing polyketides (11), and leporin B (12). In addition 
to a detailed characterization of the reaction catalyzed by TbtB/C, this chapter will also discuss a 
detailed structural and mechanistic analysis of two of such pyridine synthases involved in 
thiomuracin and GE2270 biosynthesis. 
 
3.2 Results and discussion 
3.2.1 Characterization of enzymes involved in thiomuracin thiazole formation 
We first focused on the substrate permissiveness of the TbtE/F/G thiazole synthetase. A 
series of TbtA variants were prepared by Graham Hudson in which each Cys residue was 
systematically substituted with Ala starting from either the C- or N-terminus. He found that all 
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Ala-substituted TbtA variants were converted to the pan-thiazole species with incompletely 
processed peptides typically not observed. When six additional variants of TbtA were prepared 
that each contained a single Cys at the wild-type locations, TbtE/F/G still processed each variant 
to the expected monoazole, indicating that the installation of each thiazole is independent of the 
presence of other thiazoles (6). Graham next investigated the order of thiazole formation. Through 
high resolution electrospray ionization (HR-ESI) MS/MS analysis of the iodoacetamide trapped 
intermediates of the TbtE/F/G reaction, he revealed a non-linear processing order: Thz4 -> Thz2 -
> Thz12, with the remaining three thiazoles processively introduced under the reaction condition 
(6).  
With the ability to process many variants of the TbtA core peptide, we reasoned that 
TbtE/F/G relied heavily on the LP to drive substrate binding. Indeed, previous studies on other 
RiPPs containing thiazole and oxazole heterocycles have shown that the LP is important and that 
it is bound by a specific RiPP recognition element (RRE) that exhibits homology to PqqD (13-16). 
For thiomuracin biosynthesis, PqqD-like domains are clearly present in the TbtF protein (Figure 
2.1B), and previous studies have shown that TbtF strongly binds the TbtA LP (Kd ~70 nM) (13). 
However, the region(s) of the LP that are specifically recognized were not known. To elucidate 
which parts of the LP are important for TbtF binding, Graham generated a panel of TbtA variants 
and performed competition fluorescence polarization (FP) assays with a synthetic TbtA LP 
derivatized with fluorescein isothiocyanate (FITC) at the N-terminus (FITC-TbtALP) to determine 
relative IC50 values. This experiment revealed a set of residues important for TbtF binding 
(Leu−29, Asp−26, Phe−24). Interestingly, many thiopeptide LPs are rich in Asp/Glu (17-19); we 
hypothesize that TbtF will display a binding site to electrostatically complement a polyanionic LP 
with a hydrophobic pocket to accommodate LP position −29. Graham also found that the N-
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terminal portion of the TbtA LP was bound by TbtF with near wild-type affinity while the C-
terminal half showed no binding. Additionally, the RRE of TbtF (residues 1-85) retained most of 
the binding affinity (Kd ~100 nM), whereas the TbtF protein lacking the RRE (residues 86-628) 
did not show detectable interaction with FITC-TbtALP (6). 
 
3.2.2 Characterization of enzymes involved in dehydroalanine formation 
I next evaluated the TbtB/C-catalyzed dehydration reaction (Figure 2.1A). Dehydration is 
a two-step process in which TbtB first glutamylates a targeted Ser hydroxyl of TbtA; subsequently, 
TbtC eliminates the glutamate to yield the alkene. As discussed in Chapter 2, we showed that 
dehydrations take place at positions 1/11/13/14 of the hexazole 2 (2). To determine if a thiazoline-
bearing TbtA would be accepted as a TbtB/C substrate, the dehydrogenase component (TbtE) of 
the thiazole synthetase was omitted from reactions with TbtA. These reactions cleanly produced 
the expected hexazoline of TbtA, which upon reaction with TbtB/C, resulted in at most two 
dehydrations (Figure 3.1). These data show that although TbtF/G do not require TbtE for activity, 
the hexazoline-containing TbtA is incompletely processed by TbtB/C.  
I next used the TbtA hexazole 2 as substrate for TbtB in the absence of TbtC, which 
primarily resulted in one glutamylation event (2). Analysis by ESI MS/MS localized the glutamate 
to Ser14 (Figure 3.2). Similarly, assays that included both TbtB and TbtC that were quenched 
prior to full tetra-dehydration showed that Ser13/14 were dehydrated significantly faster than 
Ser1/11 (Figure 3.3). Thus, TbtB/C prefer to modify the two isolated Ser residues over those 
adjacent to a thiazole where the Ser carbonyl group has been removed (Figure 2.1A). 
Alternatively, the dehydration of Ser1/11 sets up the [4+2] cycloaddition reaction, which we 
previously showed to be very efficient (2). TbtB may have evolved an increased level of substrate 
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TbtA: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA (1) 
Figure 3.1 Hexa-thiazoline TbtA is incompletely processed by TbtB/C. MALDI-TOF mass spectra of (A) TEV-
treated MBP-TbtA precursor peptide 1, (B) TbtA cyclodehydrated by TbtF/G to yield a hexa-thiazoline species 
(indicated on the primary sequence in brown), and (C) the hexa-thiazoline treated with TbtB/C to yield predominately 
a di-dehydrated species indicating the hexa-thiazoline version of TbtA is not a competent biosynthetic intermediate. 
 
 
Figure 3.2 MS/MS of mono-glutamylated 2. The b15 ion localizes glutamylation to either Ser13/14. The low intensity 




Figure 3.3 ESI-MS/MS analysis of dehydration intermediates of the TbtA hexazole. (A) Analysis of the tandem MS 
data for the mono-dehydrated, TbtA hexa-thiazole reveals that Ser14 is the first position to undergo dehydration by 
TbtB/C. (B) Analogous analysis of the di-dehydrated hexa-thiazole shows that Ser13 is the second residue to be 
processed by TbtB/C. 
 
I then focused on the glutamate elimination reaction. TbtC is homologous to the C-terminal 
domain of LanB proteins, which exhibit reduced activity upon mutation of a conserved Arg (20). 
Therefore, I replaced this residue in TbtC with Ala (R58A) and carried out in vitro reactions with 
2. Mass spectral analysis showed a tri-dehydrated and mono-glutamylated intermediate, with the 
latter localized to position 1 (Figure 3.4). Thus, Ser1 is acted on last, and glutamylation (and hence 





Figure 3.4 MS analysis of mono-glutamylated and tri-dehydrated intermediate. MS analysis of reactions of 2 with 
TbtB and TbtC R58A showed an intermediate carrying three dehydrations and one glutamylation, with the latter 
localized to position Ser1. (A) MALDI-TOF MS of 2 treated with TbtB and TbtC-R58A. Replacement of R58 in 
homologous dehydratases decreases catalytic efficiency (20). (B) ESI tandem MS and structure of the tri-dehydrated 
and mono-glutamylated TbtA hexazole. 
 
These enzymatic preferences do not inform on whether earlier dehydrations are important 
for subsequent ones. Therefore, a series of TbtA variants were prepared and investigated. 
Hexazole-bearing TbtA-S13A and -S14A each were dehydrated predominantly twice by TbtB/C, 
with Ser1/11 largely escaping dehydration (Figure 3.5-3.6). This observation suggests that 
dehydration at Ser1/11 is strongly promoted by prior dehydration at Ser13/14. In contrast, similarly 
treated hexazole-bearing TbtA-S1A and -S11A peptides each resulted in a tri-dehydrated product, 
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underscoring that dehydration at Ser1/11 is not important for TbtB/C to process Ser13/S14 (Figure 
3.7). Taken together, these data are consistent with C-to-N terminal dehydration. 
 
 
His6-TbtA S13A: PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCASA 
His6-TbtA S14A: PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSAA 
Figure 3.5 Ser13 and Ser14 are important for dehydration at Ser1/11. (A) MALDI-TOF-MS spectrum of the TbtA 
hexazole with replacement of Ser13 with Ala (indicated with red in the primary sequence). (B) Treatment of TbtA 
hexazole S13A with TbtB/C resulted only in di-dehydration instead of tri-dehydration. (C) MALDI-TOF-MS 
spectrum of TbtA hexazole with replacement of Ser14 with Ala. (D) Treatment of TbtA hexazole S14A with TbtB/C 
also resulted in incomplete dehydration. 
 
For thiomuracin biosynthesis, PqqD-like domains are also clearly present in the TbtB 
protein (Figure 2.1B). Thus, the binding to MBP-tagged TbtB was evaluated using FITC-TbtALP. 
Despite having a domain homologous to PqqD, TbtB only weakly bound the LP (Kd ~20 µM, 
Figure 3.8). Given the comparatively weak interaction between TbtALP and TbtB (~100-fold 
weaker than TbtF), I next investigated whether TbtB/C might act in a LP independent fashion. 
Peptide 2 was digested with endo-proteinase GluC, providing a hexazole core peptide that retains 
only three residues of the LP (Figure 2.1) (2). Upon treatment with TbtB/C, this peptide was tetra-
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dehydrated (Figure 3.9). The observed activity on the truncated peptide is in accordance with the 
abovementioned weak binding to TbtALP (Kd ~20 µM). 
 
 
Figure 3.6 ESI-MS/MS analysis of di-dehydrated intermediate of (A) TbtA S13A hexazole and (B) TbtA S14A 
hexazole. The fragment ions show that Ser11 escapes dehydration when Ser13 or Ser14 are mutated. 
 
Strikingly, the affinity of TbtB towards FITC-labeled 2 was nearly three orders of 
magnitude tighter (Kd ~30 nM, Figure 3.8). GluC-digested 2 also effectively competed for TbtB 
binding to FITC-labeled 2. These data demonstrate that the PqqD-like domain of TbtB is a non-
functioning, vestigial RRE, and that TbtB recognizes a specific conformation of the core peptide 
of TbtA induced by the posttranslational modifications. Ungapped sequence conservation analysis 
by Graham Hudson confirmed that the defunct RRE of TbtB does not contain conserved motifs, 
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whereas the RRE of TbtF contains several, including locations known to physically contact the LP 
(Figures 3.10) (13, 14, 20, 21).  
 
 
His6-TbtA S1A:   PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*ACNCFCYICCSCSSA 
His6-TbtA S11A: PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICCACSSA 
Figure 3.7 Ser1 and Ser11 are dispensable for dehydration at Ser13/14. (A) MALDI-TOF-MS spectrum of TbtA 
hexazole S1A (indicated in red in the primary sequence). (B) Upon treatment with TbtB/C, the TbtA hexazole S1A is 
tri-dehydrated. (C) MALDI-TOF-MS spectrum of TbtA hexazole S11A. (D) Upon TbtB/C treatment, TbtA hexazole 
S11A also undergoes tri-dehydration. These results stand in stark contrast to a parallel experiment with mutants of 
Ser13 and Ser 14 (Figure 3.6). 
 
The molecular details of the post-translational modifications that confer TbtB/C activity 
were next investigated using the aforementioned panel of TbtA variants that systematically 
replaced Cys with Ala starting from the C- or N-terminus. Each pan-thiazole version of these TbtA 
variants was tested as a substrate for TbtB/C. Substituting Cys2 and Cys4 with Ala, yielding the 
corresponding pentazole and tetrazole species, did not greatly affect dehydration at Ser13/14; 
however, dehydration at Ser11, and especially Ser1, was reduced (Figures 3.11A,B and 3.12). 
Triple replacement of Cys with Ala at positions 2/4/6 (triazole species) abolished dehydration at 





Figure 3.8 Fluorescence polarization analysis of TbtB binding to the TbtA leader peptide, hexazole, and core peptide. 
TbtB shows considerably greater affinity for the hexazole-containing core peptide of TbtA than the leader peptide. 
(A) FP binding experiments performed using N-terminal FITC-labeled TbtA leader peptide and MBP-TbtB. (B) FP 
binding experiments performed using N-terminal FITC-labeled TbtA hexazole (2) and MBP-TbtB (thiazole 
installation increases affinity by 630 fold). (C) FITC-labeled (2) displacement from MBP-TbtB by the hexazole-
containing core peptide of TbtA (GluC digestion retains 3 residues of leader peptide). Error bars represent s.d. (n=3). 
 
 






Figure 3.10 Sequence motif analysis of TbtB homologs. (A) Diagram of TbtB (part of the split LanB dehydratase) 
with sites of conserved sequence motifs indicated in dark grey. Frequencies of sequence motifs within TbtB homologs 
are indicated. The region of PqqD homology (RRE, RiPP recognition element) as described by Burkhart et al (13) is 
indicated in light grey. Note that the RRE of TbtB does not contain any conserved motifs, which is strikingly opposite 
to that found for TbtF. (B) Sequence of TbtB with motif locations highlighted in yellow. Residues in bold indicate 




Figure 3.11 MALDI-TOF mass spectra of TbtB/C treatment of (A) TbtA C2A pentazole, (B) TbtA C2A/C4A 
tetrazole, (C) TbtA C2A/C4A/C6A triazole, (D) TbtA C2A/C4A/C6A/C9A diazole, (E) TbtA 
C2A/C4A/C6A/C9A/C10A monoazole, and (F) TbtA C12A pentazole. 
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Figure 3.12 ESI-MS/MS analysis of tri-dehydrated TbtA C2A/C4A tetrazole and di-dehydrated C12A pentazole. (A) 
The data show that substituting Cys2 and Cys4 with Ala dramatically reduces dehydration especially at Ser1, but not 
at Ser13/14. (B) Substitution of Cys12 with Ala results only in di-dehydration at Ser13/Ser14. 
 
A similar trend was observed for tetra- and penta-substituted TbtA variants (diazole and 
monoazole species, respectively, Figures 3.11D-E, and 3.13). This suggests that a thiazole at 
position 12 might be the gatekeeper modification that turns TbtA into a substrate for TbtB. 
However, the TbtA-C12A pentazole was still dehydrated twice at Ser13/14 (Figures 3.11F and 
3.12). Conversely, replacement of both Cys10/12 with Ala (tetrazole species) abolished processing 
by TbtB/C and the Cys10 TbtA monoazole was also not a substrate (Figure 3.14 and 3.15). Hence, 
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the thiazole at Cys12 is the gatekeeper modification to elicit TbtB/C activity, although TbtB/C 
recognize their substrate with a more complicated mechanism. 
 
 
Figure 3.13 ESI-MS/MS analysis of (A) di-dehydrated TbtA C2A/C4A/C6A triazole and (B) di-dehydrated TbtA 





TbtA C10A/C12A: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNCFCYICASASSA  
Figure 3.14 TbtB/C requires thiazole formation at Cys10 and Cys12. (A) MALDI-TOF MS spectrum of TbtA with 
Cys10 and Cys12 both replaced with Ala (indicated in red in the primary sequence). (B) Reaction of TbtA C10A/C12A 
with TbtE/F/G results in the nearly complete production of the expected tetrazole species. (C) Reaction of the TbtA 
C10A/C12A tetrazole with TbtB/C does not result in observable dehydration. 
 
 
Single Cys TbtA C10: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SANAFAYIACSASSA  
Figure 3.15 TbtB/C cannot dehydrate Cys10 monoazole. (A) MALDI-TOF MS spectrum of TbtA bearing only one 
Cys at residue 10. (B) Reaction of single Cys TbtA (Cys10) with TbtE/F/G results in complete conversion to the 





3.2.3 Biochemical and structural characterization of the [4+2]-aza-cycloaddition enzyme in 
thiopeptide biosynthesis 
To characterize the [4+2] cyclase TbtD, we first investigated the importance of conserved 
residues within the [4+2] cycloaddition clade of the SpaB_C superfamily. A multiple sequence 
alignment was generated, and twenty-three residues were replaced with alanine by Graham 
Hudson (Figure 3.16). I then tested the activity of these mutant enzymes qualitatively by an 
endpoint MALDI-TOF-MS assay, and seven of them (W47, E105, H191, H290, S287, R332A and 
Y319A) were identified to be diminished in activity. The relative activities of these mutants are 
provided in Table 3.1. 
 
TbtD               MMAAGERWWRFRVDYHAGPM-DDLILDGVRPAFAAFAAQAPMAYFLRHWRRGPHLRIYVS 
gi:242129450       -----MTWTRLRVDYHDGPM-DDLILDALRPAWHEI-----RGYFLRHWVCGPHLRIFVD 
gi:552968830       -----MTWRRFDVAYHDPDL-DRLILAA-RPLLS---ESPGRSWFQRHWVRGPHLELWFD 
gi:749676247       -----MEWHSLHVVYYANDK-DRLLLEGVRPLLRRLAPEVAATSFTRHWRLGPHVRIHVK 
gi:657940957       MSGAAATWHSIHVHHHDESTEPALVLHAVRPAFEAVRASVDGAWFGRHWLRGPHLRLNFR 
gi:242129434       -----MSWRRVDVAYHDPDL-DGLILAT-RPLLA---GTPGRGWFQRHWVRGPHLELWFD 
                          *  . * ::       *:*   **             * ***  ***:.: . 
 
TbtD               TTREALEAVVRPAIEHVVGGYLRARPSPGMADPSAFLPLHERLAELEGEDGPLMPWSPDN 
gi:242129450       GDATPIV--------RAVERHLAACPSAGTTDPQALLPLHERLAELEGERGPLLPWAPDN 
gi:552968830       HPEPS-----WERVREVLGTHLRAHPSRTRIDPDRLLPQHRRLALAEQIDEPLLPFYDDN 
gi:749676247       CAPAAVPALVRPAAEEIVGGFLARHPSCTHLVPEDHLDEHRRLAELEEDDRPLLPWRPDN 
gi:657940957       TTADAWASKVRPQVVAVLETYVRDHPSTVRLDEAALAPVHERLAELEMETGPRHPWVPDN 
gi:242129434       AAQPS-----WERIRDVLEPWLRVNPSRARIDRDRLLAQHRHLAAAERIDEPLLPFYADN 
                                    :   :   **            *.:**  *    *  *:  ** 
 
TbtD               TIHAEGERPEPL----TVRDVLLADFYADTTPSVYHALERVRSGASLPTIAFDLVVATAH 
gi:242129450       TVTAEP--PGLD----TELDRFLADFYADTTEAAFDALGRVRAGTPLPGIAFDLVVATAH 
gi:552968830       TLHRAVPRSRVHVLGSAAAEDLFHDFHAAASTAAFDQLDAVVAGESRLGLAFELMIAAAH 
gi:749676247       TIHQAPFERRAHVLGSEEVADLLADFHAATADPAFRMTEAVAGGTPRLGLAFDLMVATAH 
gi:657940957       TVLEQPYDHRLPVLGSMRGSEVLADFLSDTNDLAFAMYEHLQGGGALPVLALDLMWTTAS 
gi:242129434       TLHRAAPRSRAHVLGGPAAEELFHDFHTTASAVAYDELDAVRAGESRLVMALDLMVAAAH 
                   *:                   .: ** : :   .:     : .*     :*::*: ::* 
 
TbtD               A------LSTGGLPVARTSLRSHAEAYLARRSDGVRLRELWRDHYARNREAFTERLIAVA 
gi:242129450       D------LSEGGLPTARTSLRSHAEAYLSRLPGGVR--AKWQAHYERNQEPLTARIKALT 
gi:552968830       A------HAEGGITGGFVSFRSHAEAFLAGAA---GLRERWEAEYRTRAEALRAQVAAVV 
gi:749676247       A------LSGVGITTGFMSFRSHAEAFLTTHPEAHRLRPSWDAHYRGHAASLCDRVGRVT 
gi:657940957       VAAVPFDEHSAPIARGFLSLRSHADAFLSRTHDPAAYRAAFDERYRRQADALTTRLRTVE 
gi:242129434       A------HAEGGVRGGFVSFRSHAEAFLASAP---GLRERWDAEYAARAGALRARITAVV 





Figure 3.16 (cont.) 
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TbtD               SSAE-----SAENGAHLPHVREWVRRLRPIRERARALLESGELTLEYASPAEGARDLPSL 
gi:242129450       GAG---------------EPGAWLRTIRATRDRGRTLIDEGRLSLGYAT--DGPSTRPPL 
gi:552968830       TG--------------TPRGRAWTGLLDGFAGRGDELIASGALTVEPASPT-AAAEP--- 
gi:749676247       GALD-----DGS--GGVGFTGEWTELMRSFRRRGRALLAEGRLPSETAFAPGADGRPPPL 
gi:657940957       SVLSAEPGSPEAADATVPFVREWAEAVRRCQRAAYPLLASGELTLSGAGRA----PRLPT 
gi:242129434       AG--------------IPRGRAWAGLLDRFADRGDELIASGALLVEPAGPD-AVARP--- 
                                         *   :      .  *: .* *    * 
 
TbtD               AEVSAFHRELESRPEW-ARLRDSPAFGAYRLVINCTYLHLTRLGLTPHQRFLVCHLAADA 
gi:242129450       AAVSPFHRNLETDERW-LALKDTPAFAAYRLALNCAYLHLTRLGLTPDQRFLICHLAASA 
gi:552968830       --DTEFHRALRANRTWHDEVLRSPSFRRYRLLLNLTYLQMSRLGVTAVQRSLLCHFAASA 
gi:749676247       AGASPYHRAAYRNPAV-MASMTAEWFVLYRLMLNYTYLFMTQLGVTPVERYLLCHLTAHA 
gi:657940957       RQLSDFHRLLQTDHGHDGFLRDDHWFASFRLVVNYLYVHLNRLGLKPVDRGLLCHLAAGT 
gi:242129434       --DTAFHRALRGNRTWHEEVLRSAPFRRYRLLLNLTYLQLSRLGVNAVQRALLCHFAASA 
                      : :**                 *  :** :*  *: :.:**:.  :* *:**::* : 
 
TbtD               AADVYGIAAHEEVATR------------------------- 
gi:242129450       ADDVYRAVAS------------------------------- 
gi:552968830       VEEEYGVSAIEIAVGGM------------------------ 
gi:749676247       VEELYGVSAMEQITRAPPEPVLDAGGEPR------------ 
gi:657940957       VETVHGVTAEDAFRRHVVSASP-TEDTPEWSRLSKEWAEGR 
gi:242129434       VEQEYGVSAIEIAMGGA------------------------ 
                   .   :   * 
Figure 3.16 Sequence alignment of TbtD homologs. GI numbers are given to the left of the alignment (green indicates 
the sequence from the canonical thiomuracin producer, Nonomuraea sp. Bp3714-39; blue indicates the sequence from 
the GE2270A producer, Planobispora rosea). Shown in red are residues replaced with alanine for enzymatic activity 
assessment. 
 
Table 3.1 Enzymatic activity of selected TbtD mutant proteins. Seven TbtD mutants were selected based on phenotype 
in the end-point MALDI-TOF MS assay. Conversion efficiency was monitored by comparing EIC intensity to that of 
wild-type at 90 min (i.e., fully converted). As the wild-type TbtD performed the reaction much faster than the selected 
mutants, 200 nM enzyme was used for the assay compared to 1 μM for the mutant enzymes. All experiments were 
performed in duplicate. ND = not detected. 
TbtD protein 
% conversion 
 30 min 
% conversion 
 60 min 
% conversion 
 90 min 
Wild-type 77 ± 2 87 ± 1 100 
W47A 36 ± 3 55 ± 2 64 ± 1 
E105A 25 ± 4 47 ± 7 54 ± 11 
H191A 36 ± 3 57 ± 1 67 ± 4 
S287A 14 ± 4 23 ± 1 39 ± 11 
H290A 14 ± 3 33 ± 11 42 ± 4 
Y319A 2 ± 1 5.4 ± 3.7 11 ± 1 
R332A ND ND ND 
 
Previous studies in our (Chapter 2) and other laboratories (22) have already shown that the 
[4+2] cycloaddition enzyme is LP-dependent, but a bioinformatically identifiable RRE has not yet 
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been identified. We thus evaluated binding to MBP-tagged TbtD with FITC-TbtALP, showing that 
the RRE-less TbtD bound the peptide with a considerably high affinity (Kd ~140 nM, Figure 3.17). 
To elucidate which parts of the LP were important for TbtD binding, Graham Hudson generated a 
panel of TbtA variants and performed competition FP assays with FITC-TbtALP to determine 
relative IC50 values. A set of residues important for TbtD binding were revealed (Leu−29 as with 
TbtF, but also a number of acidic residues: Asp−30/−24/−20 and Glu−14) (6).  
 
 
Figure 3.17 FP analysis of binding of TbtD to the TbtA leader peptide. TbtD engages the leader peptide of TbtA with 
nanomolar affinity as determined by fluorescence polarization. Error bars represent standard deviation of three 
independent replicates. 
 
Next, I investigated the substrate requirements of TbtD. Since many of the Cys variants 
precluded dehydration at positions 1/11, which are required for the [4+2] cycloaddition reaction, 
we focused on further defining the requirements of the leader peptide. As shown in Chapter 2, 
treatment of TbtA hexazole tetradehydrate 3 with GluC, which removes all but three residues of 
LP,  resulted in loss of TbtD activity (2). I further tested if retaining a larger portion of the LP 
would result in processing by TbtD. Thus, 3 was treated with endo-proteinase AspN, retaining 20 
residues of the LP, and found that TbtD accepted this peptide as a substrate for the [4+2] 
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cycloaddition reaction (Figure 3.18). To further determine which portion of the TbtA LP was 
required for TbtD activity, we next tested a TbtA variant where Glu(−4) was substituted with Ala. 
This variant was efficiently converted to the hexazole tetradehydrate species, analogous to 3, after 
reaction with TbtE/F/G and TbtB/C. I then treated this peptide with GluC, which owing to the 
E(−4)A substitution, now retained 13 residues of the LP. This variant was also a substrate for TbtD 
(Figure 3.19), demonstrating that the minimal LP requirement of TbtD is between TbtA residues 
(−13) and (−3), which is consistent with a recent report showing that ten amino acids from the LP 
are required for TbtD activity (23).  
 
 
AspN TbtA hexazole tetradehydrate: DSGVAVESLTAGHGMTEVGA*SCNCFCYICCSCSSA 
Figure 3.18 TbtD tolerates AspN-treated TbtA hexazole tetradehydrate as a substrate. (A) MALDI-TOF MS spectrum 
of endo-proteinase AspN-digested TbtA hexazole tetradehydrate (Calcd [M+H]+ 3271). (B) Reaction of AspN-
digested TbtA hexazole tetradehydrate with TbtD results in the formation of thiomuracin core (calcd. [M+H]+ 1366) 
and the ejected leader peptide (calcd. [M+H]+ 1887). 
 
These findings may appear to contradict the binding data of FITC-TbtALP to MBP-TbtD, 
but it is important to note that the binding experiments were performed with linear TbtA variants 
whereas the TbtD activity experiments with truncated TbtA variants were performed with 
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cyclodehydrated and dehydrated core peptide. We hypothesize that TbtD recognizes both the 
aforementioned N-terminal residues of the LP and the post-translationally modified core peptide. 
To test this hypothesis, I performed binding measurements using fluorescently tagged TbtA 
hexazole, and demonstrated that TbtD binds with nanomolar affinity (Figure 3.20). TbtD was also 
shown to have micromolar affinity with a fluorescently tagged TbtA hexazole treated with endo-




GluC TbtA E(−4)A hexazole tetradehydrate: SLTAGHGMTAVGA*SCNCFCYICCSCSSA 
Figure 3.19 TbtD accepts GluC-treated TbtA E(−4)A hexazole tetradehydrate as a substrate. (A) ESI-MS spectrum 
of endo-proteinase GluC-digested TbtA E(−4)A hexazole tetradehydrate. Reaction of GluC-digested TbtA E(−4)A 






Figure 3.20 FP binding studies of MBP-tagged TbtD towards the FITC-TbtA hexazole. Error bars represent the 
standard deviation of three replicate measurements.  
 
 
Figure 3.21 FP binding studies wild-type TbtD towards the FITC-labeled GluC-treated TbtA-hexazole. Error bars 
represent the standard deviation of three replicate measurements. 
 
Our collaborator Prof. Satish Nair and his graduate student Dillon Cogan were able to 
obtain crystal structures of both TbtD alone, and in complex with the N-terminal region of the 
leader peptide to define its LP binding site. TbtD is structurally homologous to the core of the 
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lanthipeptide dehydratase elimination domain (Pfam identifier PF14028; abbreviated as 
Lant_Dehydr_C) elucidated in NisB (20) and MibB (24), but contains numerous secondary 
structure insertions (Figure 3.22). Notable examples include a helical insertion in the region 
spanning Pro86 through Asp116 (insertion region 1), a reorganization of the region encompassing 
Pro183 through Pro241 (insertion region 2), and a large insertion spanning Gly264 through Arg301 
(insertion region 3), which is a short connection loop in the Lant_Dehydr_C domains. Importantly, 
each of the insertions help to configure the binding sites for the substrates specific to the pyridine 
synthases, and insertion 3 is only visible in structures with bound pyridine core (Figure 3.23C). 
The co-crystal structure with the N-terminal 16 residues of the TbtA leader peptide shows electron 
density corresponding to residues Leu(−32) through Leu(−22) in the vicinity of insertion region 2 
(Figure 3.22). Residues Ser200 through Ala234 of TbtD form a large, bent helical insert that abuts 
the enzyme core and form the binding pocket for the leader peptide. The equivalent region is 
abridged in both MibB (Gly990 through Glu1035) and NisB (Asp882 through Gly919) and is 
largely devoid of secondary structure (Figure 3.22).  
Binding experiments between TbtD and site-directed alanine mutants of TbtA identified 
several residues within the leader peptide that are important for binding (25). Their identity can 
now be rationalized in light of the structural data. For example, an Ala mutation at Leu(−29) 
severely impairs TbtA binding, and in the co-crystal structure, this residue is docked into a 
hydrophobic pocket that is made from residues from insertion 3. Similar hydrophobic docking 
interactions are important for leader peptide engagement by enzymes involved in the biosynthesis 
of lanthipeptides (20) and cyanobactins (26). Additionally, binding by TbtD is compromised by 
mutations at one of several acidic residues in TbtA, including Asp(−30), Asp(−26), and Glu(−23) 
(25), and the structural data reveal that TbtD engages some of these residues through electrostatic 
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Figure 3.22 (A) Overall structure of TbtD in complex with the N-terminal leader fragment, showing insertions 1 
(cyan) and 2 (green) that distinguish the [4+2] enzymes from the LanB elimination domains. (B) Simulated annealing 
difference Fourier map (Fobs – Fcalc) contoured at 2.5 showing residues from the leader peptide that bind to a region 
near insertion 2 (green) in TbtD. (C) Secondary structure based multiple sequence alignment (MSA). Included in the 
MSA are the pyridine synthases TbtD, PbtD, and TclM in addition to the class I LanB dehydratase elimination domains 
(-elim) NisB-elim, and MibB-elim generated using ALINE software (27). A majority of secondary structural elements 
are conserved in these functionally divergent enzymes and notable differences are observed in the insertion regions 





complementarity. Mutational analysis of the binding site in TbtD was performed by Dillon Cogan 
to establish the importance of residues in mediating interactions with TbtA, using a shorter peptide 
corresponding to the N-terminal 12 residues visualized in the structure. Binding of this peptide by 
the pyridine synthase is compromised upon mutations at enzyme residues that define the 
hydrophobic pocket for Leu(−29), including Phe166, Phe220, and Val335. Mutation of Arg223, 
which is involved in additional hydrophobic contacts with Leu(−29) and hydrogen-bonding 
interactions with main chain amides of the leader peptide to Ala, also diminishes TbtA binding 
(Table 3.2). These structural and mutational data establish the validity of a leader peptide-binding 
site in TbtD, and demonstrate that the C-terminal region of the leader peptide is dispensable for 
substrate binding. 
 
Table 3.2 Summary of binding parameters in FP binding studies of WT and site-directed variants of TbtD where a 
fluorescein labeled, full-length TbtA leader (FITC-TbtA leader) was competed off with an N-terminal leader peptide 








Repeated attempts by Dillon Cogan to crystallize a complex of hexazole-containing 
tetradehydrated TbtA bound to catalytically deficient variants of TbtD proved recalcitrant. The 
high affinity between the fluorescently tagged TbtA hexazole and TbtD (Figure 3.20) ruled out 
weak binding as the cause of crystallization issues. Although TbtD also binds with micromolar 
TbtD variant KI (µM) IC50 (µM) KD(labeled) (µM) 
WT   2.4 ± 0.1   8.9 ± 0.3  0.26 ± 0.02 
F166A 11.7 ± 3.0 42.3 ± 4.5 2.17 ± 0.15 
H212A   1.4 ± 0.1   5.9 ± 0.3 0.22 ± 0.01 
R215A   5.9 ± 0.3 23.5 ± 0.7 0.35 ± 0.02 
F220A 21.5 ± 1.6 96.3 ± 5.3 0.44 ± 0.02 
R223A 40.0 ± 5.5 136.9 ± 12.4 2.15 ± 0.06 
L334A   4.3 ± 0.2 18.5 ± 0.6 0.25 ± 0.02 
V335A 15.8 ± 2.2 71.9 ± 7.6 0.76 ± 0.04 
L338A   7.2 ± 09 42.7 ± 1.3 0.32 ± 0.03 
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affinity to the modified TbtA hexazole core peptide (Figure 3.21), crystallization attempts using 
this substrate were not fruitful either. Likewise, attempts at co-crystallization of PbtD with intact 
GE2270A failed. Rationalizing that flexible regions of the modified peptide substrate may interfere 
with lattice packing, we focused efforts on studies using analogs that retained the central pyridine 
moiety (Figure 3.23A). Prior studies have shown that acid hydrolysis of GE2270A produced a tri-
thiazole-substituted pyridine (TSP) (28). Thus, I treated GE2270A (obtained from Novartis) with 
6 M HCl and purified the resultant TSP (Figure 3.23A). The binding affinity of PbtD pyridine 
synthase towards TSP was measured by Dillon Cogan using Förster resonance energy transfer 
(FRET), yielding a KD of 2.1 x 10
-5 M (Figure 3.23B). 
To discern active site details of the pyridine synthases, the structure of PbtD both alone 
and in complex with the GE2270A TSP was determined by Dillon. The overall structure of PbtD 
recapitulates the architecture observed in the homologous TbtD, including the lack of interpretable 
electron density for residues Glu248 through His273 within insertion 3, despite the much higher 
resolution of this structure. In contrast, the structure with bound TSP reveals that these residues 
organize and form two short -helices that define a periphery of the binding pocket for the ligand 
(Figure 3.23C). The helix from insertion 2 forms a base at the bottom of the binding groove. Ala-
scanning mutational analysis of TbtD implicated several residues in catalysis. Indeed, substitutions 
at His191 (equivalent PbtD numbering is given in parentheses; His182), Ser287 (Thr260), His290 
(His263), Phe308 (Phe282), Tyr319 (Tyr293), and Arg332 (Arg306) diminish activity (2). Each 
of these residues is near the bound TSP, but are located ~5-7 Å from each other and are not all 
spatially clustered (Figure 3.23D). Rather, these residues line alternate sides of a shallow cleft that 
is located at the juncture of the leader peptide-binding site (on TbtD) and the location of bound 
TSP. It should be noted that some of these variants may carry out the [4+2] cyclization and only 
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be deficient in dehydration activity, but are refractory to identification as there would be no net 
change in mass. 
 
 
Figure 3.23 Structural and binding studies of the PbtD-TSP complex. (A) Chemical structure of the tri-substituted 
pyridine (TSP) core produced by acid hydrolysis of GE2270A. (B) Binding of TSP to PbtD as measured by the changes 
in FRET upon complex formation. (C) Overall structure of PbtD in complex with TSP-F shows that residues in 
insertion 3 (yellow) become ordered upon ligand binding. (D) Simulated annealing difference Fourier map (Fobs – 
Fcalc) contoured at 2.5 showing the TSP core binds to a region near insertion 3 (yellow) in PbtD. Active site residues 
implicated in catalysis, without influencing leader peptide binding, are shown in stick figures. Figure made by Dillon 
Cogan and Prof. Satish Nair. 
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A feasible model of pyridine formation involves a looped substrate embedded within the 
shallow cleft in PbtD, where the aforementioned residues may play roles in catalyzing iminol 
formation, water elimination, and/or leader peptide ejection (Figure 3.23D) as the peptide 
transverses along the binding cleft. In this model, the anchored N-terminus of the leader peptide 
would allow a flexibly tethered core peptide to form this looped structure within the cleft, orienting 
the C-terminus of the substrate away from its N-terminus and at the interface of insertion 1 and 
the periphery of the cleft (Figure 3.24). To test this hypothesis, docking of the [4+2] substrate, as 
well as various intermediates, was carried out by Prof. Taras V. Pogorelov. The stability of each 
state over a 1 ns time-course molecular dynamics (MD) simulation was evaluated. Among the 
lowest energy poses obtained, we observed the maturing substrate and product docking results to 
be consistent with the predicted substrate-binding site based on the TSP co-crystal structure (i.e. 
C-terminus and macrocycle orientations). Residues within insertion 3 that are specific to the [4+2] 
enzymes are largely disordered in the absence of substrate, and the proximity of this region to the 
active site cleft suggests that these residues may serve a role in active site capping and/or modified 
peptide core binding. Indeed, ordering of insertion 3 upon binding of TSP is consistent with this 
proposal. Recruitment of the true substrate may lead to additional ordering of insertion 3 to 
facilitate substrate threading, whereupon the resultant macrocycle becomes solvent exposed and is 
directed away from the binding cleft.  
Mapping the primary sequences of nine pyridine synthases onto the structure of the PbtD-
TSP co-crystal structure reveals a pattern of conservation at the active site (Figure 3.25A). As 
noted, this active site of the [4+2] enzyme is distinct from that of other Lant_Dehydr_C domains, 
which are built upon a common scaffold observed in the LsrG epimerase (31). LsrG contains a 
ferredoxin-like domain, a prevalent + fold observed in numerous metabolic enzymes (32) 
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(Figure 3.25B). For example, the architecture of allantoate amidohydrolase, an enzyme involved 
in purine degradation in both plants and bacteria (33), is formed through the fusion of the LsrG 
scaffold with a second domain containing a metal-binding active site (34) (Figure 3.25C). 
Likewise, the elimination active site of NisB is formed by the insertion of an additional subdomain 
onto the LsrG ferredoxin-like fold (Figure 3.25D). The data collected by Dillon Cogan 
demonstrate that the thiopeptide [4+2] cycloaddition enzymes amend the Lant_Dehydr_C fold 
with functionally relevant insertion regions to achieve gain-of-function. 
 
 
Figure 3.24 Model of pyridine formation catalyzed by PbtD. The PbtA [4+2] substrate is superimposed onto the 
structure of PbtD, with active site residues drawn as grey sticks. Five-membered heterocycles along the substrate 
backbone are represented as pentagons (purple-outline/yellow-center = thiazole; purple-outline/red-center = 
oxazoline; black-outline/blue-center = proline). Dehydroalanine and iminol double bonds involved in a formal [4+2] 
cycloaddition are drawn in green. The N-terminal leader peptide fragment (N12-mer: LNDLPMDVFELA) observed 
in the TbtD co-crystal structure has also been superimposed and is represented as yellow sticks. Figure was made by 




Figure 3.25 Pyridine synthase scaffold is conserved in enzymes with divergent functions. (A) PbtD surface rendering 
with the bound TSP shown as a stick figure in cyan. Using the ConSurf server, the surface has been color-coded 
according to conservation in primary sequence based upon the alignment of nine sequences of pyridine synthases and 
colored according to regions of most variability (cyan), modest (white) or highest conservation (magenta). The 
strongest sequence conservation occurs near the active site where the [4+2] cycloaddition occurs. (B) Ribbon diagram 
of the LsrG epimerase (PDB entry 3QMQ) with active site residues shown as yellow sticks. (C) Ribbon diagram of 
the allantoate amidohydrolase AAH (PDB entry 4PXD) with active site residues shown as yellow sticks and a 
manganese ion shown as a red sphere. (D) Ribbon diagram of the elimination domain of the lanthipeptide dehydratase 
MibB (PDB entry 5EHK) with active site residues shown as yellow sticks. The ferredoxin-like + folds of AAH and 
MibB are demarcated within the rectangle, and the active sites are colored in orange. Figure was made by Dillon 
Cogan and Prof. Satish Nair. 
 
A comparison of the TbtD/PbtD structures with that of MibB and LsrG also provides an 
unexpected occurrence of proteins that contain active sites located at different regions of the 
polypeptide, illustrating how a common scaffold can accommodate new chemistry at a new active 
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site region (Figure 3.25). Recent de novo protein design efforts by Baker and colleagues describe 
methodologies for engineering proteins with entirely new primary sequences through 
considerations of long-range interactions observed in prevalent folds such as the ferredoxin-like 
domain (35). These studies predict the possibility of engineering custom-designed large assemblies 
from such robust building blocks. The structure of the pyridine synthase provides a conspicuous 
example of how nature has already employed this strategy to yield new catalysts, based on an 
ancestral ferredoxin-like fold.  
 
3.3 Experimental methods 
General materials and methods  
Reagents used for molecular biology experiments were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Escherichia coli DH5α and BL21 (DE3) strains were used for plasmid maintenance and protein 
overexpression, respectively. Plasmid inserts were sequenced at ACGT Inc. (Wheeling, IL). 
MALDI-TOF-MS analysis was performed using a Bruker UltrafleXtreme MALDI TOF-TOF mass 
spectrometer (Bruker Daltonics) in reflector positive mode at the University of Illinois School of 
Chemical Sciences Mass Spectrometry Laboratory. ESI-MS/MS analyses were performed using a 
SYNAPT ESI quadrupole TOF Mass Spectrometry System (Waters) equipped with an ACQUITY 
Ultra Performance Liquid Chromatography (UPLC) system (Waters). HiTrap columns for Ni-





Molecular biology techniques  
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). 
Primers for T. bispora tRNAGlu were designed and the dsDNA template for in vitro transcription 
was prepared as previously described (36). Genes optimized for recombinant expression in 
Escherichia coli were synthesized by GenScript (Piscataway, NJ) as previously described (Table 
2.4) (2). Site-directed mutagenesis on TbtA was performed using the QuikChange method 
(Agilent) as per the manufacturer’s instructions using PfuTurbo DNA polymerase. The primers 
for each mutant are listed in Table 3.3. The mutations were verified by sequencing using the 
forward primer or the T7 reverse primer. 
 
In vitro dehydration of TbtA mutants  
The following reaction conditions were used for dehydration assays: HEPES pH 7.5 (100 
mM), MgCl2 (5 mM), KCl (150 mM), glutamate (10 mM), ATP (5 mM), TbtA hexazole (50 μM), 
T. bispora tRNAGlu (10 μM), E. coli GluRS (10 μM), TbtB (5 μM), TbtC (5 μM), and thermostable 
inorganic pyrophosphatase (TIPP; 0.02 U μL–1) in a final volume of 25 μL. The reaction mixture 
was incubated at 30 °C for 1.5 h, centrifuged to remove insoluble material (14,000 × g, 5 min, 25 
°C), and desalted using C18 ZipTips (EMD Millipore). The sample was mixed in a 1:1 ratio with 
2,5-dihydroxybenzoic acid matrix, spotted on a Bruker MALDI plate, and analyzed by MALDI-





In vivo cyclodehydration and purification of progressive N- to C-terminal Cys to Ala 
substitutions of TbtA  
E. coli BL21 (DE3) cells were co-transformed with a pTrc99a_TbtF,G,E plasmid encoding 
the MBP-tagged TbtF,  MBP-tagged TbtG, and TbtE and a His6-TbtA-pRSFDuet-1 plasmid 
encoding the His6-TbtA mutant peptide of interest. Cells were grown for 16 h on LB agar plates 
containing 25 μg/mL kanamycin and 50 μg/mL ampicillin at 37 °C. Single colonies were used to 
inoculate LB containing 25 μg/mL kanamycin and 50 μg/mL ampicillin and the cells were grown 
at 37 °C for 16 h. This culture was used for 1:100 inoculation into Terrific Broth (24 g/L yeast 
extract, 12 g/L tryptone, 0.4% glycerol (v/v), 17 mM KH2PO4, and 72 mM K2HPO4) and grown 
at 37 °C to an optical density at 600 nm (OD600) of 0.6 before being placed on ice for 20 min. 
Production of thiazole-installed TbtA mutant peptides was then induced with the addition of 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The expression was allowed to proceed for 
16-18 h at 18 °C. Cells were harvested by centrifugation at 5,000 × g for 15 min. Cell pellets were 
resuspended in LanA start buffer (20 mM Na2HPO4, 150 mM NaCl, 20% glycerol, pH 7.5). Cells 
were further homogenized by sonication (50% amplitude, pulse on: 2.0 s, pulse off: 5.0 s, total 
pulse time: 5 min). Insoluble debris was removed by centrifugation at 13,000 × g for 30 min and 
the supernatant was then applied to Ni resin pre-equilibrated with LanA start buffer. The column 
was washed with 20 column volumes (CV) of LanA washing buffer (20 mM Na2HPO4, 30 mM 
imidazole, 300 mM NaCl, pH 7.5). The thiazole-installed TbtA mutant peptides were eluted with 
elute buffer (20 mM Na2HPO4, 500 mM imidazole, 100 mM NaCl, pH 7.5). The combined eluted 
fractions were dialyzed with buffer (20 mM HEPES, 150 mM KCl, pH 7.5) to remove imidazole, 
and the supernatant was purified on a Shimadzu Prominence Preparative Liquid Chromatography 
system equipped with a Phenomenex Luna C18 column (250 × 10 mm, 10 μm particle size, 100 
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Å pore size). Acetonitrile and 10 mM aq. NH4HCO3 were used as the mobile phases, and a gradient 
of 2-80% aq. MeCN over 45 min at 1 mL min–1 was used for separation (notebook reference 
5/6/2016). 
 
HPLC Purification of TbtA-hexazole core peptide 
HPLC-purified TbtA-hexazole (compound 2) was dissolved in 50 mM Tris-HCl (pH 7.5) 
to a final concentration of 100 M. GluC endo-proteinase was added to a concentration of 0.02 
mg min–1, and the reaction mixture was incubated at 37 °C for 1 h, followed by addition of MeCN 
to 20% (v/v) and TFA to 2% (v/v) to precipitate proteins. The insoluble material was removed by 
centrifugation at 16,100 × g for 10 min, and the supernatant was purified on an Agilent 1260 
Infinity HPLC system with a Phenomenex Luna C18 column (250 × 4.6 mm, 10 μm particle size, 
100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were used as the mobile phases, and a 
gradient of 2–80% aq. MeCN over 45 min at 1 mL min–1 was used for separation. TbtA-hexazole 
core eluted at 38-40% MeCN (notebook reference 8/12/2015). 
 
UPLC-MS and MS/MS of TbtA mutants  
GluC endo-proteinase was added to a concentration of 0.02 mg/mL to His6-TbtA variants 
after treatment by TbtE/F/G and dehydration by TbtB/C to remove the N-terminal leader peptide. 
After 30 min of incubation at 37 °C, MeCN was added to 20% (v/v), followed by addition of TFA 
to 2% (v/v) to precipitate proteins. The insoluble material was removed by centrifugation at 16,100 
× g for 10 min, and the supernatant was used for analysis. LC-MS was performed using a Waters 
SYNAPT mass spectrometer outfitted with an ACQUITY UPLC, an ACQUITY Bridged Ethyl 
Hybrid C8 column (2.1 × 50 mm, 1.7 μm particle size, 200 Å; Waters), an ESI ion source, and a 
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quadruple TOF detector. A gradient of 2–100% aq. MeCN with 0.1% formic acid (v/v) over 20 
min was used. A ramping of cone voltage of 20-25 kV during the scan was performed to generate 
peptide fragments for MS/MS analysis (notebook reference 7/17/2016).  
 
Labeling of TbtA hexazole (2) with fluorescein isothiocyanate (FITC)  
HPLC purified TbtA hexazole (2) was dissolved in PBS buffer (pH 8.0) to a final 
concentration of 50 M. Fluorescein isothiocyanate (FITC; Sigma-Aldrich) was dissolved in a 10 
mg min–1 DMSO stock and was added drop wise to the reaction (by adding a drop or two and 
vortex, repeating this procedure until all FITC was added to a final concentration of 250 μM. This 
procedure was used to prevent any type of localized precipitation). Labeling was allowed to 
proceed for 18 h at 25 °C, and then the reaction mixture was lyophilized. The residue was extracted 
with 20% aq. MeCN. The insoluble material was removed by centrifugation at 16,100 × g for 10 
min, and the supernatant was purified on an Agilent 1260 Infinity HPLC system with a 
Phenomenex Luna C18 column (250 × 4.6 mm, 10 μm particle size, 100 Å pore size). Acetonitrile 
and 10 mM NH4HCO3 were used as the mobile phases, and a gradient of 2–80% aq. MeCN over 
45 min at 1 mL min–1 was used for separation. FITC labeled TbtA-hexazole eluted at 30-31% 
MeCN (notebook reference 3/15/2016). 
 
Fluorescence polarization (FP) binding assay  
The interaction between fluorescently labeled peptides and TbtF, TbtB and TbtD was 
quantified using an FP assay. To maximize the polarization signal, all proteins remained MBP 
tagged. In general, protein was serially diluted into binding buffer (50 mM HEPES, pH 7.5, 300 
mM NaCl, 2.5% (v/v) glycerol, 0.5 mM TCEP) and mixed with 25 nM of the appropriate FITC 
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labeled peptides. Binding assays were carried out in nonbinding-surface, 384-black-well 
polystyrene microplates (Corning) and measured using a Synergy H4 Hybrid plate reader (BioTek) 
with λex = 485 nm and λem = 538 nm and data were recorded with Gen5 software. Prior to 
measurement, the dilutions were equilibrated with shaking for 30 min at 25 °C. Dissociation 
constant (Kd) values were calculated from the 50% saturation point using a dose-response curve 
fit in Origin Pro 9.1 (OriginLab) with three independent titrations. Background fluorescence from 
the proteins alone was subtracted from the fluorescence polarization signal obtained with the 
fluorophore (notebook reference 2/8/2016). 
 
Competition FP binding assay  
In general, 300 nM protein was mixed with 25 nM of the appropriate FITC-labeled peptide 
in binding buffer. MBP-tagged peptides for FP studies with TbtF and TbtD were first cleaved by 
TEV protease at 1:10 loading for 30 min prior to serial dilution. The peptides were serially diluted 
into binding buffer. Binding assays were carried out on the same instrument and analyzed with the 
same software as above. IC50 values were calculated from the 50% saturation point using a dose-
response curve fit in Origin Pro 9.1 (OriginLab) with three independent titrations. Kd values for 
unlabeled ligands were calculated using the following equation: 
Kd = IC50 / (1 + [L] / Kd, labeled) 
 Where: 
Kd  = Dissociation constant for the unlabeled peptide  
[L] = Concentration of labeled peptide  




Enzymatic activity of selected TbtD mutant proteins  
Seven TbtD mutants were analyzed in more detail by monitoring the peak area of the EIC 
(extracted-ion chromatogram) of the macrocycle (ESI, m/z 1366.2608) produced over time. 
Experiments with macrocycle standard solutions under the same conditions of the enzymatic 
activity assay showed that the peak area of the EIC of the macrocycle responded linearly to the 
macrocycle concentration in a 0.1-25 µM range. The following reaction conditions were used for 
the assay: HEPES pH 7.5 (50 mM), 15 µM 3, and 1 µM MBP-TbtD mutant enzyme. The reaction 
was allowed to proceed at 30 °C, and was quenched by addition of MeCN to 50% (v/v) at different 
time points. The insoluble material was removed by centrifugation at 16,100 × g for 5 min, and 
the supernatant was subjected to LC-MS using a Waters SYNAPT mass spectrometer outfitted 
with an ACQUITY UPLC, an ACQUITY Bridged Ethyl Hybrid C18 column (2.1 × 50 mm, 1.7 
μm particle size, 200 Å; Waters), an ESI ion source, and a quadruple TOF detector. A gradient of 
3–100% aq. MeCN with 0.1% formic acid (v/v) over 20 min was used, and the EIC was recorded 
(notebook reference 11/30/2015). 
 
Production and purification of TSP and TSP-F 
Tri-thiazole-substituted pyridines (TSP and TSP-F) were generated by acid hydrolysis of 
GE2270A (a gift from Novartis). Hydrolysis was carried out at 110-120 °C for 12 h in the presence 
of 6 M HCl. The reaction mixture was subsequently lyophilized and extracted with 10% (v/v) 
MeCN. Insoluble material was removed by centrifugation at 10,000  g for 15 min, and the 
supernatant was purified on a Shimadzu Prominence Preparative Liquid Chromatography system 
equipped with a Phenomenex Luna C18 column (250  10 mm, 10 μm particle size, 100 Å pore 
size). MeCN and 10 mM aq. NH4HCO3 were used as the mobile phases with a gradient of 2 - 80% 
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aq. MeCN over 45 min at 7 mL min–1 for separation. TSP and TSP-F eluted from the column with 
a retention time around 13 min and 16 respectively (notebook reference 11/28/2016).  
 
Methyl-esterification of TSP and TSP-F 
In a typical reaction, 1 mg of TSP and TSP-F was dissolved in 1 mL of 2 M methanolic 
HCl (prepared by careful dropwise addition of 160 L of acetyl chloride to 1 mL of ice-cold 
methanol while stirring, with the reaction vessel on ice) and then incubated at 25 °C with shaking 
for 1h. The sample was lyophilized and re-dissolved in 1 mL of 20% MeCN (v/v) and employed 
for purified on an Agilent 1260 Infinity HPLC system with a Phenomenex Luna C18 column (250 
× 4.6 mm, 10 μm particle size, 100 Å pore size). Acetonitrile and 10 mM NH4HCO3 were used as 
the mobile phases, and a gradient of 2–80% aq. MeCN over 45 min at 1 mL min–1 was used for 
separation. Methyl-esterified TSP and TSP-F eluted from the column with a retention time around 
15 min and 18 respectively (notebook reference 2/15/2017). 
 
Table 3.3 Oligonucleotides used in this study. 
Primer Oligonucleotide Sequence 
tbtA C12A F TTTGTTGTAGCGCCAGCAGCGCCTAACTCGAGCACCACCAC 
tbtA C12A R TAGGCGCTGCTGGCGCTACAACAAATATAACAAAAGCAATTAC 
tbtA C12A, C10A 
F 
GTTATATTTGTGCGAGCGCCAGCAGCGCCTAACTCGAGCAC 




C10A, C9A F 
TTTGTTATATTGCGGCGAGCGCCAGCAGCGCCTAACTCGAG 
tbtA C12A, 
C10A, C9A R 
CTGGCGCTCGCCGCAATATAACAAAAGCAATTACAGCTTGC 
tbtA C12A, 
















Table 3.3 (cont.) 
 
 
Primer Oligonucleotide Sequence 
tbtA C12A, 
C10A, C9A, 













C6A, C4A, C2A 
R 
GCAAACGCATTCGCGCTTGCACCAACTTCGGTCATACCATG 
tbtA S1A F GGTGCAGCGTGTAATTGCTTTTGTTATATTTGTTGTAGC 
tbtA S1A R CAAAAGCAATTACACGCTGCACCAACTTCGGTCATAC 
tbtA S11A F GTTATATTTGTTGTGCTTGCAGCAGCGCCTAATG 
tbtA S11A R CTGCTGCAAGCACAACAAATATAACAAAAGCAATTACAGCTTG 
MBP-tbtB F GAGAACCTGTACTTCCAATCCATGCGTCTGGTGGAAC 
MBP-tbtB R GGTGCTCGAGTGCGGCCGCATTATTCACCCAGTTCAACCAG 
tbtC R60A F CATCTGCGTTTCGCTGTTCGTCTGCTGCCG 
tbtC R60A R CAGACGAACAGCGAAACGCAGATGCGGAC 
tbtA S13A F GTTGTAGCTGCGCAAGCGCCTAATGCGGC 
tbtA S13A R CATTAGGCGCTTGCGCAGCTACAACAAATATAACAAAAGCAATTAC 
tbtA S14A F GTAGCTGCAGCGCTGCCTAATGCGGCCGC 
tbtA S14A R GCATTAGGCAGCGCTGCAGCTACAACAAATATAACAAAAGC 
tbtA C2A F GTGCAAGCGCGAATTGCTTTTGTTATATTTGTTGTAGC 
tbtA C2A R CAAAAGCAATTCGCGCTTGCACCAACTTCG 
tbtA C2A, C4A F GCGCGAATGCATTTTGTTATATTTGTTGTAGCTGCAG 
tbtA C2A, C4A R CAAATATAACAAAATGCATTCGCGCTTGCACC 
tbtA C2A, C4A, 
C6A F 
GAATGCATTTGCGTATATTTGTTGTAGCTGCAGCAG 
tbtA C2A, C4A, 
C6A R 
CAAATATACGCAAATGCATTCGCGCTTGCACC 
tbtA C2A, C4A, 
C6A, C9A F 
ATCGAAGGTCTCATGCGTATATTGCATGTAGCTGCAGCAGCG 
tbtA C2A, C4A, 
C6A, C9A R 
TTAGCTGGTCTCACGCAAATGCATTCGCGCTTGCACCAAC 
tbtA C2A, C4A, 
C6A, C9A, C10A 
F 
ATCGAAGGTCTCATGCGTATATTGCAGCTAGCTGCAGCAGCGC 
tbtA C2A, C4A, 
C6A, C9A, C10A 
R 
TTAGCTGGTCTCACGCAAATGCATTCGCGCTTGCACCAAC 
mbp F GAGGAAGAGTTGGCGAAAGATCCACGTA 
T7 F TAATACGACTCACTATAGGG 
T7 R  GCTAGTTATTGCTCAGCGG 
tbtD H46A F ATTTTCTGCGTGCTTGGCGTCGCGGTCCGCACCTGCGCATTTAC 
tbtD H46A R CCGCGACGCCAAGCACGCAGAAAATATGCCATCGGTGCCTG 
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Table 3.3 (cont.) 
 
 
Primer Oligonucleotide Sequence 
tbtD W47A F TTCTGCGTCATGCGCGTCGCGGTCCGCACCTGCGCATTTAC 
tbtD W47A R GGACCGCGACGCGCATGACGCAGAAAATATGCCATCGGTGC 
tbtD R49A F GTCATTGGCGTGCCGGTCCGCACCTGCGCATTTACGTTAG 
tbtD R49A R CAGGTGCGGACCGGCACGCCAATGACGCAGAAAATATGCCATC 
tbtD H52A F GTCGCGGTCCGGCCCTGCGCATTTACGTTAGTACCACGCGTG 
tbtD H52A R GTAAATGCGCAGGGCCGGACCGCGACGCCAATGACGCAG 
tbtD R54A F GTCCGCACCTGGCCATTTACGTTAGTACCACGCGTGAAGCAC 
tbtD R54A R CTAACGTAAATGGCCAGGTGCGGACCGCGACGCCAATGACG 
tbtD S85A F GTGCACGTCCGGCTCCGGGTATGGCTGATCCGTCCGCGTTC 
tbtD S85A R GCCATACCCGGAGCCGGACGTGCACGCAGATAACCGCCCAC 
tbtD H98A F GTTCCTGCCGCTGGCTGAACGCCTGGCCGAACTGGAAGGCGAAG 
tbtD H98A R GCCAGGCGTTCAGCCAGCGGCAGGAACGCGGACGGATCAGC 
tbtD E105A F CTGGCCGAACTGGCAGGCGAAGATGGTCCGCTGATGCCGTGG 
tbtD E105A R CCATCTTCGCCTGCCAGTTCGGCCAGGCGTTCATGCAGCGG 
tbtD N118A F GGTCTCCGGACGCCACGATTCACGCAGAAGGTGAACGTCCGG 
tbtD N118A R GCGTGAATCGTGGCGTCCGGAGACCACGGCATCAGCGGACC 
tbtD T144A F TTTATGCAGACGCCACGCCGAGCGTTTACCACGCGCTGGAAC 
tbtD T144A R ACGCTCGGCGTGGCGTCTGCATAAAAATCGGCCAGCAGAAC 
tbtD R189A F GTACCTCACTGGCTTCGCACGCAGAAGCTTATCTGGCACGTC 
tbtD R189A R TCTGCGTGCGAAGCCAGTGAGGTACGTGCGACCGGCAGACC 
tbtD S190A F CCTCACTGCGTGCGCACGCAGAAGCTTATCTGGCACGTCGC 
tbtD S190A R GCTTCTGCGTGCGCACGCAGTGAGGTACGTGCGACCGGCAG 
tbtD H191A F CACTGCGTTCGGCCGCAGAAGCTTATCTGGCACGTCGCTCC 
tbtD H191A R TAAGCTTCTGCGGCCGAACGCAGTGAGGTACGTGCGACCGG 
tbtD E193A F GTTCGCACGCAGCAGCTTATCTGGCACGTCGCTCCGATGGTG 
tbtD E193A R GCCAGATAAGCTGCTGCGTGCGAACGCAGTGAGGTACGTGC 
tbtD S287A F TGGCTGAAGTTGCTGCGTTTCATCGCGAACTGGAAAGCCGTC 
tbtD S287A R CGATGAAACGCAGCAACTTCAGCCAGGCTCGGCAGATCGCG 
tbtD H290A F GTTTCTGCGTTTGCTCGCGAACTGGAAAGCCGTCCGGAATGG 
tbtD H290A R TCCAGTTCGCGAGCAAACGCAGAAACTTCAGCCAGGCTCGG 
tbtD R291A F CTGCGTTTCATGCCGAACTGGAAAGCCGTCCGGAATGGGCAC 
tbtD R291A R CTTTCCAGTTCGGCATGAAACGCAGAAACTTCAGCCAGGCTC 
tbtD N316A F GTCTGGTTATTGCTTGCACCTACCTGCACCTGACGCGTCTG 
tbtD N316A R CAGGTAGGTGCAAGCAATAACCAGACGATATGCGCCGAATGC 
tbtD Y319A F TTAATTGCACCGCCCTGCACCTGACGCGTCTGGGTCTGACC 
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Table 3.3 (cont.) 
 
 
Primer Oligonucleotide Sequence 
tbtD Y319A R GTCAGGTGCAGGGCGGTGCAATTAATAACCAGACGATATGC 
tbtD R324A F CTGCACCTGACGGCTCTGGGTCTGACCCCGCATCAACGTTTC 
tbtD R324A R GTCAGACCCAGAGCCGTCAGGTGCAGGTAGGTGCAATTAATAAC 
tbtD R332A F CCCCGCATCAAGCTTTCCTGGTCTGTCACCTGGCAGCAGATG 
tbtD R332A R CAGACCAGGAAAGCTTGATGCGGGGTCAGACCCAGACGCGTC 
tbtD C336A F GTTTCCTGGTCGCTCACCTGGCAGCAGATGCAGCTGCAGAC 
tbtD C336A R GCTGCCAGGTGAGCGACCAGGAAACGTTGATGCGGGGTCAG 
tbtD H337A F TCCTGGTCTGTGCCCTGGCAGCAGATGCAGCTGCAGACGTG 
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CHAPTER 4: BIOCHEMICAL AND MECHANISTIC CHARACTERIZATION OF A 
RADICAL S-ADENOSYL-L-METHIONINE (SAM) THIAZOLE C-
METHYLTRANSFERASE IN THIOMURACIN BIOSYNTHESIS d 
 
4.1 Introduction 
Radical SAM enzymes catalyze unique chemical reactions in primary metabolism and 
natural product biosynthesis (1-4). A subset of radical SAM proteins catalyze methylation of non-
nucleophilic acceptors, such as sp2 or sp3 carbons (5-7).  Currently, four distinct classes of radical 
SAM methyltransferases (MTs) have been identified that differ in their cofactor/co-substrate 
requirements and their proposed reaction mechanisms (7-10). Class A includes the RNA-
modifying enzymes RlmN and Cfr (11, 12). Class B comprises cobalamin-dependent MTs, such 
as TsrM (13, 14), Fom3 (15-19), GenK (20), CysS (21), and PoyC (22). Class C are cobalamin-
independent enzymes and found in a variety of natural product biosynthetic gene clusters (BGCs) 
(23, 24). Although class A and B enzymes have been extensively studied (17-19, 25-30), class C 
MTs have received much less attention (5, 9). The only examples of partially characterized class 
C MTs are ChuW and NosN (31, 32). Class D includes a methylenetetrahydrofolate-dependent 
enzyme involved in methanopterin biosynthesis (33).  
                                                 
d Parts of the chapter are reprinted with permission from: Mahanta, N., Zhang, Z., Hudson, G. A., van der Donk, W. A., & Mitchell, D. A. (2017). 
Reconstitution and Substrate Specificity of the Radical SAM Thiazole C-Methyltransferase in Thiomuracin Biosynthesis. J. Am. Chem. Soc., 139, 
4310-4313. Copyright © 2017 American Chemical Society. https://pubs.acs.org/doi/abs/10.1021/jacs.7b00693 
Parts of the chapter are reprinted with permission from: Zhang, Z., Mahanta, N., Hudson, G. A., Mitchell, D. A., & van der Donk, W. A. (2017). 
Mechanism of a Class C Radical S-Adenosyl-L-methionine Thiazole Methyl Transferase. J. Am. Chem. Soc., 139, 18623-18631. Copyright © 2017 
American Chemical Society. https://pubs.acs.org/doi/abs/10.1021/jacs.7b10203 
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Figure 4.1 (A) Thiomuracin GZ (4) biosynthesis. (B) Structure of thiomuracin A1 (5). (C) Structure of GE2270A (6). 
LP, leader peptide. Red, C-methylation sites. (D) Biosynthetic gene clusters from Thermobispora bispora and 
Planobispora rosea, respectively. Shown in pink and boxed are the class C radical SAM MTs (e.g. TbtI, the subject 
of the current chapter). The BGC of 6 additionally encodes two additional “classic” SAM-MTs, PbtM1 and PbtM4. 
These MTs act upon nucleophilic centers and proceed via a polar mechanism unlike the radical SAM enzymes. 
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 In both thiomuracin A1 (5) and GE2270A (6) the thiazole (Thz) arising from Cys4 is C-
methylated; in 6, the Thz at position 6 is also C-methylated (Figure 4.1) (34). These 
transformations are remarkable in that they occur on unactivated sp2 carbon centers. Inspection of 
the BGC of 5 identifies a single gene, tbtI, annotated as a class C radical SAM MT enzyme (Figure 
4.1D)  (35). Previous studies (36) on the biosynthesis of 6 suggested that TbtI is involved in 
thiazole C-methylation of 5. The BGC for 6 encodes a nearly identical radical SAM protein, 
PbtM2, in addition to a paralog, PbtM3 (Figure 4.1D). Gene deletion experiments demonstrated 
that PbtM2 and PbtM3 C-methylate Thz4 and Thz6 of 6, respectively (37). In this chapter, we 
present the investigation of the timing and substrate scope of thiazole C-methylation by TbtI 
involved in the biosynthesis of the thiopeptide thiomuracin, as well as a detailed mechanistic study 
of this remarkable transformation. 
 
4.2 Results and discussion 
4.2.1 Reconstitution and substrate specificity of the radical SAM thiazole C-
methyltransferase TbtI 
 The radical SAM thiazole C-methyltransferase TbtI was first recombinantly expressed and 
purified from Escherichia coli as an N-terminal maltose binding protein (MBP) fusion (Figure 
4.2A)  (38). Using the ferrozine and methylene blue assays, Dr. Nilkamal Mahanta found that the 
expressed enzyme contained 1.6 ± 0.2 Fe and 1.9 ± 0.3 sulfides per monomer. Fe-S cluster 
reconstitution with recombinant cysteine desulfurase (IscS), Fe (II), Cys, and dithiothreitol yielded 
3.7 ± 0.3 Fe and 4.1 ± 0.3 sulfides per protein, near the expected values for a single [4Fe-4S] 





Figure 4.2 (A) SDS-PAGE analysis of proteins used in this chapter. (B) UV-Vis spectrum of TbtI. The UV-Vis 
spectrum of MBP-tagged TbtI (30 μM) collected on a Cary 4000 spectrophotometer. Shown are spectra of MBP-TbtI 
(green) as purified from E. coli and MBP-TbtI after in vitro Fe-S cluster reconstitution with IscS (purple). Figure made 
by Dr. Nilkamal Mahanta 
 
 
Figure 4.3 TbtI reaction with thiomuracin GZ (4). Shown are MALDI-TOF-MS spectra of thiomuracin GZ (top) and 
after reaction with TbtI supplemented with SAM and sodium dithionite (bottom). No methylation was observed even 




Figure 4.4 TbtI reaction with TbtA hexazole (2). TbtA hexazole (2) was only methylated (+14 Da) in the presence of 
TbtI, SAM, and dithionite as monitored by MALDI-TOF-MS. Omission of TbtI, SAM, or dithionite resulted in no 
reaction. m/z assignments: 6052 Da, TbtA hexazole (2) which at this resolution, forms a single peak with a minor 
product at m/z 6054, corresponding to TbtA pentazole/monoazoline, due to incomplete oxidation of one of the 
thiazolines; 6072 Da, TbtA pentazole with a hydrolyzed thiazoline (+18 Da); 6068 Da, methylated TbtA hexazole; 
6086 Da, TbtA methylated pentazole with a hydrolyzed thiazoline. 
 
To determine the timing of thiazole C-methylation, Dr. Nilkamal Mahanta first evaluated 
whether 4 was a substrate. Under anaerobic conditions, 4 was treated with TbtI in the presence of 
SAM and dithionite. The reaction mixture was analyzed by matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and no mass shift (+14 Da) for 
methylation was observed (Figure 4.3). To investigate if methylation occurred at an earlier point 
in the biosynthesis, I tested the TbtA hexazole 2 and the downstream tetradehydrate 3 as substrates 
for TbtI. Analysis by MALDI-TOF-MS showed a +14 Da species consistent with a single 
methylation after the reaction with 2 (Figure 4.4). Control experiments lacking SAM, TbtI, or 
dithionite did not result in a mass shift. Under our reaction conditions, 3 was not a substrate for 
TbtI (Figure 4.5). Based on the structures of 5 and 6 (Figure 4.1) and previous gene deletion 
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experiments (37), methylation of 2 likely occurred at Thz4. To test this hypothesis, the pentazole-
containing versions of TbtA-C4A and TbtA-C4S were prepared and tested as substrates for TbtI. 





Figure 4.5 TbtI reaction with TbtA hexazole tetradehydrate (3). (A) TbtA tetradehydrate was tested as a substrate for 
TbtI. The amino acid sequence shows the site of thiazoles (blue) and dehydrated Ser (green). No methylation (+14 
Da) was observed in the presence of TbtI, SAM, and dithionite as monitored by MALDI-TOF-MS. Instead, a +6 Da 
species was observed. m/z assignments: 6892 Da, TbtA hexazole tetradehydrate (3); 6898 Da, off-pathway product of 
TbtI reaction with 3. (B) High-resolution tandem MS analysis of the +6 Da species indicates that 3 underwent 
reduction at the three most N-terminal alkene groups. This is a known reaction for dithionite (39-41), which is required 





His6-TbtA (C4A): PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNAFCYICCSCSSA 
His6-TbtA (C4S): PHHHHHHSQVDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*SCNSFCYICCSCSSA 
Figure 4.6 TbtI reaction with TbtA-C4A and TbtA-C4S pentazoles. TbtA pentazoles carrying the C4A or C4S 
substitutions were not substrates for TbtI, as visualized by MALDI-TOF-MS. Sites of thiazole installation are blue 
and the Ala/Ser substitutions are shown in red. m/z assignments: 6044 Da, TbtA-C4A pentazole; 6060 Da, TbtA-C4S 
pentazole.  
 
A prominent feature of RiPP biosynthesis is the role of the LP in substrate recognition by 
the modifying enzymes (42). TbtI lacks an identifiable RiPP Recognition Element (RRE) (43) 
which is normally an indicator of LP dependence. However, TbtD also lacks an RRE yet is LP-
dependent as discussed in Chapter 2 (44); further, the RRE-containing TbtB is LP-independent as 
discussed in Chapter 3 (45). To assess the LP-dependence of TbtI, 2 was treated with the endo-
proteinase GluC to generate 7 (Figure 4.7), which retains Val-Gly-Ala from the LP. In testing 7 
as a TbtI substrate, we observed full conversion to the methyl-thiazole 9 (Figure 4.7). Control 
experiments omitting TbtI, SAM, or dithionite did not result in observable modification of 7. The 
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site of methylation in 9 was confirmed as Thz4 by high-resolution electrospray ionization tandem 
MS analysis (HR-ESI-MS/MS; Figure 4.8). These data indicate that most of the LP (31 out of 34 
residues) is dispensable for TbtI activity and that the enzyme recapitulates in vitro the specificity 
observed in the natural product. 
 
 
Figure 4.7 (A) MALDI-TOF mass spectra of 7 treated as indicated. (B) Reaction catalyzed by TbtI to convert 7 to 9 
(for the mechanistic study of TbtI discussed below, the 15N-, 13C-depleted 7 is annotated as 7’). 
 
 




We next addressed the determinants of regioselectivity in the TbtI reaction, given that Thz4 
undergoes selective C-methylation despite the presence of five additional thiazoles. We 
hypothesized that TbtI recognizes a substructure of 2 adjacent to Thz4. Inspection of 5 and 6 shows 
that the methylthiazole is preceded in both cases by an Asn3, which in 6 undergoes additional N-
methylation (37). It has been reported that Asn3 forms a key contact with elongation factor thermos 
unstable (EF-Tu) and that substitution of Asn3 results in loss of antibiotic activity (46, 47). To 
investigate whether Asn3 governs the regioselectivity of TbtI, I replaced this residue in TbtA with 
Ala, Asp, and Gln, followed by hexazole production in E. coli. Dr. Nilkamal Mahanta found that 
no methylation was observed with any Asn3 variants, demonstrating that Asn3 in TbtA is critical 
for TbtI activity. 
We hypothesized that introducing an Asn N-terminal to one of the other thiazoles might 
redirect the location of methylation. Thus, four TbtA double-substituted variants of 7 were 
constructed by inserting Asn at a position preceding Thz 2, 6, 9 and 12 and replacing Cys4 with 
Ala. These four GluC-treated pentazole variants (S1N/C4A, C4A/F5N, C4A/I8N, and C4A/S11N) 
were then tested as TbtI substrates. Still no methylation was observed, indicating that other factors 
contribute to the regioselectivity. Further experiments performed by Dr. Nilkamal Mahanta and 
Graham Hudson have shown that TbtA with a single thiazole alone at Cys4 was not a substrate, 
and that only the 4/6 diazole was able to be fully converted to the methylated product. These data 
suggested that -Asn-Thz-Phe-Thz- may serve as the minimal substrate recognition motif for TbtI. 
To test this hypothesis, the motif was installed at positions 1-4 by Graham Hudson. This 
double-substituted variant, TbtA-S1N/N3F, was reacted with TbtE/F/G and subsequently TbtI. 
Thiazole formation was observed, but methylation was not (Figure 4.9), suggesting that while an 
N-terminal flanking Asn and a downstream thiazole are necessary, they are not sufficient for TbtI 
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methylation. Other, currently unknown structural aspects may further contribute to the substrate 
selectivity of TbtI. All results are summarized in Table 4.1. 
 
 
TbtA S1N/N3F: SRRRGSMDLNDLPMDVFELADSGVAVESLTAGHGMTEVGA*NCFCFCYICCSCSSA 
Figure 4.9 TbtI reaction with TbtA S1N/N3F double variant. TbtA hexazole featuring the substitutions Ser1Asn and 
Asn3Phe was not a substrate for TbtI as visualized by MALDI-TOF-MS. Sites of thiazole installation are blue and 
substitutions are shown in red. Laser induced deamination artifacts are denoted with a red asterisk. m/z assignments: 
5830 Da, unreacted TbtA (S1N, N3F) precursor peptide; 5710 Da, TbtA (S1N, N3F) hexazole.  
 
Table 4.1 TbtA precursor peptide variants tested for methylation by TbtI. TbtA sequence: Leader-
SCNCFCYICCSCSSA. 
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4.2.2 Mechanistic study of the class C radical SAM thiazole C-methyltransferase TbtI 
Sequence analysis of TbtI did not reveal significant homology to class A radical SAM MTs 
outside of the conserved [4Fe-4S] and SAM-binding motifs. TbtI is clearly distinguished from the 
cobalamin-dependent class B MTs (9). Class C MTs are homologous to HemN/HemZ, 
mechanistically unrelated radical SAM decarboxylases from heme biosynthesis (5).  
To start our mechanistic study of TbtI, we first assessed whether TbtI might employ a 
similar mechanism to class A radical SAM MT, even though this was inconsistent with sequence 
analysis. This class of enzymes utilizes an unusual mechanism in which a methyl group from SAM 
is first transferred to a Cys on the protein. Then, reductive cleavage of a second SAM molecule 
occurs, mediated by a reduced iron-sulfur [4Fe-4S] cluster, which generates a 5’-deoxyadenosyl 
radical (5’-dA•). The 5’-dA• species then abstracts a hydrogen atom from the methylcysteine to 
initiate the methyl transfer process (Figure 4.10). The sequence of TbtI and its orthologs from 
various thiopeptide gene clusters was first analyzed by Dr. Nilkamal Mahanta (48) and he 
identified five conserved Cys residues (Cys14, Cys18, Cys21, Cys254 and Cys343; Figure 4.11). 
Three of these appear in a canonical motif (CxxxCxxC), which typically supply the ligands for a 
characteristic radical SAM [4Fe-4S] cluster (49). TbtI variants in which these Cys residues were 
replaced by Ala (C14A, C18A and C21A) were inactive (Figure 4.12), but substitution of the 
remaining Cys residues (C89A, C254A, and C343A) did not adversely affect the activity of TbtI 




Figure 4.10 Mechanism of class A radical SAM MT RlmN (50). RlmN methylates an adenine in 23S-tRNA by first 
methylating a Cys in the enzyme, and then uses 5’-dA• derived from a second SAM to abstract a hydrogen atom from 
the methylated Cys. The resulting radical is added to the adenine, and oxidized to a cation. Deprotonation generates a 
neutral intermediate that fragments via disulfide bond formation. A tautomerization then affords the methylated 
adenine.  
 
TbtI       ------------------------------------------------MTRPLLLYVNIP 
TpdI       ------------------------------------------------MTKPLLIYANVP 
PbtM2      ------------------------------------MSTTLRGTGGAVAEQPLLIYVNVP 
PbtM3      -------------------------------MTT-EAITNALPLTGPKTDEPLLLYVNVP 
HemN       MSVQQIDWDLALIQKYNYSGPRYTSYPTALEFSEDFGEQAFLQAVARYPERPLSLYVHIP 
                                                             .** :*.::* 
 
TbtI       FCNSKCHFCDWVVQIPVRDLRLDQQAPGRIAYLDAVRAQIRGQAPVLRE-HYQPAIIYWG 
TpdI       FCNSKCHFCDWVVQVPVRDLRLGEQSPGRVAYLEAIRTQIRVQAPALRE-HYHPDIVYWG 
PbtM2      FCNSKCHFCDWVTEVPLADLRLTPDSSPRQRYIAALVQQIETHAPVLTGFGYRPEIMYWG 
PbtM3      FCNSKCHFCDWVVDVPVSDLRLTPVSAGRIDYLEALRTQIRIHAPALREAGYRSEVMYWG 
HemN       FCHKLCYFCGCNKIVT-------RQQHKADQYLDALEQEIVHRAPLFAG--RHVSQLHWG 
           **:. *:**.    :                *: *:  :*  :** :     :   ::** 
 
TbtI       GGTASILGESEIESLYTCLRSEFDLSHVRETTIEGSPESLTPQKLRRLRELGFDRISIGV 
TpdI       GGTASILGPHEIESLYGTLSAEFDLSTVREATIEGSPESLDRDKLRLLRELGFNRISIGV 
PbtM2      GGTASILSIDEIEAVAGALSSRFDMSGLTEATIEGSPESLDPDKLKLFRAAGFNRISIGV 
PbtM3      GGTATVLTEREIEQTYACLAAELDLSSLAEATIEGSPESVDLAKLTFMRDLGFDRVSLGV 
HemN       GGTPTYLNKAQISRLMKMLRENFQFNADAEISIEVDPREIELDVLDHLRAEGFNRLSMGV 
           *** : *   :*.     *  .:::.   * :** .*..:    *  :*  **:*:*:** 
 
TbtI       QSFDDQRLRRLGRAHSAEQAVEVVKNAHAAGFRNINIDLIVGFPGQTDAEVAESVRTALT 
TpdI       QSFDDARLRRLGRAHAADQALTAVQDAHEAGFTNINIDLIVGFPGQTGQEVADSVRTALT 
PbtM2      QAFDDARLRRIGRVHSAEQAVRAVEMAAEAGFDNINIDLIVGFPGQEVDEVSHMIQRAVT 
PbtM3      QSFDETRLRRIGRAHSAGQAVQSVEAAHAAGFDNINIDLIVGFPDQSLEEVEEMIRRALD 
HemN       QDFNKEVQRLVNREQDEEFIFALLNHAREIGFTSTNIDLIYGLPKQTPESFAFTLKRVAE 
           * *:.   * :.* :     .  :: *   ** . ***** *:* *   ..   :: .   
 
Figure 4.11 (cont.) 
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TbtI       LPINHFSIYPYRASPGTILRKQVERGG-HLDLNRQLAAYYITRDLLEEAGFPEYAMSYFG 
TpdI       LPINHFSIYPYRASPGTVLRKQVHRGA-QLDLNLQLQAYGIARELLEAAGFPEYAMSYFG 
PbtM2      LPVNHFSVYPYRPTNGTVMRKQVRRGNSEIDVDEQLRSYAYARDLLAEHGFDEYATAYFG 
PbtM3      LPVNHFSVYSYRATEGTVMRKQIERSGTEILLEHQLRSYRLAADMLAAAGHPEYAVSYFG 
HemN       LNPDRLSVFNYAHLPTIFAAQRKIKDADLPSPQQKLDILQETIAFLTQSGYQFIGMDHFA 
           *  :::*:: *      .  ::  :.      : :*     :  :*   *.   .  :*. 
 
TbtI       APRCEADQA-------------YYRLTMDWIGFGSGANSLLGHRYLAFRKGRLHAYNQNP 
TpdI       HPRCQSDEA-------------YYQLRMDWIGFGSGANSLIGRRYLSYEKGKLAHYNTNP 
PbtM2      GPRCESDEV-------------YYKLTMDWIGFGSGANSLIGTRFLLNERGALHRFSAAP 
PbtM3      VPRCLADEA-------------YYRLSMDWIGFGTGANSLINQRYLLNGRGRMRDFTSKP 
HemN       RPDDELAVAQREGVLHRNFQGYTTQGDTDLLGMGVSAISMIGDCYAQNQKELKQYYQQVD 
            *      .               :   * :*:* .* *::.  :    :     :     
 
TbtI       LRFDVNAPASSPQLTLHWLSQALTTVEGMDARVYQERT------------GTPLRVACEE 
TpdI       LAFDINAPAHSPQLTLHFLSQALTTAEGLDARLYQQRT------------GVPLRTACSH 
PbtM2      QRFDSDIPASSPHLTRHFLAQALTTVDGMDARTFQQRT------------GRSLRAACEE 
PbtM3      GEFEVNLPAATGSLTVQWLPRALGTSEGIDAVTFQRRT------------GMSLRAACEE 
HemN       E-----------QGNALWRGIALTRDDCIRRDVIKSLICNFRLDYAPIEKQWDLHFADYF 
                         .  :   **   : :     :                  *: *    
 
TbtI       PEVQAYLRRMSEHGRLIIDRNGIRIHREDI----ARVIIALNWIDTPGGDQKV-TRLTPVSATS 
TpdI       PEVMTYLERMNNHGRLIADHNGIRLHRDDI----AQTFIALNWIPTPDTTPNEVIPLTPSPT 
PbtM2      PAVRRMLEQINRRGRLIIDSRGIRLHRDDM----ASTYITMNSVDLYAATEQIGG----- 
PbtM3      PDLNAFLRQVNRFGDLVVDRTGIRLADDDRSSVLSRTFAAMGWVS--------------- 
HemN       AEDLKLLAPLAKDGLVDVDEKGIQVTAKGRLLIRNICMCFDTYLRQKARMQQFSRVI--- 
                 *  : . * :  *  **::  ..              :                 
Figure 4.11 Sequence alignment of select class C radical SAM MTs. Proteins shown include TbtI from the 
hypothetical thiomuracin producer Thermobispora bispora (WP_013130805.1), TpdI from known thiomuracin 
producer Nonomuraea sp. Bp3714-39 (ACS83777.1), PbtM2/M3 from GE2270A producer Nonomuraea sp. WU8817 
(AGY49586.1/AGY49595.1), and HemN from Escherichia coli (WP_001502804.1). Cys residues involved in [4Fe-
4S] cluster formation are highlighted yellow. TbtI residues chosen for Ala substitution are shown in red. HemN 
residues within 5 Å of SAM2 are shown in blue. 
 
Thus, these data show that unlike class A radical SAM MTs, which require at least two 
additional Cys other than the three used to bind the [4Fe-4S] cluster (28), TbtI does not require 
additional Cys residues for catalysis. This conclusion is further supported by the fact that a TbtI 
homolog involved in nocathiacin biosynthesis (NocN) contains only one additional Cys other than 
the three involved in [4Fe-4S] cluster coordination (8). We considered that a methyl group from 





Figure 4.12 MALDI-TOF MS analysis of the products generated by TbtI variants. (A) Spectra of TbtA hexazole 
treated with wild type (wt) TbtI or TbtI variants in which the Cys residues expected to be involved in binding to the 
[4Fe-4S] cluster were substituted with Ala. (B) Spectra of TbtA hexazole treated with wt TbtI or TbtI variants in which 
the remaining Cys residues were substituted with Ala. (C) Spectra of TbtA hexazole treated with wt TbtI or variants 
in which conserved Tyr/Trp residues were individually substituted with Ala without loss of activity. Very similar 
results were obtained for the Cys variants when DTT was removed from the assays (Experiment performed by Dr. 
Nilkamal Mahanta).  
 
To test this possibility, I incubated the enzyme with 14CH3-SAM and the peptide substrate 
without addition of reducing agents. The enzyme was isolated and analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by Coomassie staining or 
autoradiographic imaging. We did not observe a radioactive band for the protein, suggesting that 
the methyl group is not initially transferred to the enzyme. This finding could also be explained by 
a methyl group already being present on the enzyme upon isolation from E. coli; however, single 
turnover experiments presented below suggest against this possibility. We cannot completely rule 
out that transfer of the methyl group from SAM to an amino acid residue only occurs in the 
presence of all reaction components including reductants. TbtI lacks the cobalamin-binding motif 
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characteristic of class B radical SAM MTs (49, 51-58), as well as the tetrahydrofolate-binding 
domain observed in a recently discovered class D radical SAM MT (59). All these factors point 
towards a distinct mechanism for TbtI. 
 
 
Figure 4.13 Time-dependent formation of the methylated TbtA peptide, 5’-dA, and SAH. Reaction mixtures included 
the following components: TbtA hexazole (50 μM), [4Fe-4S] cluster reconstituted TbtI (10 μM), SAM (1 mM), 
flavodoxin (10 μM), flavodoxin reductase (10 μM), NAPDH (2 mM) in reaction buffer (50 mM Tris-HCl, pH 7.5). 
 
To gain insight into the mechanism of methyl transfer, I first determined the products of 
the reaction that are derived from SAM. Out of a concern that the strong reductant dithionite might 
react with the initial products of the enzymatic reaction, we replaced dithionite in our original 
assay (48) with flavodoxin/flavodoxin reductase and NADPH to deliver the reducing equivalents 
to TbtI (see Experimental Section). As anticipated based on other radical SAM proteins (60), 5’-
deoxyadenosine (5’-dA) was detected in slightly more than one equivalent compared to the 
methylated TbtA product (Figure 4.13). Additionally, S-adenosyl-L-homocysteine (SAH) was 
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detected in near stoichiometric quantities, and 5’-dA and SAH were formed at very similar rates 
(Figure 4.13). When the reaction was conducted with CD3-SAM (96% CD3 by ESI-MS; Figure 
4.14), ~90% of the 5’-dA contained a single deuterium (Figure 4.14B), suggesting that the 5’-dA• 
generated from SAM1 may abstract a hydrogen atom from another SAM molecule (SAM2) during 
catalysis. It also suggests that the small amount of unlabeled 5’-dA produced was the result of 
uncoupled SAM cleavage, as has been observed in other radical SAM enzymes (60).  
 
 
Figure 4.14 (A) ESI-MS of the CD3-SAM starting material. Error, 0.7 ppm. (B) ESI-MS analysis of 5’-dA produced 
during the methylation of TbtA by TbtI in the presence of CD3-SAM. Error, 0.4 ppm. The deuterium content of CD3-
SAM was calculated as follows: (Peak intensitym/z = 402)/ [(Peak intensitym/z = 402) + (Peak intensitym/z = 399) + (Peak 
intensitym/z = 400) + (Peak intensitym/z = 401)]. 
 
Control experiments showed that production of SAH and 5’-dA was dependent on the 
presence of both TbtI and the reducing system (Figure 4.15). It was recently reported that another 
class C radical SAM MT involved in nosiheptide biosynthesis (NosN) produces thioadenosine in 
its reaction (61). We therefore investigated if TbtI generated thioadenosine; however, I was unable 
to observe its production by LC-MS whereas an authentic standard was readily detected at the 
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concentrations expected to be produced (Figure 4.15). Another recent study on NosN also 
demonstrated that thioadenosine is not a product of the reaction (62). Based on the products we 
observed, we formulated a series of working hypotheses for the enzymatic mechanism of TbtI 
(Figure 4.16).  
 
 
Figure 4.15 Products of the TbtI reaction. (A-B) Extracted ion chromatograms to analyze production of 5’-dA and 
SAH showed their generation was dependent on the presence of both TbtI and the reducing system. (C-D) Extracted 
ion chromatograms to analyze potential production of methylthioadenosine and thioadenosine did not show the 
presence of these products under the reaction conditions. 
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Figure 4.16 Proposed potential reaction mechanisms for TbtI. 5’-dA• is generated from SAM1 in a process mediated 
by the reduced [4Fe-4S] cluster. The 5’-dA• then abstracts a hydrogen atom from the methyl group of SAM2, and the 
resulting radical adds to the thiazole. An active site base deprotonates radical 11 leading to the elimination of SAH, 
yielding radical 11. Three different pathways (a-c) can provide the product and reset the enzyme. In pathway a, the 
radical is reduced to the anion 12 and protonated. In pathway b, radical 11 abstracts a hydrogen atom from an active 
site amino acid (X-H). X-H could be the protonated base B-H. In pathway c, radical 11 abstracts a hydrogen atom 
from the methyl group of 5’-dA. Ade = adenine. 
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To evaluate the proposed mechanisms, we first investigated whether thiazole methylation 
involves transfer of the intact methyl group of SAM or a methylene group. Therefore, reactions 
with TbtI were carried out using CD3-SAM. Owing to the large molecular weight of the TbtA 
hexazole core substrate even after removal of most of the leader peptide (three residues remain, 
Val-Gly-Ala) with endo-proteinase GluC (C71H85N19O19S6, [M+H]
+ = 1700 Da), the numerous 
isotopologues visible by mass spectrometry rendered isotope labeling studies difficult to interpret. 
Therefore, we prepared the TbtA hexazole substrate from E. coli grown in minimal media using 
13C-depleted glucose and 15N-depleted (NH4)2SO4 as the sole carbon and nitrogen sources, and 
again removed the majority of the leader peptide by treatment with endo-proteinase GluC. The 
resulting TbtA hexazole core peptide 7’ (Figure 4.7B) was analyzed by electrospray ionization 
mass spectrometry (ESI-MS) and exhibited a much-simplified spectrum (Figure 4.17).  
 
 
Figure 4.17 ESI-MS analysis of the doubly charged endo-proteinase GluC digested (13C, 15N)-depleted TbtA hexazole 
7’ (top, red) and natural abundance TbtA hexazole (bottom, blue).  
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Use of CD3-SAM in a 16 h methylation assay with TbtI and peptide 7’ resulted in an 
unexpectedly complicated mass spectrum for the product in which ions were observed consistent 
with the addition of CH3, CH2D, and CHD2 groups (Figure 4.18A). These findings indicated that 
there was either an intermediate that underwent considerable solvent exchange or the product 
exchanged with solvent after initial formation (or both). To test the latter possibility, we repeated 
the experiment with CD3-SAM and quenched the reaction after only 1 h. The product was analyzed 
by ESI-MS and an ion was observed that was consistent with the transfer of a CD2H group (Figure 
4.18A, blue spectrum). This product was purified by high performance liquid chromatography 
(HPLC), exposed to the assay conditions for the extended reaction time (16 h), re-isolated, and 
then again analyzed by ESI-MS. In agreement with the original findings, a complicated mixture of 
product peptide was observed that corresponded to apparent transfer of CH3, CH2D, and CHD2 
(Figure 4.19). This exchange was dependent on the presence of TbtI and SAM; replacing SAM 
with SAH did not result in exchange. Thus, these experiments show that the initial product of the 
reaction of TbtI with CD3-SAM and 7’ mainly contains a CD2H group, but that the enzyme can 
exchange the deuterium labels with protium from solvent. Unfortunately, the large amounts of 5’-
dA produced from the abortive cleavage of SAM during the 16 h reactions precluded our ability 





Figure 4.18 ESI mass spectra to investigate the origin of the methyl protons. 13C- and 15N-depleted substrate peptides 
were obtained as described (see Experimental Section). (A) Spectra showing the doubly charged ion for the hexazole-
containing core peptide substrate 7’ (red) and the methylated product obtained with CD3-SAM in H2O after 1 h (blue) 
or 16 h (black) reactions. (B) Spectra showing substrate (red) and product obtained with CD3-SAM in D2O (blue) and 
CD3-5’,5’,4’,3’-D4-SAM in D2O (black) after 1 h.  
 
Because of the solvent exchange observed at extended reaction times, all subsequent assays 
were performed for 1 h. We first investigated whether the generation of the product containing a 
CHD2 group when using CD3-SAM in H2O involves the incorporation of a proton from solvent. 
Thus, the reaction was performed using CD3-SAM in D2O. Analysis of the product by ESI-MS 
(Figure 4.18B) showed that the major product still contained CHD2, although the relative amount 
of CD3 transfer increased. This observation suggests that a hydrogen atom in an initially non-
exchangeable position migrates to the methyl group, possibly with the intermediacy of a partially 
solvent exchangeable intermediate. The mechanisms in Figure 4.16 provide three possible sources 
for this hydrogen. First, the thiazole proton on the -carbon of 7’ that must be removed during the 
methylation process could migrate via an active site base to the methyl group of the product 
(pathway a). Alternatively, a hydrogen that originates from the protein that does not exchange 
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could be transferred to the methyl group (pathway b). Based on literature precedent, an example 
of the latter could be the -protons of Gly. Lastly, the hydrogen could originate from the methyl 
group of 5’-dA (pathway c). 
 
 
Figure 4.19 ESI-MS spectra to investigate methyl group solvent exchange. Spectra showing the doubly charged core 
peptide of the TbtA hexazole substrate 7’ (red) and product obtained with CD3-SAM in H2O after a 1 h reaction (blue) 
or the product from this reaction re-exposed to the same reaction for 16 h (black).  
 
We first considered 5’-dA as the source for the additional hydrogen in the methyl group of 
the product. Abstraction of a hydrogen atom from 5’-dA by radical 11 (pathway c, Figure 4.16) 
would explain transfer of CHD2 when employing CD3-SAM. We therefore prepared SAM from 
Met-CD3 and 5’,5’,4’,3’-D4-ATP (~ 92% CD3-5’,5’,4’,3’-D4-SAM by ESI-MS, Figure 4.20). The 
resulting CD3-5’,5’,4’,3’-D4-SAM was then reacted with TbtI and the TbtA hexazole 7’ in D2O. 
The reaction products were then analyzed by ESI-TOF MS. The amount of product that contained 
CHD2 was similar to that observed when the 5’ position of SAM was unlabeled (Figure 4.18B). 
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Hence, the hydrogen in this product does not originate from the 5’ position of the adenosine, ruling 
out pathway c. 
 
 
Figure 4.20 Synthesis and ESI-MS analysis of CD3-5',5',4',3'-D4-SAM. Error, 0.7 ppm. The deuterium content of 
CD3-5’,5’,4’,3’-D4-SAM was calculated as follows taking into account that some of the ion at 406 might arise from a 
13C-contaning isotopologue of the ion at m/z 405: [(Peak intensitym/z = 406) – (0.3 × Peak intensitym/z = 405)/ [(Peak 
intensitym/z = 406) + (Peak intensitym/z = 405) + (Peak intensitym/z = 404) + (Peak intensitym/z = 403) + (Peak intensitym/z = 402)]. 
 
We next considered pathway b to account for the product hydrogen, in which a non-
exchangeable hydrogen on the protein is transferred to the product methyl group in the first 
turnover; this hydrogen would be replaced by a solvent-derived hydrogen in subsequent turnovers. 
This behavior has previously been observed, such as the transfer of C hydrogens from a Gly 
residue (63, 64). In principle, hydrogen transfer could also originate from other amino acids or 
very tightly hydrogen bonded positions that would only exchange upon reaction. Because TbtI 
contains several conserved Gly residues (Figure 4.11), we reacted a 20-fold excess of substrate 7’ 
and CD3-SAM with TbtI in buffered D2O and analyzed the product by ESI-MS (Figure 4.21). The 
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major product again contained a CHD2 group, arguing against a protein-derived hydrogen that is 
transferred to the methyl group. 
 
 
Figure 4.21 ESI-MS spectra ruling out transfer of a non-exchangeable hydrogen derived from the protein. Spectra 
showing the doubly charged core peptide of the TbtA hexazole substrate 7’ (red) and product obtained with a 20-fold 
excess of substrate and CD3-SAM with TbtI in buffered D2O. 
 
Having ruled out pathways b and c, we next replaced the Cproton of the thiazole with 
deuterium to interrogate pathway a (Figure 4.16). We prepared TbtA hexazole using an E. coli 
strain that is auxotrophic for Cys and provided -D2-Cys to the 
13C/15N-depleted minimal media. 
Unfortunately, the expression level of the peptide under these conditions was very low. During 
optimization of the expression conditions, we noted that improved production could be achieved 
upon addition of a limited number of unlabeled amino acids to the culture media (see Experimental 
Section for details). Analysis by tandem ESI-MS confirmed the desired deuterium labeling of the 
six Cys residues in the TbtA precursor (Figure 4.22). The resulting peptide (~ 95% D2 at Cys4 by 
ESI-MS-MS) was then converted to the corresponding hexazole-containing core peptide 8 in vitro 
as previously reported (65). Owing to the need to add additional amino acids (which were not 13C- 
and 15N-depleted), the monoisotopic purity of the hexazole 8 was lower than that of the substrate 
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7’. Nevertheless, an ion consistent with the hexa-deuterated TbtA hexazole core peptide as the 
major product was observed by ESI-MS. 
 
 
Figure 4.22 Tandem ESI-MS on TbtA core peptide containing six D2-Cys residues. The tandem MS analysis was 
performed on the precursor peptide pre-treated with endo-proteinase GluC to remove most of the leader peptide (65). 
Analysis of the tandem MS data reveals that six D2-Cys were incorporated into the peptide.  The deuterium content at 
Cys4 was estimated by determining the deuterium content of the b7 ion in comparison to the deuterium content of the 
b6 ion: [peak intensity of the b7 ion (m/z = 639)/ (peak intensity of the b7 ion (m/z = 639) + the peak intensity of b7 − 
1 ion (m/z = 638))] – [peak intensity of the b6 ion (m/z = 534)/ (peak intensity of the b6 ion (m/z = 534) + the peak 
intensity of b6 − 1 ion (m/z = 533))]. 
 
With peptide 8 in hand, we conducted a series of single turnover experiments. If the proton 
in the transferred CHD2 was protein-derived in Figure 3b, then a single turnover experiment in 
D2O with substrate 8 and CD3-SAM should still result in CHD2 transfer. However, when the 
experiment was performed with a three-fold excess of TbtI over substrate 8, CD3 transfer was 
observed as the major product (Figure 4.23A). This result provided additional data against 
pathway b: a non-exchangeable hydrogen from the enzyme was not the source of hydrogen in the 
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methyl group of the product. We tentatively propose that the small amount of CHD2 transfer 
observed may originate in part because of incomplete deuteration of the reagents. We then repeated 
the single turnover experiment with CD3-SAM in D2O but employed substrate 7’. A considerable 
amount of CD3 transfer was observed, indicating that solvent exchange occurred in the single 
turnover experiments with excess enzyme (Figure 4.23B), but importantly, the relative amount of 
CD3 transfer declined considerably compared to experiments conducted with substrate 8. 
Collectively, these data provide strong support for pathway a being operative during TbtI catalysis. 
These experiments also argue against TbtI already containing a covalently bound methyl group 
introduced during expression in E. coli; this methyl group would have been unlabeled and 
therefore, we would have observed a considerable amount of product containing CH3 and CH2D. 
To identify residues that may mediate the transfer process, Dr. Nilkamal Mahanta 
substituted conserved residues Tyr8 and Glu105 of TbtI with Ala (Figure 4.11). The 
corresponding residues are near the SAM-binding site in HemN (66, 67), a radical SAM 
decarboxylase from the heme biosynthetic pathway that is homologous to TbtI. Replacement of 
either residue resulted in TbtI variants with severely decreased activity (Figure 4.24). Two 
additional conserved residues (Trp23 and Tyr200) were targeted for Ala substitution given that 
they could participate in electron or hydrogen atom transfer; however, the activity of the resulting 




Figure 4.23 A solvent exchangeable proton migrates from the -position of thiazole 4 to the methyl group in the 
product. (A) Spectra showing the doubly charged core peptide of the TbtA hexazole substrate 8 that is deuterated at 
the -carbon of each thiazole (red) and the corresponding product obtained with CD3-SAM in D2O (blue) in a single 
turnover reaction. (B) Spectra showing the doubly charged core peptide of the TbtA hexazole substrate 7’ (red) and 
the corresponding product obtained with CD3-SAM in D2O (blue) in a TbtI-catalyzed single turnover reaction. 
 
A combination of product analysis and isotope labeling studies has allowed us to formulate 
a mechanism for TbtI that is consistent with all of our available data. The observation of 5’-dA as 
a product suggests that the TbtI-catalyzed reaction is initiated in a manner similar to canonical 
radical SAM proteins: electron transfer from the reduced [4Fe-4S] cluster initiates the reductive 
cleavage of SAM1 to form methionine and 5’-dA• (Figure 4.16) (60). We propose that the 5’-dA• 
then abstracts a hydrogen atom from the methyl group of SAM2. This hypothesis is supported by 
the observation that use of CD3-SAM resulted in the incorporation of one deuterium into 5’-dA. 
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This reaction appears irreversible since we never observed multiple deuteriums in 5’-dA (Figure 
4.14). Use of two molecules of SAM is also consistent with (i) the observed stoichiometry of 5’-
dA and SAH to the methylated product, (ii) the previously reported crystal structure of HemN with 
two bound SAM molecules (66, 67), and (iii) recent results reported for the class C radical SAM 
MT NosN (62). Although HemN and TbtI catalyze different reactions (decarboxylation and 
methylation, respectively), the use two molecules of SAM might be a general property of class C 
radical SAM enzymes. 
 
 
Figure 4.24 MALDI-TOF MS analysis of the products generated by TbtI variants. Spectra of TbtA treated with wt 
TbtI or TbtI variants in which the class C rSAM-conserved Glu and Tyr residues were substituted with Ala. According 
to the crystal structure of HemN, these residues are near the SAM-binding site (Experiment performed by Dr. Nilkamal 
Mahanta). 
 
Upon hydrogen atom abstraction from the methyl group of SAM2, we propose that the 
resulting methylene radical adds to the electrophilic C=C bond of the thiazole, generating 
resonance-stabilized radical 10 (Figure 4.16). This may trigger deprotonation from the -position 
 130 
by an active site base B to eliminate SAH and form resonance-stabilized radical 11 that partially 
restores thiazole aromaticity (Figure 4.16). This proton is adjacent to an enoxy-radical and 
previous studies on 2-hydroxyglutaryl-CoA dehydratase (68) have suggested that the pKa of such 
protons are on the order of ~14. One candidate residue for the active site base is Glu105, which 
upon substitution with Ala severely decreases TbtI activity (Figure 4.24). The equivalent Glu in 
HemN (Glu145) is near the SAM-binding site (66, 67); thus, an alternative role for Glu105 could 
be to bind SAM. Reduction of radical 11, possibly by the [4Fe-4S] cluster, would produce 
resonance-stabilized anion 12, which can then be protonated by the conjugate acid of the active 
site base, possibly Glu105. This pathway would explain the observed deuterium transfer from the 
 position of the thiazole to the methyl group in the product (Figure 4.13). 
A variation of this mechanism features abstraction by radical 11 of a hydrogen atom from 
a redox active amino acid in the active site (e.g. Tyr/Trp/Gly; Cys can be ruled out since their 
replacement with Ala had no effect on activity, Figure 4.12). The amino acid radical would then 
be reduced and protonated to reset the enzyme for another turnover (Figure 4.16, pathway b). The 
single turnover experiments argue against the possibility that this hydrogen is in a non-
exchangeable position in the first turnover but becomes a solvent-derived hydrogen in subsequent 
turnovers. Hence, the involvement of Gly radicals is unlikely, but other redox active amino acids 
cannot yet be ruled out. For instance, a tyrosinate could serve as the base that deprotonates radical 
10 and the resulting phenol moiety could then provide a hydrogen atom to radical 11. Tyr8 is 
conserved in the class C radical SAM proteins (Figure 4.11). In HemN, the equivalent Tyr56 -
stacks with the adenine of SAM2. Substitution of TbtI Tyr8 with Ala severely decreased activity 
(Figure 4.24), and hence Tyr8 might be a hydrogen atom donor that generates the final product. 
We ruled out the possibility, at least in vitro, that the final hydrogen atom donor is 5’-dA by 
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conducting experiments with SAM that was deuterated at both the methyl group and the 5’ position 
(Figure 4.16, pathway c). Use of this deuterated SAM analogue did not result in an increase in the 
deuterium content of the final product. However, from an efficiency perspective, hydrogen atom 
abstraction from 5’-dA would be attractive as it would directly regenerate the 5’-dA• and would 
not require the additional electron required for pathways a and b. Furthermore, as shown by the 
SAM-dependent solvent exchange of the methyl group in the product, 5’-dA• may abstract a 
hydrogen atom from the methyl group in the product, which would be the microscopic reverse of 
the last step of pathway c. Hence, while pathway c clearly is not consistent with our in vitro 
findings, perhaps under the right conditions pathway c might be operational in vivo. 
The proposed mechanism accounts for the observed solvent exchange upon prolonged 
reaction times by realization that the methylated peptide product, SAM1, and SAH can likely still 
bind to the active site since these three molecules can occupy nearly identical positions as the 
substrate peptide, SAM1, and SAM2 at the start of catalysis (the only difference is that the methyl 
group of SAM2 is transferred to the peptide). Reductive cleavage of SAM1 would generate 5’-
dA• and the methyl group of the product peptide would be in a very similar position as the methyl 
group of SAM2 during productive turnover. Thus, hydrogen atom abstraction could again generate 
radical 11 and either pathway a or b would result in hydrogen transfer by an active site residue, 
thus affecting the observed exchange (Figure 4.25A). Alternatively, the exchange could occur by 




Figure 4.25 Proposed mechanisms for exchange of the methyl protons of the product peptide. (A) The methylated 
product and SAH can bind to the enzyme, SAM1 can be cleaved to initiate the hydrogen atom abstraction from the 
methylated peptide. Its methyl group would be expected to occupy a very similar position as the methyl group of 
SAM2 during normal turnover. Reduction of the resulting radical to the anion and protonation results in exchange 
(analogous to pathway a in Figure 4.16), or hydrogen atom abstraction from a redox active residue in the active site 
(analogous to pathway b, Figure 4.16) would result in exchange. (B) An alternative mechanism involves 
deprotonation of the methyl group, the reverse of the protonation step that provides the product in pathway a. The 
mechanism in panel (A) requires SAM cleavage whereas the mechanism in (B) does not. Unfortunately, we were not 
able to determine whether a hydrogen is transferred from the methyl group to 5'-dA during prolonged reactions because 
of extensive abortive SAM cleavage. Ade = adenine. 
 
In summary, our study suggests that methyl transfer catalyzed by TbtI involves two SAM 
molecules. Our data are consistent with a mechanism in which one SAM is reductively cleaved to 
5’dA• as in other radical SAM enzymes. The 5’dA• then abstracts a hydrogen atom from a second 
SAM, and the resulting carbon-based methylene radical attacks the thiazole at position 4 of the 
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peptide substrate. This SAM-derived radical is unprecedented in radical SAM enzymology. We 
note that like the class A radical SAM MTs and a recent report on the class C MT NosN (62), TbtI 
formally transfers a methylene group from SAM to the substrate and hence might not be considered 
a true methyl transferase. Regardless, the manner by which this is accomplished adds a 
fundamentally different use of SAM in this class of enzymes, and highlights their versatility and 
catalytic diversity in natural product biosynthesis. Additional biochemical and structural studies 
on TbtI are underway to gain further insights to the mechanism of this remarkable transformation. 
 
4.3 Experimental methods 
General materials and methods 
Reagents used for molecular biology experiments were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Escherichia coli DH5α and BL21 (DE3) strains were used for plasmid maintenance and protein 
overexpression, respectively. E. coli JW3582-2 that is auxotrophic for cysteine was purchased 
from the Coli Genetic Stock Center at Yale University 
(https://cgsc2.biology.yale.edu/Strain.php?ID=108920). Plasmid inserts were sequenced at the 
University of Illinois core sequencing facility and ACGT Inc. (Wheeling, IL). MALDI-TOF-MS 
analysis was performed using a Bruker UltrafleXtreme matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometer (Bruker Daltonics) in reflector positive mode at 
the University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. ESI-
MS/MS analyses were performed using a SYNAPT electrospray ionization (ESI) quadrupole TOF 
Mass Spectrometry System (Waters) equipped with an ACQUITY Ultra Performance Liquid 
 134 
Chromatography (UPLC) system (Waters). HiTrap columns for Ni-NTA affinity chromatography 
were purchased from GE Healthcare. 
 
Molecular biology techniques 
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). 
Genes optimized for recombinant expression in E. coli were synthesized by GenScript 
(Piscataway, NJ) in pUC57 (kanamycin, Kan) vectors with BamHI and XhoI sites flanking each 
gene at the 5’ and 3’ ends, respectively. E. coli DH5α were transformed with pUC57-Kan vectors 
containing each gene for replication and subsequent isolation using a QIAprep Spin Miniprep Kit 
(Qiagen). The isolated DNA was then treated with BamHI-HF and XhoI-HF (New England 
Biolabs; NEB). The digested genes were separated on a 1% (w/v) agarose gel, purified using a 
QIAQuick gel extraction kit (Qiagen), and ligated into an appropriately endonuclease-digested and 
gel-purified pET28 vector with maltose binding protein (MBP) 5’ to the multiple cloning site using 
T4 DNA ligase (NEB). Ligation reactions were used to transform chemically competent DH5α 
cells, which were plated on Luria-Bertani (LB) agar plates containing 50 μg/mL kanamycin and 
grown at 37 °C. Colonies were picked at random and grown in LB broth for 16–20 h prior to 
plasmid isolation using a QIAprep Spin Miniprep Kit. The construct encoding for tbtA with either 
one Cys at position 4 or two Cys at positions 2 and 4 of the core as well as all Cys replaced with 
Ala was previously described and the latter was used for downstream site-directed mutagenesis 
(SDM) (45). SDM was performed using the QuikChange method (Agilent) as per the 
manufacturer’s instructions using PfuTurbo DNA polymerase. The primers for each mutant are 
listed in Table 4.2. The mutations were verified by sequencing using a custom MBP forward 
primer or the T7 reverse primer (Table 4.2). 
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MBP-tagged TbtI overexpression  
E. coli BL21(DE3) cells were co-transformed with a pET28 plasmid encoding the MBP-
tagged TbtI and the pSUF plasmid encoding the Fe-S biosynthetic operon (38). Cells were grown 
for 24 h on LB agar plates containing 50 μg/mL kanamycin and 34 μg/mL chloramphenicol at 37 
°C. Single colonies were used to inoculate 10 mL of LB containing the same concentration of 
antibiotics and grown at 37 °C for 16–18 h. This culture was used to inoculate 1 L of LB (5 g/L 
yeast extract, 10 g/L tryptone and 10 g/L NaCl) supplemented with the same concentration of 
antibiotics and grown to an optical density at 600 nm (OD600) of 0.6 before being placed on ice for 
15 min. Protein expression was then induced with the addition of 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and supplemented with 100 mg/L of ferrous ammonium sulfate 
(Fe(NH4)2(SO4)2) and 100 mg/L of cysteine. Expression was allowed to proceed for 12–16 h at 15 
°C. Cells were harvested by centrifugation at 3,000 × g for 20 min, washed with phosphate-
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4), and 
harvested by centrifugation. The cells were flash-frozen and stored at –80 °C for a maximum of 
one week before use (notebook reference 5/5/2016). 
 
MBP-tagged TbtI purification  
Protein purification was performed in a Coy anaerobic chamber. All buffers were degassed 
and stored for 24–48 h in the anaerobic chamber before use. Cells were resuspended in lysis buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2.5% glycerol (v/v), and 0.1% Triton X-100 (v/v)) 
containing 4 mg/mL lysozyme, 2 μM leupeptin, 2 μM benzamidine, and 2 μM E64 to inhibit 
proteolysis. Cells were further lysed by sonication (3 × 45 s with 10 min agitation periods at 4 °C). 
Insoluble debris was removed by centrifugation at 20,000 × g for 40 min at 4 °C. The supernatant 
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was then applied to lysis-buffer pre-equilibrated amylose resin (NEB; 15 mL of resin per L of 
initial cell culture). The column was washed with 10 column volumes (CV) of lysis buffer followed 
by 10 CV of wash buffer (lysis buffer with 400 mM NaCl and lacking Triton X-100). The MBP-
tagged proteins were eluted using elution buffer (lysis buffer with 300 mM NaCl, 10 mM maltose, 
but omitting Triton X-100) until the eluent no longer contained protein detectable with the 
Bradford reagent. Eluent was concentrated using a 30 kDa molecular weight cut-off (MWCO) 
Amicon Ultra centrifugal filter (EMD Millipore). A buffer exchange with 10× volume of protein 
storage buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 300 
mM NaCl, 2.5% glycerol (v/v)] was performed prior to final concentration, freezing in liquid 
nitrogen, and storage at –80 °C. Protein concentrations were determined using both absorbance at 
280 nm (theoretical extinction coefficients were calculated using the ExPASy ProtParam tool; 
http://web.expasy.org/protparam/protpar-ref.html) and a Bradford colorimetric assay. Purity was 
assessed visually by analysis of Coomassie-stained SDS-PAGE gels (Figure 4.2A). All wash, 
elution, and storage buffers were supplemented with 0.5 mM tris-(2-carboxyethyl)-phosphine 
(TCEP) (notebook reference 5/6/2016). 
 
His6-tagged cysteine desulfurase (IscS) overexpression  
E. coli BL21 (DE3) cells were co-transformed with a His6-IscS-pET15 plasmid encoding 
His6-tagged IscS (plasmid obtained from Prof. Tadhg Begley group at Texas A&M University). 
Cells were grown for 24 h on LB agar plates containing 100 μg/mL ampicillin at 37 °C. Single 
colonies were used to inoculate 10 mL of LB containing 100 μg/mL ampicillin and grown at 37 
°C for 16–18 h. This culture was used to inoculate 1 L of LB (5 g/L yeast extract, 10 g/L tryptone 
and 10 g/L NaCl) and grown to an optical density at 600 nm (OD600) of 0.6 before being placed 
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on ice for 15 min. Protein expression was then induced with the addition of 0.5 mM IPTG. 
Expression was allowed to proceed for 12–16 h at 15 °C. Cells were harvested by centrifugation 
at 3,000 × g for 20 min, washed with PBS and harvested by centrifugation. The cells were flash-
frozen and stored at –80 °C for a maximum of one week before use (notebook reference 6/3/2016). 
 
His6-tagged IscS purification  
Cells were resuspended in lysis buffer (20 mM Na2HPO4, 500 mM NaCl, 10 mM 
imidazole, pH 7.4, 2.5% glycerol (v/v), and 0.1% Triton X-100) containing 4 mg/mL lysozyme, 2 
μM leupeptin, 2 μM benzamidine, and 2 μM E64. Cells were further lysed by sonication (3 × 45 s 
with 10 min agitation periods at 4 °C). Insoluble debris was removed by centrifugation at 20,000 
× g for 40 min. The supernatant was then applied to a pre-equilibrated Ni-NTA resin (Thermo 
Scientific; 15 mL of resin per L of cells). The column was washed with 10 CV of lysis buffer 
followed by 10 CV of wash buffer (lysis buffer with 30 mM imidazole and lacking Triton X-100). 
The His6-tagged proteins were eluted using elution buffer (lysis buffer with 300 mM NaCl, 300 
mM imidazole and lacking Triton X-100) until the eluent no longer contained protein detectable 
with the Bradford reagent. Eluent was further buffer exchanged with storage buffer (20 mM Tris-
HCl , 300 mM NaCl, 2.5% glycerol (v/v), pH 7.4) using PD-10 column, and the protein solution 
was concentrated and stored and the protein concentration was assayed as described for TbtI (vide 
supra). Purity and possible truncation were assessed by Coomassie-stained SDS-PAGE gel 
(Figure 4.2A). All wash, elution, and storage buffers were supplemented with 0.5 mM tris-(2-




In vitro reconstitution of the Fe-S cluster in TbtI  
TbtI (50 μM) was equilibrated with 1 mM ferrous ammonium sulfate [Fe(NH4)2(SO4)2], 
cysteine (2 mM), dithiothreitol (DTT, 2 mM) and IscS (2 μM) in 50 mM Tris-HCl pH 7.5 buffer 
in the anaerobic chamber. The reaction mixture was buffer exchanged using a 10 kDa MWCO gel 
filtration column (EMD Millipore) before concentration and use for assays. The reactions were 
allowed to proceed for 4–6 h (notebook reference 9/5/2016). 
 
In vitro methylation of TbtA by TbtI  
Reaction mixtures generally included the following components: substrate (50 μM), 
purified TbtI from E. coli heterologous expression after in vitro reconstitution of the Fe-S cluster 
(2 μM), S-adenosyl-L-methionine (SAM, 1 mM) and sodium dithionite (5 mM) in reaction buffer 
(50 mM Tris-HCl pH 7.5). The reaction was allowed to proceed for 6–12 h at 25 °C in an anaerobic 
chamber. Reaction mixtures were desalted via C18 ZipTip (EMD Millipore) per the 
manufacturer’s instructions, and the product was eluted using a saturated solution of sinapinic acid 
in 60% aq. MeCN. Reactions were monitored using MALDI-TOF-MS. 
The in vitro methylation reaction was also carried out using flavodoxin/flavodoxin 
reductase/NADPH as the reducing system. Briefly, under this condition, the in vitro methylation 
reaction mixtures generally included the following components: TbtA hexazole substrate (50–100 
μM), purified TbtI from E. coli heterologous expression after in vitro reconstitution of the [4Fe-
4S] cluster (10 μM), SAM (1 mM), flavodoxin (10 μM), flavodoxin reductase (10 μM), reduced 
nicotinamide adenine dinucleotide phosphate (NAPDH, 2 mM) in reaction buffer (50 mM Tris-
HCl, pH 7.5). The reaction was allowed to proceed for 1 h at 25 °C in an anaerobic chamber (Coy 
laboratory) (notebook reference 9/5/2016). 
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For reactions performed in D2O, all reagents that participate in the reaction were first 
dissolved in D2O, lyophilized and re-dissolved in D2O followed by adjusting of the pD. The buffer 
containing the proteins was exchanged with D2O storage buffer (50 mM Tris, 300 mM NaCl, pD 
7.5) by repeated concentration by ultrafiltration and dilution (four times) before addition into the 
reaction. The reaction was allowed to proceed in D2O reaction buffer (50 mM Tris, pD 7.5) for 1 
h at 25 °C in the anaerobic chamber (notebook reference 6/3/2017). 
For single turnover reactions, a reaction mixture generally included the following 
components: TbtA hexazole substrate (20 μM), purified TbtI after in vitro reconstitution of the 
[4Fe-4S] cluster (60 μM), SAM (1 mM), flavodoxin (30 μM), flavodoxin reductase (30 μM), 
reduced nicotinamide adenine dinucleotide phosphate (NAPDH, 2 mM) in reaction buffer (50 mM 
Tris-HCl, pH 7.5). The reaction was allowed to proceed for 10 min at 25 °C in the anaerobic 
chamber. 
To determine the specific activity of the TbtI used, the enzyme (10 μM) was incubated with 
the hexazole substrate peptide (100 μM), SAM (1 mM), flavodoxin (20 μM), flavodoxin reductase 
(20 μM), reduced nicotinamide adenine dinucleotide phosphate (NAPDH, 2 mM) in reaction 
buffer (50 mM Tris-HCl, pH 7.5). The reaction was allowed to proceed at 25 °C in an anaerobic 
chamber, and aliquots were removed at set time points (30, 60, 90, and 120 s). At 120 s the 
conversion was 15%. Product formation over time was linear with a velocity of 15.6 × 10-3 
μmol/min/mg of TbtI (i.e. 0.72 min-1). To assure that under these conditions the reaction catalyzed 
by TbtI was rate limiting, the amounts of flavodoxin and flavodoxin reductase were doubled, and 
no change in velocity was observed. Similarly, to assure that all substrates were saturating, the 
concentrations of SAM, NADPH and peptide were doubled without observing a change in velocity 
(notebook reference 11/2/2017). 
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Generation of 13C- and 15N-depleted TbtA hexazole  
Isotopically depleted TbtA hexazole was produced in E. coli cultured in modified M9 
minimal media (69). E. coli BL21(DE3) cells containing a pTrc99a_TbtF,G,E plasmid encoding 
MBP-tagged TbtF, MBP-tagged TbtG, and TbtE and a His6-TbtA-pRSFDuet-1 plasmid encoding 
the His6-TbtA were grown overnight at 37 ºC in lysogeny broth (LB) containing 25 μg/mL 
kanamycin and 50 μg/mL ampicillin. After harvesting the cells, the supernatant was discarded and 
the cells were washed with 5 mL of wash buffer (22 mM KH2PO4, 42 mM Na2HPO4, 8.5 mM 
NaCl, pH 7.4). Following washing, the cells were resuspended in wash buffer and used to inoculate 
(1:100) the modified M9 minimal media, with the following composition per 100 mL: 10 mL of a 
10× stock of minimal media (220 mM KH2PO4, 420 mM Na2HPO4, 85 mM NaCl, pH 7.4), 0.3 
mL of 40% aqueous (14NH4)2SO4 (Sigma-Aldrich), 2 mL of 20% aqueous 
13C-depleted glucose 
(Cambridge Isotope Laboratories), 0.1 mg of FeSO4, 10 μg of thiamine, 200 μL of 1 M MgSO4, 
10 μL of 1 M CaCl2, and 75 μL of a trace element solution (5 mM CaCl2, 1.25 mM ZnCl2, 260 μM 
CuCl2•H2O, 252 μM CoCl2•6H2O, 250 μM Na2MoO4•2H2O, pH 7.4). The media also contained 
50 μg/mL ampicillin and 25 μg/mL kanamycin. The cells were grown at 37 °C and induced at 
OD600 = 0.6-0.8 by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5 mM and grown for an additional 16-18 h at 18 °C before harvesting. 
Purification of TbtA hexazole was carried out as previously described (45) (notebook reference 
3/4/2017). 
 
Generation of TbtA hexazole deuterium labeled at each thiazole 
-D2-cysteine labeled MBP-tagged TbtA was generated using E. coli strain JW3582-2. A 
lysogenization step was performed to JW3582-2 before production of MBP-tagged TbtA so that 
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the host strain could be used to express target genes cloned in T7 expression vectors. 
Lysogenization was performed using the λDE3 Lysogenization Kit (Novagen) as per the 
manufacturer’s instructions. The lysogenized JW3582-2 was transformed with a pET28a_MBP-
TbtA plasmid containing the ampicillin resistance gene and encoding MBP-tagged TbtA.  
Expression of -D2-cysteine labeled MBP-TbtA was performed in modified M9 minimal 
media as described above, except that amino acids were added into the culture (final 
concentrations: 0.5 mM Arg, 1 mM His, 1 mM Leu, 1 mM Lys, 0.5 mM Met, 2 mM Pro, 3 mM 
Thr, 0.4 mM Trp and 1 mM of -D2-Cys). Purification and in vitro cyclodehydration of the -D2-
cysteine-labeled MBP-tagged TbtA was carried out as previously described (65) (notebook 
reference 6/12/2017). 
 
Preparation of SAM 
E. coli strain DM22-(pK8), which overexpresses E. coli SAM synthetase, was constructed 
by G. D. Markham et al. (Fox Chase Cancer Center, Philadelphia, PA) (70). DM22-(pK8) was 
grown in LB containing 30 μg/mL tetracycline at 37 °C while being shaken and harvested by 
centrifugation 12 h after inoculation. The cells (∼12 g) were resuspended in 36 mL of 0.1 M Tris-
HCl (pH 8.0) containing 1 mM ethylenediaminetetraacetic acid (EDTA) and 50 μg/mL lysozyme 
and gently stirred at room temperature for 30 min. Phenylmethylsulfonyl fluoride (PMSF) was 
added to a final concentration of 1 mM, and cells were lysed with a MultiFlex C3 Homogenizer 
(Avestin). The cell lysate was centrifuged for 30 min at 26,500 × g at 4 °C. The cleared lysate was 
dialyzed against 4 L of 100 mM Tris-HCl (pH 8.0), 1 mM EDTA, in 2 × 30 mL 20,000 molecular 
weight cut-off (MWCO) Slide-A-Lyzer dialysis cassettes (Pierce) at 4 °C overnight, and was 
divided into three portions, frozen in liquid nitrogen, and stored at –80°C.  
 142 
SAM was generated enzymatically by incubating an aliquot of the lysate in a buffered 
solution (0.1 L) containing 0.1 M Tris-HCl (pH 8.0), 50 mM KCl, 1 mM EDTA, 20% acetonitrile, 
26 mM MgCl2, 13 mM adenosine triphosphate (ATP), and 10 mM methionine. After the mixture 
had been gently stirred for 5 h at room temperature, the reaction was quenched by adjusting the 
pH to 5.0 with HCl. The mixture was placed on ice for 15 min and centrifuged at 4,000 × g for 30 
min at 4 °C to remove precipitated material. The supernatant was diluted to 1 L with 1 mM sodium 
acetate (pH 5.0) and loaded on a CM-52 cation exchange resin (Whatman) that had been charged 
with 0.2 M sodium acetate (pH 5.0) and equilibrated in 1 mM sodium acetate (pH 5.0). The column 
was rinsed with 1 L of 1 mM sodium acetate (pH 5.0), and SAM was eluted with 0.5 L of 40 mM 
H2SO4. The presence of SAM was monitored by UV-Vis absorption at 260 nm, and fractions 
containing SAM were combined. The pH of the solution was adjusted to 5.2 with Ba(OH)2 and 
then filtered to remove the BaSO4 precipitate. The filtered solution was concentrated by rotovap 
to a volume of 4 mL, and was divided into several fractions and stored at −80 °C. Deuterium-
labeled SAM was prepared using the same procedure but with labelled methionine or ATP 
(notebook reference 2/18/2017). 
 
Radioactive assay with 14CH3-SAM 
The assay to determine whether the SAM methyl group is transferred onto TbtI was 
performed with 14CH3-SAM (0.02 mCi/mL, 300 μM, PerkinElmer). The in vitro reconstitution of 
the [4Fe-4S] cluster of MBP-TbtI was performed as previously described, followed by addition of 
TbtA hexazole inside an anaerobic chamber. After incubation at room temperature for 1 h, the 
reaction mixture was taken out of the anaerobic chamber and moved into an anaerobic bag filled 
with nitrogen gas, and 1:1 14CH3-SAM/unlabeled CH3-SAM mixture was then added into the 
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reaction inside the anaerobic bag. The reaction mixture included the following components: MBP-
TbtI (10 μM), TbtA hexazole (100 μM), 1:1 14CH3-SAM/unlabeled CH3-SAM mixture (300 μM) 
in a final volume of 100 μL. The reaction was incubated at room temperature for 1 h, and 30 μL 
of the reaction mixture was loaded on a 4-20% polyacrylamide gel. Electrophoresis was performed 
for 45 min at 150 V (constant voltage), and then the gel was stained with Coomassie blue solution 
(40% methanol, 10% acetic acid, 0.1 % Coomassie blue R250 in H2O) for 30 min and destained 
in destain buffer (20% methanol, 10% acetic acid in H2O) for 3 h. After drying the gel overnight 
with a gel-drying kit (Promega) in accordance with the manufacturer’s procedure, the dried gel 
was exposed on a phosphorimager cassette for 4 days. The film was visualized with a STORM840 
Phosphorimager Scanner (Amersham Biosciences). Whereas the Coomassie stained gel clearly 
showed the presence of the protein, no radioactivity was observed in the gel (notebook reference 
11/5/2017). 
 
Table 4.2 Oligonucleotides primers used in this study. All sequences are provided 5′ to 3′. F indicates a forward primer 
while R indicates the reverse primer. 
Primer Name Oligonucleotide Sequence 
tbtI C14A F ATATCCCGTTCGCTAACTCTAAATGCCACTTCTGCGACTGG 
tbtI C14A R CATTTAGAGTTAGCGAACGGGATATTCACATACAGCAGCAG 
tbtI C18A F GTAACTCTAAAGCCCACTTCTGCGACTGGGTTGTCCAAATC 
tbtI C18A R TCGCAGAAGTGGGCTTTAGAGTTACAGAACGGGATATTCAC 
tbtI C21A F AATGCCACTTCGCCGACTGGGTTGTCCAAATCCCGGTGCGT 
tbtI C21A R ACAACCCAGTCGGCGAAGTGGCATTTAGAGTTACAGAACGG 
tbtI C89A F CTCTGTATACGGCCCTGCGTTCAGAATTCGATCTGTCGCAC 
tbtI C89A R TCTGAACGCAGGGCCGTATACAGAGATTCGATTTCGCTTTC 
tbtI C254A F GTGCACCGCGTGCCGAAGCAGATCAGGCATATTACCGCCTG 
tbtI C254A R TGATCTGCTTCGGCACGCGGTGCACCGAAGTAGCTCATCGC 
tbtI C343A F TGCGTGTCGCAGCTGAAGAACCGGAAGTGCAAGCCTACCTG 
tbtI C343A R TCCGGTTCTTCAGCTGCGACACGCAGCGGCGTACCGGTACGT 
tbtI W23A F ACTTCTGCGACGCGGTTGTCCAAATCCCGGTGCGTGATCTG 
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Table 4.2 (cont.) 
 
 
Primer Name Oligonucleotide Sequence 
tbtI W23A R ATTTGGACAACCGCGTCGCAGAAGTGGCATTTAGAGTTACA 
tbtI Y200A F ATTTTAGTATCGCTCCGTACCGTGCATCCCCGGGTACCATT 
tbtI Y200A R GCACGGTACGGAGCGATACTAAAATGGTTAATCGGCAGCGT 
tbtI E105A F AAACCACGATTGCAGGTAGTCCGGAATCCCTGACCCCGCAG 
tbtI E105A R TCCGGACTACCTGCAATCGTGGTTTCGCGGACGTGCGACAG 
tbtI Y8A F CGCTGCTGCTGGCTGTGAATATCCCGTTCTGTAACTCTAAA 
tbtI Y8A R GGGATATTCACAGCCAGCAGCAGCGGGCGCGTCAT 
 tbtA N3A F GTGCAAGCTGTGCTTGCTTTTGTTATATTTGTTGTAGCTGC 
 tbtA N3A R TAACAAAAGCAAGCACAGCTTGCACCAACTTCGGTCATACC 
 tbtA N3D F GTGCAAGCTGTGATTGCTTTTGTTATATTTGTTGTAGCTGC 
 tbtA N3D R TAACAAAAGCAATCACAGCTTGCACCAACTTCGGTCATACC 
 tbtA N3Q F GTGCAAGCTGTCAATGCTTTTGTTATATTTGTTGTAGCTGC 
 tbtA N3Q R TAACAAAAGCATTGACAGCTTGCACCAACTTCGGTCATACC 
 tbtA C4A F CAAGCTGTAATGCCTTTTGTTATATTTGTTGTAGCTGCAGC 
 tbtA C4A R ATATAACAAAAGGCATTACAGCTTGCACCAACTTCGGTCAT 
 tbtA C4S F CAAGCTGTAATAGCTTTTGTTATATTTGTTGTAGCTGCAGC 
 tbtA C4S R ATATAACAAAAGCTATTACAGCTTGCACCAACTTCGGTCAT 
tbtA S1N/C4A F AAGTTGGTGCAAACTGTAATGCATTTTGTTATATTTGTTGT 
tbtA S1N/C4A R AATGCATTACAGTTTGCACCAACTTCGGTCATACCATGACC 
tbtA F5N/C4A F GCTGTAATGCAAATTGTTATATTTGTTGTAGCTGCAGCAGC 
tbtA F5N/C4A R CAAATATAACAATTTGCATTACAGCTTGCACCAACTTCGGT 
tbtA I8N/C4A F CATTTTGTTATAATTGTTGTAGCTGCAGCAGCGCCTAATGC 
tbtA I8N/C4A R CAGCTACAACAATTATAACAAAATGCATTACAGCTTGCACC 
tbtA S11N/C4A F ATATTTGTTGTAACTGCAGCAGCGCCTAATGCGGCCG 
tbtA S11N/C4A R GCGCTGCTGCAGTTACAACAAATATAACAAAATGCATTACA 
tbtA C4,6 F CGAATTGTTTTTGTTATATTGCGGCGAGCGCCAGCAGCGCC 
tbtA C4,6 R GCCGCAATATAACAAAAACAATTCGCGCTTGCACCAACTTC 
tbtA C4,9 F TTGCGTATATTTGTGCGAGCGCCAGCAGCGCCTAACTCGAG 
tbtA C4,9 R GCTGGCGCTCGCACAAATATACGCAAAACAATTCGCGCTTG 
tbtA C4,10 F CGTATATTGCGTGTAGCGCCAGCAGCGCCTAACTCGAGCAC 
tbtA C4,10 R CTGCTGGCGCTACACGCAATATACGCAAAACAATTCGCGC 
tbtA C4,12 F TTGCGGCGAGCTGTAGCAGCGCCTAACTCGAGCACCACCAC 
tbtA C4,12 R TAGGCGCTGCTACAGCTCGCCGCAATATACGCAAAACAATTC 
tbtA S1N/N3F F AAGTTGGTGCAAACTGTTTTTGCTTTTGTTATATTTGTTGTAGCTGCAGC 
tbtA S1N/N3F R AACAAAAGCAAAAACAGTTTGCACCAACTTCGGTCATACCATGACCTGCGG 
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CHAPTER 5: CHARACTERIZATION OF THE ATP AND TRNA DEPENDENT 




Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a large and 
diverse class of natural products (1). Included in this family of natural products is the lanthipeptide 
nisin, which has been used for decades against food-borne pathogens with no evidence of stable 
resistance (2). During the maturation of the compound, Ser and Thr residues are first glutamylated 
by the LanB dehydratase, NisB, in a glutamyl-tRNA dependent mechanism (3, 4). Subsequently, 
the glutamate is eliminated to generate dehydroamino acids (Figure 5.1A). Our recent studies in 
thiopeptide biosynthesis (4), as well as studies by Onaka’s laboratory on goadsporin maturation 
(5) have further revealed that the glutamylation and elimination steps for dehydroamino acids 
formation can also be carried out by a split LanB dehydratase enzyme. Our survey of the available 
genomes revealed a large number of genes encoding LanB-like proteins lacking the putative 
elimination domain. In these clusters, the elimination domain is absent entirely from the 
biosynthetic gene cluster and the entire genome. This observation suggests that these stand-alone 
glutamylation domains of LanB dehydratases (sLanB) might add an amino acid in a tRNA-




Figure 5.1 (A) LanB enzymes glutamylate Ser/Thr residues and subsequently eliminate the glutamate to form 
dehydroamino acids. sLanB proteins lack the elimination domain. Dha, dehydroalanine; Dhb, dehydrobutyrine. (B) 
Biosynthetic gene cluster in P. syringae encoding a sLanB. (C) Inferred biosynthetic pathway towards 3-
thiaglutamate. 
 
In Pseudomonas syringae such a sLanB (PmaB) is encoded near an open reading frame of 
a 50-amino acid peptide (PmaA; Figure 5.1B). Through the joint effort of Dr. Michael Funk and 
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Dr. Chi Ting, reconstitution of the activity of enzymes in the neighborhood of the PmaA and PmaB 
revealed a biosynthetic pathway where a small-molecule is biosynthesized with a ribosomally 
synthesized small peptide serving as a catalytic scaffold (Figure 5.1C). First, a cysteine residue is 
transferred from tRNACys to the C-terminus of the peptide, a reaction that replaces ribosomal 
protein synthesis. Then, a translocation of the cysteine thiol from the -carbon to the -carbon is 
catalyzed by an oxidase that removes the -carbon as formate. The resulting thiol is 
carboxymethylated and proteolysis releases 3-thiaglutamate, in the process regenerating the 
peptide scaffold. This gene cluster is intriguing in that the biosynthetic pathway is fundamentally 
different from other known pathways. Unlike RiPPs, the final product in this pathway is not 
encoded in the genome since the pathway does not contain a gene-encoded core peptide (6). But 
unlike non-ribosomal peptides, or other ribosome-independent peptide ligases (7-9), the current 
pathway utilizes a ribosomal scaffold and aminoacyl-tRNA to extend a peptide sequence. sLanB-
encoding genes are abundant in bacterial genomes, with some clusters encoding multiple such 
proteins. Thus, this mechanism of peptide bond formation appears to be widespread and is likely 
driven by the catalytic use of leader peptides as scaffolds for small molecule production. Thus, it 
is very appealing to characterize this aminoacyl-tRNA dependent peptide ligase.  
Previous work by Dr. Michael Funk has shown that co-expression of His6-PmaA and PmaB 
in Escherichia coli and subsequent affinity purification of the peptide resulted in an increase in 
mass by 103 Da (Figure 5.2A). Further high resolution tandem mass spectrometry analysis of the 
peptide suggested that the adduct was attached to the C-terminal alanine (Figure 5.2B), through a 
linkage of a terminal amide. Michael was also able to demonstrate that if PmaB catalyzes the 
reaction in buffer made with H2
18O, the product contains one 18O atom (Figure 5.2C). In this 
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chapter, I present a detailed biochemical and mechanistic investigation of the aminoacyl-tRNA 
dependent peptide ligase PmaB. 
 
 
Figure 5.2 (A) Matrix-assisted laser desorption ionization with time-of-flight (MALDI-TOF) mass spectra of PmaA 
coexpressed with PmaB. (B) Analysis of the PmaB product by tandem electrospray ionization (ESI) mass 
spectrometry. (C) MALDI-TOF MS of PmaA-Cys prepared by in vitro PmaB reaction in 85% H218O results in 18O 
enrichment in the product. 
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5.2 Results and discussion 
5.2.1 Biochemical characterization of PmaB 
I first identified the minimal substrate for PmaB. For this purpose, the PmaA precursor 
peptide was systematically truncated from the N-terminus, and the remaining peptides were used 
in the in vitro cysteine addition reaction. Matrix-assisted laser desorption ionization with time-of-
flight (MALDI-TOF) mass analysis of the reaction suggested that removal of the first 30 out of 50 
amino acids at the N-terminus of the PmaA peptide does not affect PmaB activity (Figure 5.3A). 
However, when PmaA was treated with endo-proteinase AspN to remove the N-terminal 39 
residues, the resulting peptide could be partially converted (Figure 5.3B). When one more amino 
acid residue was retained on the peptide, then complete activity of PmaB was detected again 
(Figure 5.3C), suggesting a PmaA 12mer possesses enough information for PmaB recognition. 
This is find suggests that most part of the peptide is dispensable for the amino acyl ligation 
reaction, and further implies a division of precursor peptide recognition region amongst the various 
biosynthetic enzymes to ensure efficient downstream modifications. 
We next evaluated the substrate specificity of PmaB towards the last amino acid of PmaA. 
A series of PmaA variants were prepared in which the last Ala residue was systematically 
substituted with seven other amino acids, ranging from polar, charged to aromatic (Figure 5.4A). 
These PmaA variants were co-expressed with PmaB in E. coli. All the variants were accepted by 
PmaB except for the charged Glu or Lys residues. An interesting observation was that, as long as 
the charge is blocked, the PmaA variant was converted into the cysteinylated product (see product 
formation using the A50N variant). However, if the last Ala residue is removed from the PmaA 
peptide, no product formation would be detected (Figure 5.4B). These data suggest that PmaB is 
relatively permissive towards the change to the last amino acid of its peptide substrate, and the 
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active site of the protein is large enough to accommodate the different size of amino acid side 
chains. If this last amino acid is removed from the substrate PmaA, the C-terminal carboxylate 
group may not be able to reach into the active site for cysteine addition. 
 
 
Figure 5.3 Identification of the minimal substrate for PmaB. MALDI-TOF mass spectra of (A) PmaA N-terminal 20-
mer and its product for in vitro cysteine addition reaction with PmaB; (B) PmaA 11-mer and its product for in vitro 






Figure 5.4 PmaB is relatively promiscuous towards a change of the last amino acid of PmaA. MALDI-TOF mass 
spectra of (A) PmaA A50 variants and their co-expression products with PmaB in E. coli. (B) PmaA A50 variant 
and its co-expression product with PmaB in E. coli. 
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The previous in vitro reactions were all performed using E. coli cell extract, and the 
complicated nature of the cell extract may hamper mechanistic study of PmaB. As lanthipeptide 
dehydratases glutamylate Ser and Thr residues in a glutamyl-tRNA dependent manner (3, 4), the 
PmaB was anticipated to perform the cysteinylation reaction by utilizing cysteinyl-tRNACys as a 
substrate. Hence, the P. syringae tRNACys was prepared by in vitro transcription. Reaction of 
PmaA with Cys, ATP, P. syringae tRNACys and P. syringae GluRS resulted in clean conversion 
of PmaA. A previous group member Dr. Rebecca Splain showed in another sLanB system that the 
sLanB enzyme requires the presence of ATP for activity. Thus, a cysteinylation assay with purified 
cysteinyl-tRNACys was performed with or without ATP. Subsequent MALDI-TOF-MS analysis 
confirmed that the amino acid ligation reaction catalyzed by PmaB is indeed ATP dependent 
(Figure 5.5).  
 
 
Figure 5.5 In vitro cysteinylation reaction by PmaB requires the presence of ATP. MALDI-TOF mass spectra of in 
vitro cysteine addition reaction with purified cysteinyl-tRNACys in the absence and presence of ATP. 
 
5.2.2 Mechanistic study of the PmaB catalyzed amino acyl ligation reaction 
To investigate whether PmaB adopts a similar ping-pong mechanism involving the 
formation of acyl-enzyme intermediate as the cyclodipeptide synthases (10), we first analyzed the 
sequence of PmaB and its orthologs from various sLanB gene clusters and identified four 
 160 
conserved Ser or Thr residues (Ser 11, Ser 180, Thr 540, and Ser 780; Figure 5.6). PmaB variants 
were generated in which these Ser or Thr residues were replaced by Ala and co-expressed with 
PmaA in E. coli. All of the PmaB mutants remained active (Figure 5.7), suggesting that no 
conserved Ser or Thr residues in sLanB families anchor an amino acid to generate the 
corresponding acyl-enzyme intermediate. Further mutagenesis of the conserved Tyr in PmaB to 
Phe ruled out the possibility of a Tyr to serve the purpose of forming an acyl-enzyme intermediate 
(Table 5.1), and no conserved Cys residue was identified during the alignment. These data indicate 
that PmaB does not utilize a ping-pong mechanism to generate an acyl-enzyme intermediate for 
catalysis. 
Further multiple sequence alignment identified sixteen more residues that are conserved. 
Each of the residues was replaced with Ala and co-expressed with PmaA in E. coli (Table 5.1). A 
set of nine residues (R10A, R173A, K177A, D179A, D542A, H566A, K752A, E801A and R803A) 
was identified as possibly involved in substrate binding or catalysis. To confirm that the 
diminished activity did not result from improper folding of the enzyme, the nine PmaB variants 
were individually expressed and purified from E. coli (Figure 5.8), and tested for in vitro activity 
(Figure 5.9). The consistency between the in vivo and in vitro experimental data further 
corroborated important roles of the seven residues in catalysis. 
 
WP_010898202.1      MLSVKQSSINEDHNNWDFFGHFVLRSTGFPYEWMKEL----------------------- 
WP_095098125.1      ---------------MRCADYFWLRSAGFPADQLMQATSFPSLPAF----TSLMALHQLR 
WP_048368865.1      ---------------MESSQYFWLRSTGFPIHYLTDLGRLSELPACRAFEQDFRAFQALK 
PmaB                ---------------MESSHYFWLRSTGFAVHHLTRLGKMAELPLLKDFETDYRSLNTLR 
WP_117166554.1      ---------------MESSLYFWLRSTGFPIHHLTQLGKMDELPLLKDFEDSYRCVAVLR 
                                        :* ***:**.   :                           
 
WP_010898202.1      ------------------------KMQQTFDLIFQN-------------AKWEQVESKFN 
WP_095098125.1      GRLLQQFEQQMAVVGEVQCRKFARKLAAQQAVSVSDLPLPLRDVLQQPLDEWHNVNAKIV 
WP_048368865.1      AMMLEEANSHSLLT----CRKLIRKLNEGQSLLLSDLPQALREPLNTAVLKWNDLLKRLV 
PmaB                DSLLEKSISHSSQA----CRKLIRKLNENLPLQVSDLPEALRDDAVDELAHWNERLGRLK 
WP_117166554.1      SKLLQKSMSHSAQA----SRKLIRKLNENLPLQVSDLPEALRESSREDLERWNEQLARLA 
                                            *:     : ..:               * :   .:  
 
 
Figure 5.6 (cont.) 
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WP_010898202.1      -QELAIK----------REQLKAYFDSEDFRQAVFISNPDMYQHIDRYMKHFQSHSRPSK 
WP_095098125.1      AQETTLRPVFANFNEQGRQQLIDFLSRADVSEAIFISNPDAAQRINALIT--ERHAPHDS 
WP_048368865.1      -IGDVARHEYSTYLERARQGLINFLDDDAVSEALFISNPSARARIQELIK--DRHSRSDS 
PmaB                -QRVEVDQEYAVFLESARQALIDFVNDEDVEQAVFISNPTALTRLRELRQ--ERHARTDS 
WP_117166554.1      -QRTDVDQEYALYLEDARQALIDFLDDEDVAQALFISNPAALARVRELIG--ERFSRTDS 
                                     *: *  :..   . :*:*****    .:       : .:  .. 
 
WP_010898202.1      VKRIEKKL-FTYLQRFCGKNESASFFGPLNYGQVEPNIDEYWDGSFIETKDLQKREAFLS 
WP_095098125.1      RKKQKIRLGWSYAQRFCTKNDTCSFFGPIAWGRFDDRQTVLANVKWSMGSWLSQRKTFFE 
WP_048368865.1      RKKQKLRLGWSYAQRFCAKNDTSSFFGPLAWGHFKDQQIANVQLTQNDTTWLKDRHTFFE 
PmaB                RKKQKLRLAWSYAQRFCSKNDTSSFFGPLAWGRFDRTQVEHVRITQHGPGWIRERHTFFE 
WP_117166554.1      RKKQKLRLAWSYAQRFCSKNDTSSFFGPLAWGRFDRLQAENVRITSGEGSWIKERHTFFE 
                     *. : .* ::* **** **::.*****: :*...         .      : .* :*:. 
 
WP_010898202.1      YWAVKALAKAVAKENELAPYVPLQIPSWIVVRKEYVVLSSGKRINLPAWMMEIMHYIQ-- 
WP_095098125.1      SWVIQRLVAQINAQCPEPMCLPLSVNPGCYLQGDVLHYPLGKSRRLTGPTFDVLKALTMA 
WP_048368865.1      NWVMQRLVEQINQQCPNTDCMPLKLNASCYLREQHLFMPINKSQRLTPLTAQVLHTINAQ 
PmaB                SWVVQRLVEQLNRHCVDVQFMPLQLNPGCFLNQDTLHLPVNKRRQVSALTARVLGYIQCQ 
WP_117166554.1      SWVIQRLVDQLNKQCPDPHFMPFQLNQGCYLIDTTLHMPVNKRQTLNPLTAQVLDYIQRP 
                     *.:: *.  :         :*:.:     :    :  . .*   :      ::  :    
 
WP_010898202.1      -ETSSCLWELQNHFNHIEAGQLKASLEKLISKGLIHREWIIPSTVVHPLHRLLEQLRELP 
WP_095098125.1      VVSEKQLRDRL----DNNPGQ---VVKHLISAGIVQRGFQLSPRDPAALTTILEAMRTAA 
WP_048368865.1      HKEDVTFKQILNACSDISPYTLRDLLDHLVNKRIVRRGWDISPRERNPIVRLQHYLATTG 
PmaB                SAVAPTLFGLQAELQDVSAGQLRDLIDHLVAQQIVRRGWQISPRERKPVQVLHTFLADAR 
WP_117166554.1      ASSAPTFYGLLAALPQADAGQLEALLEHLVARQIIRRGWQVSPRERQPVQVMLSFLSDSR 
                          :          ..      :.:*:   ::.* : :..    .:  :   :     
 
WP_010898202.1      DSPA-KNKWCQALDELASEVTKLANLPIVEKRRSFAHLEETFTKLTGEPSRRGKASLYAD 
WP_095098125.1      LPERFVAHWSECFQRLERQRETYAGGDLQQRQQALAAMNQTLSD-AGVSLARDSGKMYVG 
WP_048368865.1      VSPDFQKAWHSRLHALEQARCDYANGDLIRRTEILEKLNRLLGE-AGVDLCRESGTMYVG 
PmaB                LSDDFRTQWHERLSGLEAIRQDYATGDLAVRIASLDKLNRLLGE-AGVDISRESGAMYVG 
WP_117166554.1      LSDAFRAQWRERLTELEATRNRYALGDLSVRMASLEQMNLLLSE-AGVDLSRESGAMYVG 
                     .      * . :  *       *   :  .   :  ::  : . :*    * .. :*.. 
 
WP_010898202.1      RFIYYEDAQGHIQEFRFGKPFIEDLQTKLAGSLNMSA----AYGEEIWAYYQELGRNVYE 
WP_095098125.1      RYPVYEDCARAS-TLTFNRKLQQALDVDFAPLMSLYQWLTRATGVLLHQAWLD----VYQ 
WP_048368865.1      RYPIYEDCSRNI-NISFGQTVFHQVNKELAPLMRINQWLIKAIAHQLNSVFVE----AWE 
PmaB                RYPVYEDCSRNI-DISLGGALLDQVNADLAPLMRIHQWLIKACARQLHGFYAQ----VWQ 
WP_117166554.1      RYPVYEDCSRNI-EVSLGRSLLEQVNADLAPLMRIHQWLIKACARQLHAFYVE----VWQ 
                    *:  ***.      . :.  .   :: .:*  : :      * .  :.  : :    .:: 
 
WP_010898202.1      DMQVEARNDEKRQLANSGIPF-------SSFINKLRQTYPDVPQLPKSSFSNKIEAIIRE 
WP_095098125.1      LIPPCPDGQDVSLLAFLHLLHPQQAAIQQQVCDRVRTMLNEAWQPLLSVVHTE-ELQLSA 
WP_048368865.1      QRQAINPCRTVDFLDLINTLAPLLPAIETSIIVDLNQRLETAWTQLLREFPAQSEVRLCA 
PmaB                RLQAEDEHNPVNFLAFLGAVQPVIAHAEAGIIEELDAVLADAWQQVLSDKHDPEQVQLTH 
WP_117166554.1      GFQAADAAAPVDFLAFLGAVQPRLAQVEANIIERTDALLDQAWQQVLEGRAEEAQVHLSA 
                                 *                .          .            :  :   
 
WP_010898202.1      KGTEQRVVKLTSD--QLNVFPSNRSFYSSPDLFLQAENIEALRNGDVQIILAKLHHHLLM 
WP_095098125.1      AQLEQVLAALNQQCPAAADFPVFGDDFHSPDFMLAADNLEALNRGEYQVVLGETHPGV-- 
WP_048368865.1      TDIDHLISRLNKDF-DVSDFTVFGSDYHSPDLLLSSASIEAFNLGHYEIIVGEVHPAV-- 
PmaB                EDIERLIVELNTRL-DVRTFSVFGSHFHSPDFLISSTSTDALNQGDYSIILGEVHPGV-- 
WP_117166554.1      ADVERLIEMLNARL-DVQAFTVFGSDFHSPDFLIASSSTQALNQGDYEIILGEVHPGV-- 
                       :. :  *.        *.   . : ***::: : . :*:. *  .:::.: *  :   
 
WP_010898202.1      HNWMTYFYQEKERLERDLVQLVQKLDHEDGTVLSGLEIMRRN------KAYYDYPTTVIE 
WP_095098125.1      -------HTLSQPVAAPFCPVTAEIDQGVNALLGRERLILADSPESYQRSHIDWPLVSHY 
WP_048368865.1      -------HTLSQPVADPFGPYNSQICQQVETIFQRPRLILADSPDSYQRSHIDWPLQPFY 
PmaB                -------HTLSQPVAEPFGPFNKEIEQEVRQIFDGPRLVLADSPDSYQRSHIDWPLLECY 
WP_117166554.1      -------HTLSQPVAEPFGPFNHDINRDVQRLFGGSRMVLADSPDSYQRSHIDWPLLSCY 
                           :  .: :   :     .: .    ::    ::  :      .:: *:*      
 
WP_010898202.1      YAEKPDSSKESIKLTDLIVVRN-----DDGHLELQEKNTSRPIELYVPLADQVHYLPFAM 
WP_095098125.1      VQLILPGGGGSVAAEKRYPAGRARLHCKTGRLTVEDMDGAFHEDLLCVSGTSLHQLLFRL 
WP_048368865.1      LQLVLPSGGGCVEPHQQFAAGRAKVLFVNGRLQVVDTLGQFSEDLLCVYPTPLHRIGFTL 
PmaB                QQLILPSGGGCVPADQRFAVGRARLVMNEGRLRVEDIAGQFSEDLVCVYPTPMHRLGFAL 
WP_117166554.1      QQLVLPSGGGCVDPGQRFAAGRARLVMLQGRLHVEDVAGEFAEDLLCVYSTPMHRLGFAL 
                          ..  .:   .   . .       *.* : :       :*       :* : * : 
Figure 5.6 (cont.) 
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WP_010898202.1      FSKPMLLHVPISSGKHTPRIVIDDVVYQRERWFFYTKQLVDLFHQLQGPLLLKKVEEWRQ 
WP_095098125.1      AGDVLPRHEP-------RRIRVNRTLYKRRTWAFNAGGWPEAVS--DEFMAFIQWRDWQQ 
WP_048368865.1      ADSAVAKHEY-------RRIWLGRTLYKRASWLFTREQLPEPKGTIEELEYTMQWRAWAV 
PmaB                AGSVVAKNDR-------RRIGLGKTLYKRASWWFSPEQLPCSEFSVDKLDDVLAWRAWAV 
WP_117166554.1      AGSAVARGDR-------RRIWLGKTLYKRASWWFTQEQFPCPEFSVDKLDDTLAWRAWAQ 
                     .. :             ** :. .:*:*  * *            :          *   
 
WP_010898202.1      AEGIPEVVYIKGSDVRKPYWVDFKNYFSLELMQQILLENNEITIEEMLPDPHHLWLKSRK 
WP_095098125.1      RQALPRWVFIKCDSEPKPLFIDFDNPLSLDALATALKKARVIQVSEMLPTPDELWFNDAR 
WP_048368865.1      SQGLPRYAFIKIDTEPKPLFLDFDNPLSLDGIINALKSAGHVKFSEMRPGPDELWLEDAR 
PmaB                EHGLPRYVFAKIDIEPKPIFIDFDNPLSLDGVSNSMKKAGHVKFSEMCPAPDQLWLEETR 
WP_117166554.1      EHGLPRYVFAKIDIEPKPIFIDFDNPLSFDGVSNSMKKATHVKFSEMCPSPDELWLEEAR 
                      .:*  .: * .   ** ::**.* :*:: :   : .   : ..** * *  **::. . 
 
WP_010898202.1      GSHSCELRMSVYKLGIKEVSEHA 
WP_095098125.1      GRVCCEIRTTFSPIKQETTENAE 
WP_048368865.1      GRFCCEIRTTFSINKALAT---- 
PmaB                GHFCCEIRTTFRDNGVTRDE--- 
WP_117166554.1      GRFCCEIRTTFTSDGVVPDEQ-- 
                    *  .**:* :.             
Figure 5.6 Sequence alignment of PmaB homologs (WP_010898202.1 is from genome of Bacillus halodurans; 
WP_095098125.1 is from genome of Serratia ficaria; WP_048368865.1 is from genome of Pseudomonas helleri; 
WP_117166554.1 is from genome of Pseudomonas cichorii). Shown in red are residues replaced with alanine for 
enzymatic activity assessment in this study. 
 
 
Figure 5.7 MALDI-TOF mass spectra of PmaA co-expressed in E. coli with PmaB variants in which selective Ser or 




Table 5.1 Activity of alanine-substituted PmaB proteins. Sixteen positions of PmaB were targeted for alanine 
replacement by site-directed mutagenesis using the alignment of Figure 5.6. These proteins were assayed for 
enzymatic activity by co-expressing with PmaA and analyzed using a MALDI-TOF-MS. +++ indicates enzyme 
activity roughly equal to wild-type (full conversion to product); ++ indicates modestly reduced enzyme activity (~50% 
conversion to product); + indicates severely reduced enzyme activity (low but detectable product formation); - 







Wild-type +++ D404A +++ 
R10A - D542A - 
K161A +++ H566A ++ 
Y170F +++ R704A +++ 
R173A - W707A +++ 
K177A - K746A +++ 
D179A ++ K752A + 
R397A +++ E801A - 
E403A +++ R803A - 
 
 
Figure 5.8 SDS-PAGE analysis of PmaB variants which have diminished activity. All proteins were expressed as N-
terminus His6-tag fusions. 
 
The requirement for ATP by PmaB seems counterintuitive since cysteinyl-tRNACys is a 
molecule already at high energy state with an activated amino acyl-ester, and it alone would be 































analysis was performed using purified cysteinyl-tRNACys and ATP. Phosphate and ADP were 
detected as the products of the reaction (Figure 5.10), suggesting the presence of a 
phosphorylation step for to activate the substrate. Quenching the assay by adding NH2OH into the 
reaction mixture suggests that it is the C-terminal carboxylate of PmaA that is activated, as a 
PmaA-NH2OH adduct was detected by MALDI-TOF-MS (Figure 5.11A). The identity of this 
PmaA-NH2OH adduct was confirmed by electrospray ionization high resolution (ESI-HR) MS and 
MS/MS analysis of the endo-proteinase GluC digested peptide (Figure 5.11B, C), and the NH2OH 
addition was located at the very C-terminal carboxylate of PmaA. 
 
 
Figure 5.9 MALDI-TOF mass spectra of in vitro cysteinylation reaction of PmaA with PmaB variants which have 




Figure 5.10 31P NMR analysis shows ADP and phosphate as products of the PmaB reaction. 
 
 
Figure 5.11 NH2OH interception of C-terminal carboxylate activated PmaA. (A) MALDI-TOF mass spectra of 
NH2OH treated assay with PmaA and PmaB in the absence and presence of ATP. (B and C) ESI-HR-MS and MS/MS 
analysis of the endo-proteinase GluC digested PmaA-NH2OH adduct.  
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To provide direct evidence that the C-terminal carboxylate of PmaA was activated by 
phosphorylation, we labeled one of the C-terminal carboxylate oxygen with an 18O through 
hydrolyzing a PmaA thioester in H2
18O (see experimental methods). According to ESI-MS analysis 
of the endo-proteinase GluC digested PmaA, ~85% of the C-terminal carboxylate was labeled with 
an 18O (Figure 5.12A). 31P NMR analysis of a multiple turnover assay indicates a clear 18O 
incorporation into phosphate (18O-Pi), which could only originate from the C-terminal carboxylate 
of PmaA (Figure 5.12B). However, this NMR spectrum still could not confirm direct 
phosphorylation of the carboxylate, as two mechanisms could explain the 18O incorporation into 
the generated phosphate (Figure 5.13) in a multi-turnover assay. 
 
 
Figure 5.12 (A) ESI-MS analysis of the GluC digested 18O labeled PmaA. (B) 31P NMR analysis shows 18O 
incorporation into phosphate when using 18O labeled PmaA for the multiple turnover in vitro cysteinylation reaction. 
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To test the feasibility of both mechanisms, 31P NMR analysis of a single turnover assay 
was performed (see experimental methods). If PmaB utilized the proposed mechanism shown in 
Figure 5.13A, no 18O-Pi would be detected in the first turnover. However, 18O-Pi was found to 
account for ~50% of the 16O-Pi, thus ruling out the possibility of the intermediacy of a PmaA-
PmaB anhydride (Figure 5.13A and Figure 5.14). Integration of the peak corresponding to ADP 
and phosphate (16O-Pi + 18O-Pi) indicated some discrepancies, as the peak area of labeled and 
unlabeled phosphate combined is more than that of ADP, and the amount of 18O-Pi to 16O-Pi 
deviates from the theoretical ratio (~100：74; Figure 5.14). These discrepancies probably resulted 
from the prolonged time for 31P NMR recording, and a portion of ADP was hydrolyzed to generate 
18O-Pi. If the difference between the peak area of phosphate and ADP is subtracted from that of 
the 16O-Pi, the ratio of 18O-Pi to 16O-Pi would reach ~71%, which is very close to the theoretical 
ratio of the single turnover reaction. These data strongly support the mechanism B in Figure 5.13, 
in which the C-terminal carboxylate of PmaA is directly activated by phosphorylation during 
reaction. 
The PmaB-catalyzed peptidyl-transfer reaction uses a similar activation strategy as the 
ATP-grasp domain-containing enzymes from the ADP-forming carboxylate-amine/thiol ligase 
superfamily (11-14). Recent mechanistic analysis of PglC, a prototypic dual domain phosphor-
glycosyl transferase from Campylobacter concisus, revealed a ping-pong mechanism with a 
covalent aspartyl-phosphate intermediate (15). To probe whether PmaB has a similar acyl-
phosphate intermediate during catalysis (Figure 5.15), a chemical trapping approach was adopted 
by following protocols used in the study of phosphotransferases (16). In this method, experiments 
were carried out by reacting PmaB with or without ATP, recovering the protein by precipitation, 
followed by treatment with sodium borohydride (NaBH4). In this case, the acyl-phosphate 
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intermediate, if generated, would be reduced to the corresponding protein-based alcohol, which 
would be amenable to protease digestion and MS analysis. However, LC-ESI-MS analysis of the 
endo-proteinase chymotrypsin or GluC digested samples did not reveal a modified peptide, 
suggesting PmaB may not generate an acyl-phosphate intermediate when catalyzing the peptidyl-
transfer reaction.  
 
 
Figure 5.13 Two proposed mechanisms that would result in 18O incorporation into phosphate in multi-turnover 
reaction. In mechanism A, the activation happens on a carboxylic residue on PmaB enzyme, and involves the 
intermediacy of a PmaA-PmaB anhydride. This would result in 18O-labeled PmaB which could deposit the label into 






Figure 5.14 31P NMR analysis of single turnover PmaB reaction using 18O labeled PmaA. 
 
 
Figure 5.15 A potential ping-pong mechanism with a covalent acyl-phosphate intermediate. 
 
Repeated attempts to crystallize PmaB proved recalcitrant. Thus, a predicted model of 
PmaB was generated using Phyre2 web portal (Figure 5.16) (17). As shown in the PmaB model 
structure, an Arg/Lys-rich region suitable for interacting with the negatively charged phosphor-
diester groups of amino acyl-tRNA was revealed. We were also able to identify a helix-turn-helix 
structural motif, which is predicted to be the leader peptide binding element (RRE) engaged in 
precursor peptide recognition. Moreover, the nine residues identified to have diminished activity 
through Ala substitution assays all clustered at the putative active site, which further corroborates 
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a role of these residues during catalysis. NH2OH quenching assays with the PmaB mutants that 
had no detectable enzyme activity suggests that R10, R173 and K177 do not participate in the 
phosphorylation of PmaA during catalysis, as mutation of these residues did not affect the NH2OH 
addition to the PmaA, whereas residues D542, E801 and R803 could potentially be involved in the 
phosphorylation step of the reaction (Figure 5.17), either through ATP binding or catalyzing the 
acyl-phosphate formation on PmaA, since these residues did affect NH2OH addition. 
 
 
Figure 5.16 Phyre2 model of PmaB. The overall structure is shown in pink. The Arg/Lys-rich region putatively 
involved in tRNA binding is colored in navy. The RRE motif engaged in precursor peptide recognition is colored in 




Figure 5.17 MALDI-TOF mass spectra of NH2OH quenching assays with PmaA and PmaB variants in the absence 
and presence of ATP. 
 
In summary, we performed a detailed biochemical and mechanistic study of the PmaB 
enzyme involved in the biosynthesis of 3-thiaglutamate. We found that PmaB catalyzed complete 
amino acyl ligation reaction using only 12 out of 50 residues of the precursor peptide PmaA. With 
the exception of charged residues, PmaB is very promiscuous towards the last amino acid of the 
substrate peptide. We also found that PmaB performs its activity in an ATP and tRNA dependent 
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manner, which is fundamentally different from other known pathways. 18O labeling assays 
suggested the role of ATP in the reaction, and provided strong evidence for the direct activation 
of the PmaA C-terminal carboxylate. Further mutagenesis study of PmaB identified several 
residues important for catalysis, and their potential function in catalysis was probed by NH2OH 
quenching assays and Phyre2 model prediction. Combining all the data we obtained, the 
mechanism in Figure 5.14B is consistent with all of our observations, and is thus favored by this 
study. 
 
5.3 Experimental methods 
 
General materials and methods 
Reagents used for molecular biology experiments were purchased from New England 
BioLabs (Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), or Gold Biotechnology Inc. 
(St. Louis, MO). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Escherichia coli DH5α and BL21 (DE3) strains were used for plasmid maintenance and protein 
overexpression, respectively. Co-expression vector pRSFDuet-1 was obtained from Novagen. 
MALDI-TOF-MS analysis was performed using a Bruker UltrafleXtreme MALDI TOF-TOF mass 
spectrometer (Bruker Daltonics) in reflector positive mode at the University of Illinois School of 
Chemical Sciences Mass Spectrometry Laboratory. ESI-MS/MS analyses were performed using a 
SYNAPT ESI quadrupole TOF Mass Spectrometry System (Waters) equipped with an ACQUITY 
Ultra Performance Liquid Chromatography (UPLC) system (Waters). 31P NMR spectra were 
recorded on an Agilent 600 MHz spectrometer in 10% D2O. HiTrap columns for Ni-NTA affinity 




Molecular biology techniques 
DNA was prepared using MiniPrep kits (Qiagen) using the manufacturer's instructions 
from E. coli DH10b cells (New England Biolabs) made chemically competent by the KCM method 
(18). Genomic DNA from P. syringae pv. maculicola ES4326 (Pma) was prepared using an 
UltraClean Microbial DNA isolation kit (Mo Bio Laboratories) according to the manufacturer's 
instructions; Pma cells were grown in liquid KB medium with vigorous aeration. Plasmids were 
constructed with type-II restriction enzymes using the New England Biolabs Golden Gate 
Assembly Tool (http://goldengate.neb.com/editor) or manually designed and prepared by Gibson 
assembly. For plasmids assembled by Golden Gate Assembly, two primer pairs were designed for 
PCR to prepare both the gene and the vector with complementary sticky ends for type IIs restriction 
digest. BsaI and T4 DNA Ligase were used for single step DNA ligation. For plasmids assembled 
by Gibson Assembly, one primer pair was designed for PCR amplification of the gene with an 
overhang complementary to the vector. The vector was linearized by restriction digest with NdeI 
and XhoI and ligated with the gene of interest using NEBuilder® HiFi DNA Assembly Master 
Mix. Restriction enzymes and PCR polymerases were obtained from New England Biolabs. Genes 
for each of the pma gene cluster products and the P. syringae cysteine tRNA synthetase (CysRS) 
were identified using the Joint Genome Initiative Integrated Microbial Genomes and Microbiomes 
webtool (http://img.jgi.doe.gov). Primers for cloning and site-directed mutagenesis were obtained 
from Integrated DNA Technologies. Primers for P. syringae tRNACys were designed and the 
dsDNA template for in vitro transcription was prepared as previously described (19). Mutagenesis 
was accomplished using the QuikChange II Site-Directed Mutagenesis Kit according to 
manufacturer's instructions. Mutagenesis primers were designed using the QuikChange Primer 
Design webtool. Primers are listed in Table 5.2. 
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In vitro transcription of P. syringae tRNACys  
Primers for P. syringae tRNACys were designed according to a previously described method 
(19). The tRNAGlu dsDNA template was generated from two overlapping synthetic 
deoxyoligonucleotides (Table 5.2). To prepare the dsDNA template for in vitro transcription, 5′ 
overhangs were filled in using the following conditions: NEB Buffer 2 (1×), primers (4 μM each), 
dNTP (100 μM each), and DNA polymerase I large (Klenow) fragment (1 U μg–1 DNA) in a final 
volume of 50 μL. The reaction was incubated at 25 °C for 15 min, quenched with EDTA (10 mM) 
at 75 °C for 25 min, and dsDNA tRNACys template was precipitated with cold EtOH overnight. In 
vitro transcription was performed using a previously described method (20). The transcribed 
tRNACys was then purified by acidic phenol extraction using a previously described method (21) 
(notebook reference 6/4//2018).  
 
Peptide expression and purification  
For peptide expression, E. coli BL21(DE3) cells (New England Biolabs) expressing N-
terminal His6-PmaA from His6-PmaA-pRSF-Duet-1 were grown with 50 µg/mL kanamycin in 
autoinduction (AI) media (for 1 L total: 10 g bacto tryptone, 5 g yeast extract, 5 g NaCl, 3 g 
KH2PO4, 6 g Na2HPO4) with 1X AI sugar solution containing 0.5% (vol/vol) glycerol, 0.05% 
(w/vol) glucose, and 0.2% (w/vol) lactose (20 mL of 50X stock)). Cultures were shaken at 37 ºC 
for 6-7 h following inoculation with 1 mL of saturated culture. Cells were harvested and lysed by 
sonication. Peptides were purified by immobilized metal affinity chromatography (IMAC). The 
lysate was clarified by centrifugation at 29,000 rcf and applied to a 5 mL NiNTA-agarose column 
(GE Healthcare) using a peristaltic pump. The immobilized peptide was washed with 5 column 
volumes (CV) of 90% lysis buffer (50 mM HEPES, 100 mM NaCl, pH 7.5), 10% elution buffer 
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(50 mM HEPES, 100 mM NaCl, 500 mM imidazole, pH 7.5; final imidazole concentration in 
wash: 50 mM) and eluted with 100% elution buffer. The elution fraction was concentrated using 
a 3 kDa MWCO Amicon spin filter and washed with 10-20 CV of deionized water to remove 
imidazole. Crude peptide was desalted with a VYDAC® Bioselect C4 cartridge. Peptide elution 
fractions were lyophilized (notebook reference 11/20/2017).   
 
Protein expression and purification for PmaB and CysRS.  
The general expression protocol for the pma cluster enzymes PmaB is as follows: E. coli 
BL21 (DE3) cells (50 μL) were electroporated with His6-PmaB-pET28a (50 ng), and cells were 
plated on LB agar plates supplemented with kanamycin and grown at 37 °C for 12–15 h. A single 
colony was used to inoculate 20 mL of LB broth supplemented with kanamycin, grown for 12–15 
h at 37 °C, and the culture was used to inoculate 2 L of TB media, supplemented with kanamycin, 
to an OD600 of 0.025. Cultures were grown at 37 °C to a final OD600 of 0.6–0.8. Protein 
overexpression was induced by the addition of IPTG to a final concentration of 0.2 mM, and 
cultures were grown at 18 °C for 18 h. Cells were harvested by centrifugation, collected in 50 mL 
tubes and frozen in liquid nitrogen. For purification of His6-PmaB and His6-CysRS, cells were 
thawed, resuspended in lysis buffer (50 mM HEPES, 100 mM NaCl, pH 7.5; 30 mL per 10 g wet 
cell paste) and lysed by treatment with lysozyme (100 µg/mL) and sonication (3 min active time; 
1 s pulse, 2 s rest at 60 % max amplitude using a 1 cm tip). Proteins were purified by immobilized 
metal affinity chromatography (IMAC). Phenylmethylsulfonyl fluoride (PMSF) was added to 
prevent degradation by serine proteases and 1 mM TCEP was included to maintain reduced thiols. 
The eluate was concentrated to 2.5 mL in a 30 kDa MWCO centrifuge filter and desalted on a PD-
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10 size-exclusion column (GE Healthcare Life Sciences). Protein was separated into aliquots and 
stored at –70 ºC. Protein purity was judged by SDS-PAGE (notebook reference 4/4/2018). 
 
HPLC peptide purification and LC-MS  
Following IMAC and C4 desalting, PmaA was purified using an Agilent 1200 HPLC. 
HPLC buffers were 0.1% TFA in water (HPLC buffer A) and 0.1% TFA in acetonitrile (HPLC 
buffer B). The desalted material was lyophilized, resuspended in buffer A, and applied to a 
Phenomenenx Luna C18 column equilibrated with 95% HPLC buffer A, 5% HPLC buffer B. A 
linear gradient to 100% HPLC buffer B was run over 20 min at 0.1 mL min–1. PmaA eluted near 
the end of the gradient. PmaA-Cys behaved similarly and eluted slightly later. Full-length and 
AspN or trypsin-digested peptides were analyzed by LC-MS/MS on a Waters Synapt Q-TOF 
equipped with a Waters UPLC and Phenomenex C18 Luna or C4 Jupiter columns. Buffers for LC-
MS were 0.1% formic acid in water (LC-MS buffer A) or 0.1% formic acid in LC-MS grade 
acetonitrile (LC-MS buffer B). 
 
In vitro assay of PmaB  
In a 0.5 mL centrifuge tube, reaction components were combined to the following 
optimized final concentrations: PmaA (50 M), PmaB (5 µM), CysRS (10 µM), ATP (5 mM), L-
cysteine (5 mM), TCEP (1 mM),  tRNACys (10 µM), P. syringae CysRS (10 µM), and HEPES 
assay buffer (100 mM HEPES pH 7.5; 5 mM MgCl2, 100 mM NaCl).  The assay mixture was 
incubated at 30 ºC for 30 min, desalted and concentrated by ZipTip, eluted in 50% acetonitrile, 
50% water, 0.1% TFA, and analyzed by MALDI-TOF MS. For 31P NMR analysis, reaction 
components were combined to final concentrations as follows: PmaA (50 M), PmaB (5 µM), 
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Cys-tRNACys (50 µM), ATP (0.5 mM), Tris assay buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 100 
mM NaCl). Cys-tRNACys was obtained using a similar procedure for preparation of Glu-tRNAGlu 
reported previously (4). For single turnover reaction prepared for 31P NMR analysis, the reaction 
reaction components were combined to final concentrations as follows: PmaA (10 M), PmaB (50 
µM), Cys-tRNACys (50 µM), ATP (10 M), Tris assay buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 
100 mM NaCl). The reaction was incubated at 30 ºC for 15 min, then Chelex resin was added to 
remove Mg2+. After using Amicon Ultra 3K MWCO (3,000 Da cut-off) tube to remove proteins 
and tRNA, the sample was added into NMR tube for analysis (notebook reference 7/6/2018). 
 
LC-MS analysis anhydride intermediate 
Assays were performed by reacting 25 µM PmaB in the presence or absence of ATP (5 
mM) for 5 min at 30 ºC. Then assays were quenched with 20% ice-cold trichloroacetic acid and 
kept on ice for 20 min to precipitate the protein. The precipitate was separated by centrifugation 
(10,000 × g for 10 min) at 4 °C, washed with 3 × 400 μL of 10 mM ice-cold HCl, dried under 
vacuum, and dissolved in 20 μL of DMSO. To this solution, 15 μL of 0.1 M NaBH4 in DMSO was 
added and incubated at 30 °C for 10 min, followed by addition of 1 mL of ice-cold perchloric acid 
(0.44 M). The mixture was incubated on ice for another 30 min, followed by centrifugation at 
10,000 × g for 20 min at 4 °C. The resulting precipitate was washed with 3 × 400 μL of 10 mM 
ice-cold HCl, and dried under vacuum. The dried protein was re-dissolved in 6 M guanidine HCl 
and dilute to with H2O to 1 M guanidine HCl in the solution. The protein was digested with 0.02 




NH2OH quenching assay 
Assays were performed by reacting 50 µM PmaB and 50 µM PmaA in the presence or 
absence of ATP (5 mM) for 5 min at 30 ºC. Then assays were quenched with NH2OH to final 
concentration of 1 M and incubate at 30 ºC for another 20 min. The assay was then desalted by 
ZipTip and analyzed by MALDI-TOF-MS (notebook reference 8/29/2018). 
 
Preparation of plasmid pTXB1-PmaA-intein-chitin 
The genes coding for PmaA was amplified by PCR using appropriate primers (Table 5.2), 
and purified by gel extraction from a 1% (w/v) agarose gel using the QIAquick Gel Extraction Kit. 
The vector pTXB1 was digested using NdeI and SapI (NEB) restriction endonucleases and purified 
by gel extraction as described previously. The DNA fragment was inserted by Gibson one-step 
isothermal DNA assembly, and an aliquot of 20 μL of the Gibson assembly reaction was used to 
transform E. coli DH5α cells using the heat shock method. The cells were plated on LB plates 
supplemented with ampicillin (100 μg/mL) and the plates were incubated at 37 °C for 12–15 h. 
Single colonies were picked and grown in LB supplemented with ampicillin (100 μg/mL) at 37 °C 
for 12–15 h and the plasmids were isolated using a QIA prep Spin Miniprep Kit. Insert integrity 
was verified by sequencing the plasmids with the appropriate primers (Table 5.2). 
 
Preparation of C-terminal 18O labeled PmaA 
E. coli BL21 (DE3) cells (50 μL) were electroporated with pTXB1-PmaA-intein-chitin (50 
ng), and cells were plated on LB agar plates supplemented with kanamycin and grown at 37 °C 
for 12–15 h. A single colony was used to inoculate 20 mL of LB broth supplemented with 
ampicillin, grown for 12–15 h at 37 °C, and the culture was used to inoculate 2 L of TB media, 
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supplemented with ampicillin, to an OD600 of 0.025. Cultures were grown at 37 °C to a final OD600 
of 1.0. Protein overexpression was induced by the addition of IPTG to a final concentration of 1 
mM, and cultures were grown at 37 °C for 3 h. The cells were harvested by centrifugation, and 
then frozen in liquid nitrogen and stored at –80 oC.  
For the purification of the PmaA peptide, the cell paste was placed into a metal sonication 
cup using a minimal amount of resuspension buffer (20 mM Tris-HCl, 500 mM NaCl, 1mM 
EDTA, pH 7.5) to transfer all of the cell paste. The cell paste was lysed by sonication (65% 
amplitude with 3 s pulses and 9 s delays) for 16 min. The sonicated cells were centrifuged for 30 
min at 13,000 × g. The supernatant was poured into a column containing 20 mL of chitin beads 
pre-equilibrated with resuspension buffer. The supernatant and beads were gently shaken/rocked 
at 4 oC for 2 h to allow binding of the PmaA-intein-chitin binding domain fusion protein to the 
resin. The column was drained and washed with 600 mL of resuspension buffer to remove all 
impurities. The chitin beads were then added with 40 mL of cleavage buffer (50 mM HEPES, 200 
mM NaCl, 1mM EDTA, 20 mM 2-mercaptoethanesulfonate, pH 7.7) and the column was capped 
and sealed with parafilm. The column was shaken at 4 oC for 6 h, and the solution was drained 
from the column directly into an Amicon Ultra 3K MWCO (3,000 Da cut-off) tube. The Amicon 
was then centrifuged until the protein solution had been concentrated to ~10 mL. The concentrated 
peptide solution was frozen in liquid nitrogen and lyophilized till dry. 
The lyophilized peptide was re-dissolved in basic H2
18O buffer (100 mM Na2CO3, pH 10.0) 
and incubated at 30 °C for 1 h, and was purified on a Shimadzu Prominence Preparative Liquid 
Chromatography system equipped with a Phenomenex Luna C18 column (250 × 10 mm, 10 μm 
particle size, 100 Å pore size). Acetonitrile and 10 mM aq. NH4HCO3 were used as the mobile 
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phases, and a gradient of 2-80% aq. MeCN over 45 min at 5 mL min–1 was used for separation 
(notebook reference 7/10/2018).   
 
Table 5.2 Oligonucleotides used in this study. All sequences are provided 5′ to 3′. Lowercase m indicates 2′ O-
methylation of the following residue; methylation suppresses random addition of bases at the end of the RNA by T7 
RNA polymerase. 
Primer Oligonucleotide Sequence 
PmaA (-Ala)_F GCAAGGTCTTTTGAAGCTTGCGGCCGCATAATG 
PmaA (-Ala)_R CGCAAGCTTCAAAAGACCTTGCTCTCGATGACTTCAATGTC 
P. syringae tRNACys F AATTCCTGCAGTAATACGACTCACTATAGGCCGAGTAGCAAAATGGTTATGCAGC 
P. syringae tRNACys R mUmGGAGGCCGAGGTCGGAATCGAACCGGCGTAGGCGGATTTGCAATCCGCTGCATAACC 
PmaB_Seq_623 CTGGATCAGAGAACG 
PmaB_Seq_1549 GGCTGATTGTCGAGC 
PmaA_ 40mer_F GAGAACCTGTACTTCCAATCCAACCAGCAAGCGTCC 
PmaA_ 30mer_F GAGAACCTGTACTTCCAATCCCTCGAAAACACTCCGCAG 
PmaA_ 20mer_F GAGAACCTGTACTTCCAATCCGCGTTGTTTGAAGAGTTTGACC 
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PmaA_ A50F_F CAAGGTCTTTTTCTGAAGCTTGCGGCCG 
PmaA_ A50F_R CAAGCTTCAGAAAAAGACCTTGCTCTCGATGACTTC 
PmaA_ A50K_F CAAGGTCTTTAAATGAAGCTTGCGGCCG 
PmaA_ A50K_R CAAGCTTCATTTAAAGACCTTGCTCTCGATGACTTC 
PmaA_ A50E_F CAAGGTCTTTGAATGAAGCTTGCGGCCG 
PmaA_ A50E_R CAAGCTTCATTCAAAGACCTTGCTCTCGATGACTTC 
PmaA_ A50Q_F CAAGGTCTTTCAGTGAAGCTTGCGGCCG 
PmaA_ A50Q_R CAAGCTTCACTGAAAGACCTTGCTCTCGATGACTTC 
PmaA_ A50P_F CAAGGTCTTTCCATGAAGCTTGCGGCCG 
PmaA_ A50P_R CAAGCTTCATGGAAAGACCTTGCTCTCGATGACTTC 
PmaA_ A50S_F CAAGGTCTTTTCTTGAAGCTTGCGGCCG 
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